Interrupting malaria transmission: the effects of drugs and immunity on the transmissinility of plasmodium falciparum. by Bousema, T.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/30238
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
Interrupting
              the effects of drugs and immunity on 
the transmissibility of Plasmodium falciparum
malaria transmission:
Teun Bousema
Interrupting m
alaria transm
ission: the effects of drugs and im
m
unity on the transm
issibility of Plasm
odium
 falciparum
 Teun B
ousem
a 2007
Interrupting malaria transmission: 
the effects of drugs and immunity on the 
transmissibility of Plasmodium falciparum 
 
Teun Bousema 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Interrupting malaria transmission: the effects of drugs and immunity on the 
transmissibility of Plasmodium falciparum 
 
ISBN 978-90-6464-128-2 
 
Copyright 2007, Teun Bousema, Nijmegen, the Netherlands 
 
Printed by: Ponsen & Looijen B.V. 
 
Cover design: Jan Timorason 
Photography: Teun Bousema  
  
The studies were financially supported by The Netherlands Foundation for the 
Advancement of Tropical Research (NWO-WOTRO), partly through PRIOR. 
A travel grant was awarded by the Ter Meulen Fund (KNAW). 
Financial support for the publication of this thesis was provided by bioMérieux 
bv, Boxtel, the Netherlands. 
 
 Interrupting malaria transmission: 
the effects of drugs and immunity on the 
transmissibility of Plasmodium falciparum 
 
 
 
Een wetenschappelijke proeve op het gebied van de Medische Wetenschappen 
 
 
Proefschrift 
ter verkrijging van de graad van doctor 
aan de Radboud Universiteit Nijmegen, 
op gezag van de rector magnificus prof. mr. S.C.J.J. Kortmann, 
volgens besluit van het College van Decanen 
in het openbaar te verdedigen op donderdag 28 juni 2007 
om 13.30 uur precies 
 
 
door 
 
Jan Teun Bousema 
geboren op 4 september 1977 
te Wymbritseradeel 
  
Promotor 
Prof. dr. R.W. Sauerwein 
 
Copromotor 
 Dr. C.J. Drakeley  
London School of Hygiene and Tropical Medicine, London, UK 
Joint Malaria Programme, Moshi, Tanzania 
 
Manuscriptcommissie 
 Prof. dr. ir. G.A. Zielhuis (voorzitter) 
 Dr. ir. W. Takken  
Wageningen Universiteit en Researchcentrum, Wageningen 
 Dr. D.M. Burger 
 
 
 5 
Contents 
 
 
Chapter 1 General introduction      7 
 
Chapter 2 Plasmodium falciparum gametocyte carriage in  23 
asymptomatic children in western Kenya  
 
Chapter 3 Treatment failure of pyrimethamine-sulphadoxine   33 
and induction of P. falciparum gametocytaemia  
in children in western Kenya    
 
Chapter 4 Plasmodium falciparum dhfr but not dhps    41 
mutations associated with sulphadoxine- 
pyrimethamine treatment failure and gametocyte  
carriage in northern Ghana  
 
Chapter 5 (Sub)microscopic Plasmodium falciparum    57 
gametocytaemia in Kenyan children after treatment  
with sulphadoxine-pyrimethamine monotherapy or  
in combination with artesunate  
 
Chapter 6 Moderate effect of artemisinin-based combination   69 
therapy on transmission of Plasmodium falciparum  
 
Chapter 7  Submicroscopic Plasmodium falciparum gametocyte  87 
densities frequently result in mosquito infection  
 
Chapter 8 Submicroscopic Plasmodium falciparum gametocyte  101 
carriage is common in an area of low and seasonal 
transmission in Tanzania  
 
Chapter 9 Rapid onset of transmission-reducing antibodies in  113 
Javanese migrants exposed to malaria in Papua,  
Indonesia 
 
Chapter 10  Transmission reducing immunity is inversely related  127 
to age in P. falciparum gametocyte carriers  
 
  6
Chapter 11 A longitudinal study of immune responses to   141 
Plasmodium falciparum sexual stage antigens in  
Tanzanian adults 
 
Chapter 12 Sexual-stage antibody responses to P. falciparum   159 
in endemic populations  
 
Chapter 13 General discussion       175 
 
Chapter 14  
Summary         194 
Samenvatting        196 
List of publications       199 
Dankwoord        202 
Curriculum vitae       205 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1 
 
 
 
General introduction 
 
 
 
Parts of this chapter have been published in:  
The epidemiology of Plasmodium falciparum  
gametocytes: weapons of mass dispersion1.  
 
Trends in Parasitology 22,424-30 (2006) 
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Each year, an estimated 300-500 million clinical cases of malaria occur, resulting 
in an estimated 1 million deaths 2, 100 000 children with permanent learning 
problems 3 and a reduction in economic growth of 1.3% in countries with intense 
malaria transmission 4. While four malaria species commonly infect humans 
(Plasmodium falciparum, P. vivax, P. ovale and P. malariae), P. falciparum is 
almost exclusively responsible for malaria associated severe disease and 
mortality. Around 90% of P. falciparum associated deaths occur in sub-Saharan 
Africa 5 with pregnant women and especially young children as most vulnerable 
groups. The life cycle of malaria is given in figure 1.1 and shows two distinct 
phases, an asexual phase where parasites are replicating in the human 
vertebrate host and a sexual phase where fertilisation of sexual stage parasites 
takes place inside the mosquito midgut 6,7.  
 
 
Figure 1.1 The malaria lifecycle. Plasmodium parasites enter the human body by the injection 
of infected saliva of Anopheles mosquitoes. Within minutes, these sporozoites enter liver cells 
where they mature and multiply. After approximately one week, liverschizonts burst and release 
merozoites that invade red blood cells. Asexual replication of parasites takes place in red blood 
cells with erythrocytes releasing merozoites 48 hours after infection. A fraction of asexual 
parasites transforms into sexual stage parasites, gametocytes. Once ingested by mosquitoes that 
are taking a blood meal, each individual gametocyte forms 1 female macrogamete or 6-8 male 
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microgametes. In the mosquito midgut, the fusion of gametes results in the formation of a zygote 
that in turn develops into a motile ookinete that can penetrate the midgut wall to form oocysts. 
The oocyst enlarges over time and bursts to release sporozoites. These sporozoites migrate to the 
mosquito salivary gland, ready to infect a new human being.  
 
While asexual forms are responsible for malaria associated morbidity and 
mortality, sexual forms assure malaria transmission by infecting Anopheles 
mosquitoes. Mosquito infection depends on the presence of mature sexual stage 
parasites, gametocytes, in the peripheral blood. Gametocytes are essential for 
malaria transmission but microscopic examination shows that gametocytes are 
only observed in the peripheral blood of a proportion of the malaria infected 
individuals. The trigger of gametocytogenesis has been the source of much 
debate. Several factors have been related to the appearance of gametocytes 
including stress factors induced by immune cells 8-11. However, the role of 
‘immune stress’ is not free of controversy. If immune responses would stimulate 
the appearance of gametocytes, one would expect gametocytes to be most 
common in immune individuals. In endemic settings this would implicate that 
gametocytes are most common in adults. Epidemiological studies on the 
contrary consistently find higher levels of gametocytes in children 12-16, probably 
as a result of the age-dependent acquisition of antibodies against asexual stage 
parasites 17,18 or antibodies affecting both asexual parasites and gametocytes 19.  
Studies on gametocytes in naturally infected individuals have almost 
exclusively focused on patients treated with antimalarial drugs 20-29, leaving 
many questions about their occurrence in the asymptomatic population 
unanswered. The low sensitivity of microscopy has certainly contributed to this 
limited understanding of gametocyte dynamics. Despite their distinctive shape 
and colour, P. falciparum gametocytes (figure 1.2) are particularly prone to 
being missed during routine examination of slides. The reason for this is that 
gametocytes typically occur at low densities 6,30, making it tedious to detect 
gametocytes by microscopy. Gametocyte prevalence increases by 29% when the 
number of fields of a thick film examined is doubled from to 200 to 400 31 and by 
3 fold (from 7 to 21%) when 1000 fields are screened 32.  
The low sensitivity of routine microscopy, typically screening 100 fields of a thick 
film, has led to the development of molecular tools for gametocyte detection 
that have tremendously improved the sensitivity of gametocyte detection 33-35. 
One of these molecular techniques is the quantitative nucleic acid sequence-
based amplification (QT-NASBA) 35,36 that uses three enzymes (AMV-RT, RNase 
H and T7 RNA polymerase) and two target-specific primers (one of which 
includes a T7 polymerase/promoter) to amplify parasitic RNA at a temperature 
of 41°C 37. The QT-NASBA allows stage-specific parasite quantification in 50μL 
finger prick blood samples with a lower detection limit of 10 asexual 
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parasites/mL 38 and 20-100 gametocytes/mL 35. The QT-NASBA technique has 
been adapted for use in the field and parasitic ribosomal and messenger RNA 
was found to be stable for at least 2 months when bound to silica and stored dry 
at -20°C 37. The QT-NASBA can be used to determine the prevalence of 
submicroscopic gametocyte carriage in different populations and the relative 
importance of submicroscopic gametocytaemia for malaria transmission. 
 
 
Figure 1.2 Gametocyte detection by microscopy. A thin blood smear with a gametocyte (left) 
and two asexual parasites (right) 
 
 
Antimalarial drugs and malaria transmission 
The most important tool to reduce gametocyte carriage is treatment with 
antimalarial drugs. Successful treatment limits the lifespan of malaria parasites; 
the rate at which the parasite biomass is reduced depending on the type of drug 
39,40. Although most antimalarial drugs have been developed to clear asexual 
parasites, they will indirectly influence the production of gametocytes that are 
derived from asexual parasites. In this manner successful antimalarial treatment 
with any drug will reduce the gametocytaemic period of infected individuals 41,42.  
In addition, drugs can also have direct effects on gametocyte survival or 
infectiousness 41,43-45. These effects are of particular importance for P. falciparum 
since gametocytes of this species have a long lifespan of up to 24 days 41,46. 
Drugs that actively reduce gametocyte survival can therefore have a beneficial 
effect on post-treatment malaria transmission. Nearly all currently available 
drugs for P. falciparum fall into two groups: the quinolines (chloroquine, quinine, 
primaquine and mefloquine) and the antifolates (sulphadoxine, pyrimethamine, 
proguanil and dapsone). The direct effect of the most of these antimalarials is 
limited to asexual stage parasites 47. The most commonly used antimalarial 
drugs in sub Saharan Africa, chloroquine (CQ) and sulphadoxine-pyrimethamine 
General introduction 
11 
(SP), do not actively clear gametocytes and treatment with these drugs is even 
followed by an initial increase in gametocyte prevalence and density 
20,21,23,24,27,48. Artemisinin has a mode of action than is not completely understood 
but is different from the quinolines and antifolates. It is believed to involve the 
cleavage of a peroxide bridge, a structural feature of artemisinin. This cleavage 
results in highly reactive radicals that inhibit a variety of parasite molecules, 
resulting in parasite death 49. Artemisinin (qinghaosu) is isolated from the plant 
Artemisia annua 50, and artemisinin derivatives have a short half-life 40,51-53 and 
are the most potent antimalarial compounds available for human use 40,51-55. 
Because artemisinin alone is often not completely curative, its preferred use is in 
combination with longer acting drugs such as SP, CQ or amodiaquine 40,56-58. 
Artemisinin based combination therapy (ACT) reduces gametocyte carriage after 
treatment 23,27,40,59-61 and may thereby reduce malaria transmission 27,59,62. The 
efficacy of ACT in reducing submicroscopic gametocyte densities is unknown. 
 
Antimalarial drug resistance and malaria transmission 
In the past decades parasite resistance to commonly used antimalarial drugs has 
increased in sub Saharan Africa 5,57,63-67, contributing to an increase in malaria 
morbidity and mortality 68,69. Drug resistance in malaria is defined as the ability 
of a parasite strain to multiply or to survive in the presence of concentrations of 
a drug that would normally destroy parasites or prevent their multiplication 70. 
The emergence of resistance comes in two phases. The first is the initial genetic 
event which produces the resistant mutant; the second is the subsequent 
selection process in which the survival advantage of the mutant parasite leads to 
a preferential transmission 71. As a consequence of the preferential transmission, 
mutant parasite strains can outcompete wildtype parasite strains in the presence 
of drug pressure 72,73.  
Several parasite mutations have been identified that are associated with 
CQ 73,74 and SP 74,75 treatment failure. SP is a drug combination of sulphadoxine 
and pyrimethamine that work synergistically by blocking different enzymes 
needed for folic acid synthesis, which is essential for DNA and RNA synthesis. 
Sulphadoxine inhibits the malarial enzyme dihydropteroate synthase (DHPS); 
pyrimethamine inhibits dihydrofolate reductase (DHFR) 76,77. Mutations in the 
parasite's dihydrofolate reductase and dihydropteroate synthase genes (dhfr, 
dhps) have been related to a reduced efficacy of SP 74,75,78. Multiple mutations 
can occur in both genes simultaneously. The predictive value of these mutations 
for clinical treatment outcome varies for different populations 75,79,80 as a result 
of geographical variation in parasite populations and differences in human 
immune responses 79,81.  
The transmission of drug resistant parasite strains is crucial for 
determining the effective shelf-life of antimalarial drugs 27,57,59,82,83. Drug 
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resistant parasites may persist after antimalarial drug treatment and, by doing 
so, have a better chance to produce gametocytes and subsequently infect 
mosquitoes. For CQ resistant parasites, there have been several reports that 
drug pressure elicits a higher production of gametocytes 20,21,24. For SP, that was 
introduced as firstline antimalarial treatment in east Africa in the last decade 84, 
the relation between drug resistance and malaria transmission is unclear 29,85.  
 
Infectiousness of gametocytes in membrane feeding assays 
The presence of gametocytes in the peripheral blood does not equal the 
infectiousness of an individual to mosquitoes. This is influenced by a number of 
factors including gametocyte density and fitness 12,86-89 and human immune 
factors such as complement, granulocytes and specific antibodies 90-98. 
Membrane feeding assays are the designated tools to directly determine the 
infectiousness to mosquitoes and associated factors. In these assays 
gametocytes are offered to reared Anopheles mosquitoes in an experimental set-
up (figure 1.3).  
 
 
 
Figure 1.3 Membrane feeding assay. Mosquitoes taking a blood meal through a parafilm 
membrane  
 
 
Three membrane feeding approaches are commonly used to answer 
different questions: i) venous blood samples can be offered to mosquitoes 
directly, without serum replacement or other modifications, to determine the 
infectiousness of naturally infected individuals; ii) venous blood samples can also 
be offered to mosquitoes in the presence of (autologous) test serum and control 
serum 16,87,88 to determine the transmission reducing activity of serum; iii) in 
vitro cultured gametocytes can be offered to mosquitoes in the presence of test 
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or control serum 99,100. The latter method is called the standard membrane 
feeding assay (SMFA) and is the gold standard for determining the transmission 
reducing capacity of sera. In all membrane feeding assays, mosquito infection is 
assessed by the detection of oocysts on the mosquito midgut 7-9 days after 
feeding 20,27,101. 
Transmission reducing activity can be determined in the last two 
approaches by comparing the number of developed oocysts in mosquitoes fed 
with test versus control serum. Serum from malaria endemic populations may 
reduce malaria transmission and this activity is associated with antibodies 
against sexual stage specific parasite antigens 93,95-98. Two main groups of 
antigens are potential targets for human sexual stage immune responses: pre-
fertilisation and post-fertilisation antigens. Antibodies against pre-fertilisation 
antigens such as Pfs230 and Pfs48/45 can block malaria transmission by 
preventing the formation of zygotes in the mosquito midgut 93,95,96,98. Post-
fertilisation antigens are involved in the sporogonic development after zygote 
formation. Antibodies against Pfs25, the most extensively studied post-
fertilisation antigen, can prevent the penetration of ookinetes through the 
midgut epithelium 102-104. The development of naturally occurring sexual stage 
immunity appears to differ from asexual stage immunity 91,105-107, but little is 
known about the acquisition and longevity of sexual stage antibodies. Most 
available data is derived from cross-sectional studies in microscopically 
confirmed gametocyte carriers. Studies in the general population and 
longitudinal studies are scarce. 
 
 
Outline of this thesis 
This thesis deals with four aspects of malaria transmission: i) the epidemiology 
of gametocytaemia, ii) the relation between gametocyte density and malaria 
transmission, iii) the influence of antimalarial drug treatment and treatment 
failure on gametocytaemia and malaria transmission and iv) human immune 
responses influencing malaria transmission. Both microscopy and QT-NASBA are 
used to determine gametocyte carriage and chapters are organised based on 
detection method: studies using microscopy are followed by studies using QT-
NASBA. 
 
i) the epidemiology of gametocytaemia 
The objectives are to determine: 
o risk factors for microscopic gametocytaemia in asymptomatic individuals 
(chapter 2) 
o the prevalence of (sub-)microscopic gametocytaemia in symptomatic 
individuals (chapter 5,6) 
Chapter 1 
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o the prevalence of (sub-)microscopic gametocytaemia in the general 
population (chapter 8) 
 
ii) the relation between gametocyte density and malaria transmission 
The objectives are to determine: 
o the relation between (sub-)microscopic gametocyte density and mosquito 
infection rates (chapter 7) 
o the relevance of submicroscopic gametocytaemia for malaria transmission 
in symptomatic malaria patients (chapter 6,7) 
 
iii) the influence of antimalarial drug treatment and treatment failure on 
gametocytaemia and malaria transmission 
The objectives are to determine: 
o the relation between parasite resistance to sulphadoxine-pyrimethamine 
and gametocytaemia (chapter 2-4) 
o the impact of antimalarial drugs on (sub-)microscopic gametocytaemia 
(chapter 5,6)  
o the impact of antimalarial drugs on post-treatment malaria transmission 
(chapter 6) 
 
iv) human immune responses influencing malaria transmission  
The objectives are to determine: 
o the relation between exposure to malaria and sexual stage specific 
immunity (chapter 9,11,12)  
o the relation between age and sexual stage specific immunity (chapter 9-
12) 
o the longevity of sexual stage specific immunity (chapter 11) 
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Summary 
Studies on Plasmodium falciparum gametocyte development and dynamics have 
almost exclusively focused on patients treated with antimalarial drugs, while the 
majority of parasite carriers in endemic areas are asymptomatic. This study 
identified factors that influence gametocytaemia in asymptomatic children in the 
absence and presence of sulphadoxine –pyrimethamine (SP) antimalarial 
treatment. 
A cohort of 526 children (6 months – 16 years) from western Kenya was 
screened for asexual parasites and gametocytes and followed weekly up to four 
weeks. Children with an estimated parasitaemia of ≥1,000 parasites/μl were 
treated with SP according to national guidelines. Factors associated with 
gametocyte development and persistence were determined in untreated and SP-
treated children with P. falciparum mono-infection. 
Gametocyte prevalence at enrolment was 33.8% (22/65) in children below 
five years of age and decreased with age. In the absence of treatment 18.6% of 
the children developed gametocytaemia during follow-up; in SP-treated children 
this proportion was 29.8%. Age, high asexual parasite density and gametocyte 
presence at enrolment were predictive factors for gametocytaemia. The 
estimated mean duration of gametocytaemia for children below five, children 
from five to nine and children ten years and above was 9.4, 7.8 and 4.1 days, 
respectively. 
This study shows that a large proportion of asymptomatic untreated 
children develop gametocytaemia. Gametocytaemia was particularly common in 
children below five years who harbour gametocytes for a longer period of time. 
The age-dependent duration of gametocytaemia has not been previously shown 
and could increase the importance of this age group for the infectious reservoir. 
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Introduction 
The transmission of Plasmodium falciparum parasites from humans to 
mosquitoes requires the presence of infectious gametocytes in the human 
peripheral blood. The prevalence of gametocytes is therefore commonly used as 
a parameter of malaria transmission. Any strategy that interferes with 
gametocyte development or persistence could result in a reduction of malaria 
transmission. For this purpose, it is important to identify parameters that 
influence gametocyte development as well as gametocyte dynamics under 
natural conditions. Although the majority of parasite carriers in endemic 
countries are asymptomatic 1, studies on gametocyte development and 
dynamics have almost exclusively focused on patients treated with antimalarial 
drugs 2-11. In these studies, gametocytaemia is influenced by the duration of 
symptoms 3,7, anaemia 4,7, type of antimalarial treatment 2,4,5,9, response to 
treatment 3,7,10 and the age of infected individuals 6,8,11. The relation between 
asexual parasites and gametocytes remains equivocal; a positive relation has 
been described between asexual parasite density at enrolment and gametocyte 
prevalence after treatment 6, but this was contradicted by several other studies 
2-4. 
In this study, we describe the dynamics of gametocytaemia in a cohort of 
asymptomatic children naturally exposed to malaria in western Kenya. Children 
with microscopically detectable parasitaemia were observed longitudinally. Those 
developing parasitaemia at levels requiring antimalarial treatment were treated 
with the first line drug sulphadoxine- pyrimethamine (SP). We identified factors 
associated with P. falciparum gametocyte production in the absence or presence 
of SP-treatment. Within the group of gametocyte carriers, we determined factors 
associated with gametocyte persistence. 
 
 
Methods 
Study area and design 
This five week study was conducted in October – November 2001 in Mbita and 
Lwanda, small rural villages on the shores of Lake Victoria in Suba district, 
western Kenya. The transmission of P. falciparum is variable, depending upon 
local environmental conditions that support mosquito populations. The 
entomological inoculation rate (EIR) was recently estimated at six infectious 
bites per person per month 12. Whilst variation in EIR may influence the clinical 
spectrum of malaria and gametocytaemia, it is unlikely to be a factor in this 
short study. Data were collected as described elsewhere (Chapter 3) 13. Briefly, 
apparently healthy children (aged six months – sixteen years) were recruited 
from primary schools and the community. Screening for asexual parasites and 
gametocytes of P. falciparum took place weekly for a period of five weeks. Finger 
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prick blood samples were collected and thick blood smears were dried, stained 
with 10% Giemsa and examined microscopically. A slide was considered 
negative if no asexual parasites were seen after examination of 100 fields. 
Gametocyte and asexual parasite densities were assessed by counting against 
500 and 200 leukocytes, respectively, and converted to numbers of parasites per 
μL by assuming a standard leukocyte count of 8,000/μL. Children with a positive 
blood smear with an estimated parasite density higher than 1,000 parasites/μL 
on the initial or any subsequent visits were treated immediately with 
pyrimethamine-sulphadoxine (SP) according to national guidelines. Only children 
who were treated once in the first or second week of the study were included in 
the analyses to achieve a minimum follow up period of three weeks. In case of 
treatment failure, alternative treatment was administered under supervision of 
the Clinical Officer. This resulted in the exclusion from the further study and 
follow-up. 
Children or guardians signed an informed consent form. This study was 
approved by the ethical committee of the Kenya Medical Research Institute 
(KEMRI) and by the National Institute of Health (NIH) ethical review board of the 
United States. 
 
Data analyses 
Children who presented on at least three consecutive visits were used for 
analyses. Those who reported the use of antimalarial drugs in the two weeks 
prior to enrolment or had a Plasmodium malariae mixed infection were excluded. 
The influence of age on transformed (natural logarithm) parasite densities was 
analysed in linear regression models. Discrete data were compared using chi-
square or Fisher's exact test, trends in binary outcomes using the Cochran-
Armitage test for trend. Predictive factors for gametocyte prevalence on days 
seven or fourteen were tested in non-treated and SP-treated children separately, 
using multiple regression models with SAS Generalized Estimating Equations 
(GEE). Presentation parasitaemia was included in the models as a continuous 
variable and non-parasitaemic children were excluded from the analyses. A 
random effect was included in the models to allow for correlations within 
individuals. The Kaplan-Meier estimator was used to determine the proportion of 
parasitaemic children developing gametocytaemia during the follow-up period. 
Only for this analysis, gametocyte carriers at enrolment were excluded. 
The duration of gametocytaemia in gametocyte carriers was estimated 
using the method described by Drakeley et al. 14, assuming that a single 
gametocyte positive slide represented gametocytes circulating in the peripheral 
blood for at least 2.5 days 15. When children had gametocyte positive blood films 
on successive weeks, the estimated duration of gametocytaemia was the interval 
between observations plus 2.5 days. 
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Results  
Gametocyte prevalence at enrolment was 33.8% (22/65) in children below five 
years of age and was negatively associated with age (table 2.1). Mean 
gametocyte density at enrolment was 24.5 (IQR 16–32) gametocytes/μL with no 
difference between age groups, whilst both asexual parasite prevalence and 
density decreased with age. SP treatment was given to 27.2% (143/526) of the 
children who presented with asexual parasites on the first or second visit with a 
geometric mean density of 1,108.0 (IQR 249–4,235) parasites/μL. A group of 
121 parasitaemic children exhibited relatively low parasitaemia at presentation 
(geometric mean density of 203.0 (IQR 80–400) parasites/μL) and was not 
given treatment throughout the study.  
The Kaplan-Meier estimator of time to gametocytaemia for these two 
groups of parasitaemic children is presented in figure 2.1.  
 
Table 2.1 Parasitological data at enrolment 
Age N 
Asexual parasite 
prevalence, 
 % (n)¥ 
Asexual parasite 
density,  
mean (IQR)† 
Gametocyte 
prevalence,  
% (n)¶ 
Gametocyte 
density,  
mean (IQR)‡ 
<5 years 65 
 
73.8  
(48) 
 
2302.4  
(530–14149) 
 
33.8  
(22) 
 
25.3  
(16–32) 
5–9 years 211 
 
50.2  
(106) 
 
357.8  
(120–1040) 
 
10.4  
(22) 
27.9  
(16–32) 
10–16 years 250 
 
30.4  
(76) 
 
202.7  
(80–440) 
 
5.2  
(13) 
 
18.8  
(16–23) 
Total 526 
 
43.7  
(230) 
 
444.8  
(120–1220) 
 
10.8  
(57) 
 
24.5  
(16–32) 
IQR = interquartile range ¥ Cochran-Armitage test for age-dependent trend in prevalence of 
asexual parasites (Z = -6.75, P < 0.001). † Geometric mean of parasite carriers only 
(parasites/μl). Linear regression for log-transformed asexual parasite density and age groups, β = 
-1.155; se = 0.147, P < 0.001. ¶ Cochran-Armitage test for age-dependent trend in prevalence of 
gametocytes (Z = -5.91, P < 0.001). ‡ Geometric mean of gametocyte carriers only (parasites/μL). 
Linear regression for log-transformed gametocyte density and age groups, β = -0.123; se = 
0.166, P = 0.46. 
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At the end of the four week follow-up period, the cumulative proportion of 
gametocytaemia was lower in children not receiving antimalarial treatment than 
in SP treated children, 18.6% and 29.8%, respectively. In both groups, 
gametocyte prevalence during the first two weeks of follow-up was 
independently associated with several factors (table 2.2).  
 
Figure 2.1 The cumulative proportion of gametocytaemia in SP-treated and untreated 
children. Kaplan-Meier estimator of the time to gametocytaemia for untreated children (dotted 
line) and SP-treated children (solid line). Groups differed in asexual parasite density at enrolment. 
Patients with incomplete follow-up are marked on the curve. Gametocyte carriers on day 0 were 
excluded, as well as children who reported the use of antimalarial drugs prior to enrolment. Log-
rank P = 0.05 
 
The risk for gametocytaemia during follow-up was positively associated 
with asexual parasite density at enrolment and negatively with age. Children 
with detectable gametocytes at enrolment were more likely to show 
gametocytes during follow-up, after adjustment for age and asexual parasite 
density at the start of treatment. In children who received SP treatment, the 
probability of gametocyte prevalence seemed higher on day seven after 
treatment compared to day fourteen, although this was not statistically 
significant. R1 resistance did not increase the risk of gametocytes during follow-
up while R2/R3 resistance did show such an association, OR 3.40 (95% CI 1.61–
7.19). The estimated mean duration of gametocytaemia was 9.4 days (range 2.5 
– 23.5) for children below five years of age, 7.8 days (range 2.5 – 23.5) for 
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children aged five to nine years and 4.1 days (range 2.5–16.5) for children aged 
ten years and above. The duration of gametocytaemia was negatively associated 
with age (β = -1.65, se = 0.73; p = 0.02), after adjustment for asexual parasite 
density and gametocyte density at enrolment. Treatment with SP did not 
independently influence the duration of gametocytaemia. 
 
Table 2.2 Adjusted odds ratio (OR) of the probability of gametocyte prevalence, using a 
multivariate random effect logistic model for untreated and SP-treated children 
separately. 
Risk factors for gametocytaemia Adjusted OR (95% CI) 
  No treatment Treatment with SP 
    
Day of follow-up Day 7 1.48 (0.62 – 3.56)¥ 1.77 (0.93–3.34)¥ 
 Day 14 1 (ref) 1 (ref) 
    
Age <5 years 6.34 (1.15–34.90) 5.38 (1.91–15.17) 
 5–9 years 3.07 (0.98–9.55)¥ 3.22 (1.19–8.72) 
 10–16 years 1 (ref) 1 (ref) 
 
Asexual parasite density 
at enrolment 
Per 100 parasites/μL 1.05 (1.00–1.11) 1.01 (1.00–1.01) 
 
Present 
Absent 
 
3.35 (1.22–9.18) 
1 (ref) 
 
4.12 (2.11–8.02) 
1 (ref) 
Gametocyte prevalence 
at enrolment 
   
 
SP treatment  
 
R2/3 resistance 
 
- 
 
3.40 (1.61–7.19) 
outcome Rl resistance - 1.06 (0.45–2.47)¥ 
 Adequate response - 1 (ref) 
Adjusted = adjusted for all other variables in the model, OR = odds ratio, CI = confidence interval, 
ref = reference group, ¥ = not statistically significant, - = not applicable. A GEE model was used to 
allow for correlation between observations from the same individuals. Children reporting the use of 
antimalarial drugs prior to enrolment were excluded from these analyses. 
 
 
Discussion  
This descriptive study on the largely neglected group of asymptomatic children 
was part of a larger study on SP and gametocytes. A direct comparison between 
SP-treated and untreated children was not the aim of the current study and 
would require a different study design. SP-treated and untreated children 
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differed with regards to treatment and asexual parasite density at enrolment and 
were therefore analysed separately. 
In this study, 18.6% of the asymptomatic non-treated children developed 
gametocytaemia during a four week follow-up period. Gametocytaemia was 
particularly common in children <5 years of age, of whom one-third were 
already carrying gametocytes on enrolment. The high gametocyte prevalence in 
young children is in line with previous findings 6,11, although the longer duration 
of gametocytaemia for this age group has not been reported before. The age 
dependent duration of gametocytaemia could not be explained by asexual 
parasitaemia, gametocyte density or SP treatment, suggesting a role for age-
dependent immune suppression of gametocytaemia. Acquired sexual stage 
specific immunity has previously been reported to influence gametocyte 
prevalence 16, but remains poorly defined. Although the exact duration of 
gametocytaemia could not be determined because of weekly intervals in data-
collection, the longer estimated duration of gametocytaemia in the youngest age 
group combined with their higher gametocyte prevalence could increase the 
importance of this age group for the infectious reservoir in this area. The 
importance of children as the infectious reservoir has been stressed elsewhere 
17.  
Differences in gametocytaemia during follow up between SP-treated and 
untreated children should be interpreted carefully since they are at least partially 
explained by differences in asexual parasite density at enrolment. The observed 
peak in gametocytaemia on day seven after SP treatment has been previously 
described 3-6 and may include gametocytes circulating prior to treatment since 
seven days may be short for gametocytogenesis, as was suggested by in vitro 
observations 18. This study determined predictive factors for gametocytaemia for 
SP-treated and untreated children independently and found that risk factors 
were similar in both groups. Age and gametocyte presence at enrolment were 
previously described as predictors for gametocytaemia in symptomatic treated 
children 4,6-8,11. Asexual parasitaemia at enrolment was positively associated with 
gametocytaemia during follow-up. Other studies 2-4 may not have found such an 
association because they only included patients with a high parasitaemia, 
resulting in little variation in asexual parasite density. Parasitological treatment 
failure was an important predictor of gametocytaemia in the SP-treated group 
(Chapter 3) 13. 
 
This study shows that many asymptomatic children develop gametocytes, 
even in the absence of treatment. Gametocyte prevalence is especially high in 
children below five years of age who also appear to harbour gametocytes for a 
longer period of time. Risk factors for gametocytaemia are similar to those 
Gametocytes in asymptomatic children 
31 
described in symptomatic children and do not appear to differ between treated 
and untreated children. 
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Summary 
Sub-Saharan Africa faces increasing levels of resistance of Plasmodium 
falciparum parasites to the first-line drug sulphadoxine- pyrimethamine (SP). 
Successful treatment with SP is reported to induce gametocytes and drug-
resistance may further increase gametocytaemia after treatment.  
Treatment success, gametocyte prevalence and gametocyte density were 
determined in 224 asymptomatic children in western Kenya on day 7 after 
treatment with SP. Treatment failure (R2 or R3 resistance) was observed in 22% 
(49/224) of the children. The risk to show gametocytes on day 7 after treatment 
was higher in children with treatment failure compared to children with a 
sensitive infection, odds ratio 4.1 (95% CI 1.4-11.6) after adjustment for age 
and trophozoite density at the start of treatment. In addition, gametocyte 
density was also higher upon SP treatment failure.  
These findings are reason for concern since the increased gametocyte 
prevalence and density after SP treatment failure may increase the spread of 
SP-resistant parasite strains in the population. 
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Introduction 
Chloroquine (CQ) resistance is a major problem in treating malaria in sub-
Saharan Africa and many countries have switched to sulphadoxine-
pyrimethamine (SP), which is an affordable alternative 1. In Kenya, SP was 
chosen to replace CQ as the first-line anti-malarial drug in treating 
uncomplicated malaria in 1997 2. SP rapidly eliminates Plasmodium falciparum 
parasites and ensures an infection-free period for the host through its long 
residual time in the body; however this long residual time may enhance the 
selection of resistant parasite strains 3.  
While it has been suggested that the prevalence and density of 
gametocytes in the population can be reduced following treatment of asexual 
stages 4,5, other studies report that P. falciparum chemotherapy with SP 
promotes the appearance of gametocytes 6-8. Parasite resistance against SP is 
becoming increasingly common 2,9 and may further increase gametocytaemia 
and transmission. Recrudescent infection is a known risk factor for gametocyte 
carriage after treatment 10 and increased gametocytaemia and transmission 
have been clearly described in CQ resistant infections 8,11,12. While an opposite 
effect was suggested for SP resistance 13, recent studies indicate that SP 
treatment failure can also result in a higher gametocyte prevalence but not in a 
higher gametocyte density 11,14.  
In this study, we establish the level of SP treatment failure in a rural area 
in western Kenya and the prevalence and density of gametocytaemia in SP-
sensitive and SP-resistant infections. 
 
 
Methods 
This study was conducted in Mbita and Lwanda, small rural villages on the 
shores of Lake Victoria in Suba district, western Kenya. The transmission of P. 
falciparum is highly variable and the entomological inoculation rate (EIR) was 
recently estimated at 6 infectious bites per person per month 15 
A cohort of apparently healthy children was recruited from primary 
schools within the compound of the ICIPE Mbita Point Field Station and the 
surrounding community. Screening for asexuals and gametocytes of P. 
falciparum took place weekly for a period of 5 weeks. Finger prick blood samples 
were collected and thick blood smears were dried, stained with 10% Giemsa and 
examined microscopically. A slide was considered negative if no asexual 
parasites were seen after examination of 100 fields. Gametocyte and trophozoite 
densities were assessed by counting against 500 and 200 leukocytes, 
respectively. Gametocyte and trophozoite counts were converted to numbers of 
parasites per μL by assuming a standard leukocyte count of 8000/μL 16. Children 
with high blood parasitaemia (≥3000/μL) or with concomitant diseases requiring 
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hospitalisation were referred to the Mbita Health Centre but were excluded from 
this study. The inclusion criterion for the study was a positive blood smear with 
an estimated parasite count between 1000-3000 parasites/μL. Children fulfilling 
this criterion were referred and accompanied to the Mbita Health Centre for first 
line anti-malarial treatment with sulphadoxine- pyrimethamine (SP) and follow-
up. Drug administration was supervised in close collaboration with the Clinical 
Officer at the Mbita Health Centre and the administered dosage was 0,5 tablet 
500/25 mg SP per 10 kg bodyweight, according to the National Malaria 
Treatment Guidelines.  
Information about previous SP use and the duration of symptoms was 
recorded in a short questionnaire. Selected children were followed up for 5 
weeks to study the dynamics of gametocytaemia. In this study, we determined 
the effect of SP on gametocyte prevalence and density on day 7 after treatment, 
comparing sensitive infections and treatment failures. SP sensitive infection was 
defined as the clearance of asexual parasites by day 7 after treatment. If 
parasites were still present on day 7, treatment was considered a failure and 
children were referred to the health centre for appropriate alternative treatment. 
Alternative treatment was installed under supervision of the Clinical Officer 
according to the National Malaria Treatment Guidelines. The outcome of this 
study was success or failure of the initial treatment; children were not monitored 
after this. In terms of WHO standards, this study compares sensitive and R1 
resistant infections with R2 and R3 resistant infections 17. To study the effects of 
SP on gametocytaemia, children without any detectable level of gametocytaemia 
at the start of treatment and without reported use of SP in the two weeks prior 
to the screening were selected and followed up for 7 days after treatment. 
Children or guardians were asked to sign an informed consent form. This 
study was approved by the ethical committee of the Kenya Medical Research 
Institute (KEMRI) and by the National Institute of Health (NIH) ethical review 
board of the United States. 
 
Statistical analysis 
Differences between the sensitive and treatment failure group in baseline 
parameters were tested for statistical significant differences using the non-
parametric Wilcoxon-rank sum test in case of continuous variables and the 
Fisher's exact test in case of dichotomous variables. Geometric means of 
trophozoite and gametocyte densities were calculated using the geometric mean 
of Williams [exponential (arithmetic mean (Loge (xi + 1)))-1]. Multiple logistic 
and linear regression models were used to test differences between the sensitive 
and treatment failure group on day 7 after treatment, allowing adjustment for 
potential confounders. All variables that altered the regression coefficient for 
treatment success were entered in the regression model as covariables. The 
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dependent variable in the logistic regression models was the presence or 
absence of gametocytes. Crude and adjusted odds ratios (OR) with 95% 
confidence intervals (95% CI) were presented. The dependent variable in the 
linear regression model was the log-transformed gametocyte density with a 
detection level of 16 gametocytes/μL. For non-gametocyte carriers, a 
gametocyte density of 1 gametocyte/μL was assumed to allow log-
transformation. Crude and adjusted relative differences with 95% CI were 
presented.  
 
 
Results 
A total of 843 children were included in the study, with a mean age of 7.7 years 
(range 0-16 years). Asexual parasite prevalence at first visit was 49.0% 
(350/715), gametocyte prevalence 16.8% (120/715). During the study 224 
children with estimated asexual parasite counts ≥1000/μL were treated for 
uncomplicated malaria with SP. A total of 78% (175/224) of the children 
responded well to the therapy and the remaining 22% (49/224) still had 
detectable asexual parasites on day 7 after treatment.  
The prevalence of gametocytes clearly differed between the sensitive and 
the treatment failure group (table 3.1).  
 
Table 3.1. Comparison of malariometric indices between SP-treatment success and 
failure. 
 SP-treatment outcome on day 7  
 Success Failure P-value 
N 120 28  
Age, mean (25-75th percentiles) 8.3 (5.0-12.0) 6.9 (3.3-10.8) 0.09 
Sex, male (%) 56 (46.7) 14 (50.0) 0.84 
Trophozoite density/μL on day 0, 
geometric mean (25-75th percentiles) 
1,265.6  
(520 – 3,240) ¥ 
2,095.2  
(766-5,389) ¥ 
0.048 
Prevalence of gametocytes on d7 (%) 13 (10.8) 10 (35.7) 0.001 
Gametocyte density/μL on d7, 
geometric mean (range) 
0.41 (0 – 112) ¥  2.37 (0 - 64) ¥ 0.001 
¥ Geometric mean of Williams. Children with gametocytes at enrolment were excluded (n = 76). 
 
The risk to show gametocytes on day 7 after treatment in children with 
treatment failure was higher compared to children with a sensitive infection, 
after adjustment for age and trophozoite density at the start of treatment, OR 
4.1 (95% CI 1.4-11.6). Fever at the start of treatment (>37.4°C) did not 
confound the relation and was not included in the regression model. Next to the 
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increased gametocyte prevalence, gametocyte density also appeared to be 
higher upon unsuccessful SP treatment. On average, the gametocyte density 
was 2.1 (95% CI 1.3-3.3) times higher following SP treatment failure, after 
adjustment for age and trophozoite density at the start of treatment (table 3.2).  
 
Table 3.2 Comparison of gametocytaemia and gametocyte density on day 7 after 
treatment between SP-treatment success and failure. 
 Treatment outcome on day 7 
 Success Failure 
Risk of gametocytaemia    
 Crude OR (95% CI) 1.00 (ref) 4.6 (1.7-12.0) 
 Adjusted OR (95% CI) 1.00 (ref) 4.1 (1.4-11.6) ¥ 
Gametocyte density    
 Crude relative difference (95% CI) 1.00 (ref) 2.4 (1.5-3.9) † 
 Adjusted relative difference (95% CI) 1.00 (ref) 2.1 (1.3-3.3) ¥, † 
OR = odds ratio, 95% CI = 95% confidence interval. ¥After adjustment for age and trophozoite 
density at the start of treatment. †For non-gametocyte carriers, a density of 1 gametocyte/μL was 
assumed to allow log-transformation. 
 
Discussion 
The high level of treatment failure (R2 and R3 resistance) of SP that was 
observed in this study is comparable with SP resistance rates recently found in 
Kenya, ranging from 9.5% to 34.5% 2,18. Children with treatment failure were 
more likely to show gametocytes on day 7 after treatment than children with a 
sensitive infection.  
 
The increased risk of gametocytaemia and the elevated gametocyte 
density for treatment failure could not be explained by differences in age, 
trophozoite density or by the previous use of SP. Duration of parasitaemia and 
symptoms before treatment could also influence gametocytaemia 8,10,11 but were 
not known for the majority of children. The latter was probably not relevant in 
this study, considering the asymptomatic status of the children at enrolment.  
The observed increased risk of gametocytaemia following SP treatment failure is 
in line with recent observations 11,14, the higher gametocyte density was not 
found in a previous study 11.  
Although the exact influence of SP on the process of gametocytogenesis 
remains unclear, the higher prevalence of gametocytes after SP treatment 
failure is certainly reason for concern. While the infectiousness of SP resistant 
gametocytes remains to be established, a strong suggestion for an increased 
transmission comes from the finding that the elevated gametocyte prevalence 
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after successful SP treatment in comparison with CQ treatment results in a 
higher estimated average probability of transmission at a population level 6. This 
study clearly suggests that parasite resistance for SP could worsen the situation 
by further increasing the risk of gametocytaemia and thereby possibly the 
transmission of SP resistant parasites. 
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Summary 
Both use of sulphadoxine-pyrimethamine (SP) and SP-resistance of Plasmodium 
falciparum are increasing in sub-Saharan Africa. Mutations in the P. falciparum 
dihydrofolate reductase (dhfr) and dihydropteroate synthase (dhps) genes can 
predict treatment failure of SP, however, the degree of this relationship varies 
regionally. In northern Ghana, pre-treatment dhfr/dhps genotypes were 
examined in 126 children and associations with PCR-corrected SP treatment 
outcome and gametocyte carriage were analysed.  
 SP treatment failure within four weeks of follow-up occurred in 28% 
(35/126) of the children. Among all pre-treatment isolates, the dhfr triple 
mutation (Ile-51+Arg-59+Asn-108) was detected in 47%. As compared to dhfr 
wildtype parasites, the presence of the dhfr triple mutation increased the risk of 
treatment failure ten-fold. Likewise, parasite clearance was delayed in the 
presence of dhfr variants. Dhfr mutants and dhps Gly-437 were selected in 
treatment failure isolates. Gametocytaemia one week following treatment was 
strongly associated with dhfr mutations. Remarkably, this was also true for the 
prevalence of gametocytes at recruitment. Dhps alleles did neither influence 
treatment outcome nor gametocyte carriage. 
 In northern Ghana, the prevalence of the dhfr triple mutation can be used 
as a tool to screen for and to monitor SP resistance. The lack of association 
between dhps alleles and SP treatment outcome suggests a minor role of these 
molecular markers in this region at present. 
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Introduction 
Facing the aggravation of chloroquine (CQ) resistance 1, sulphadoxine-
pyrimethamine (SP) has evolved into the first-line drug for uncomplicated 
malaria in several African countries. However, considering the ease of selecting 
resistant Plasmodium falciparum by SP pressure and the increasing spread and 
intensity of resistance, this drug is feared to have a short useful therapeutic life 
in Africa 2-5. In Ghana, two recent trials demonstrated SP treatment failure 
within two weeks in 14% and 22% of the treated individuals 6,7. Currently, 
amodiaquine-artesunate is being introduced as first-line antimalarial in this 
country 8. Nevertheless, because SP is comparatively cheap and much if not 
most of antimalarial treatment is home-based 9 the drug's usage may still 
continue. Moreover, SP is used in intermittent preventive treatment in 
pregnancy 10 and, possibly, in infancy 11. Monitoring SP resistance thus remains 
an important task. Molecular markers of SP resistance, i.e. mutations in the 
parasite's dihydrofolate reductase and dihydropteroate synthase genes (dhfr, 
dhps), are easy and relatively cheap to assess and reasonably predictive for 
treatment outcome. A dhfr codon 108 exchange (Ser-108 → Asn-108) 
represents the core mutation which in the presence of Ile-51 and Arg-59 confers 
pronounced resistance to pyrimethamine and predicts SP treatment failure in 
some areas. Thr-108 or Val-16 in combination with Asn-108 are linked with 
resistance to cycloguanil, and Leu-164 in addition to the dhfr triple mutation 
(Asn-108+Ile-51+Arg-59) with high-grade resistance to pyrimethamine. As for 
dhps, mutant Gly-437 is associated with sulphonamide resistance while 
additional changes (436-Ala, 540-Glu, Gly-581, 613-Ser) appear to increase its 
degree (reviewed in 12).  
The predictive value of these markers varies geographically, depending on 
baseline prevalences, age and immunity 13-15. Dhfr/dhps patterns have not been 
related to SP treatment outcome in Ghana where the drug has served as a 
second-line antimalarial so far. Moreover, while gametocyte carriage is known to 
be elevated following SP failure (Chapter 3)16, dhfr mutants were associated with 
increased gametocytaemia despite a high therapeutic efficacy of SP in Colombia 
17. In northern Ghana, we examined associations of dhfr/dhps mutations with SP 
treatment outcome and with pre- and post-treatment gametocyte carriage. 
 
Methods 
P. falciparum isolates were obtained from children with uncomplicated malaria 
who participated in a randomised, placebo-controlled, and double-blind 
treatment trial on SP, SP plus amodiaquine, and SP plus artesunate. That trial 
was conducted at the end of the rainy season of 2002 (August – December), in 
Tamale, Northern Region, Ghana, and the results are described elsewhere 6. In 
the present report, data from 126 children with complete clinical and 
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parasitological follow-up of four weeks after treatment with SP alone are 
analysed. The study protocol was approved by the Ethics Committee, Ministry of 
Health, Tamale, Northern Region, by the Health Research Unit, Ministry of 
Health, Accra, and by the World Health Organization Secretariat Committee on 
Research Involving Human Subjects. Written informed consent of patients' 
parents was obtained. 
Patients were febrile children aged 6 to 59 months with P. falciparum 
monoinfection (≥2,000 ≤200,000/μL; WHO 2002). None had severe malnutrition, 
a febrile disease other than malaria, “danger signs” 18, severe malaria 19, severe 
anaemia (haemoglobin (Hb) < 5 g/dl), or a history of hypersensitivity to SP. 
Patients with mixed Plasmodium species infections or developing a concomitant 
disease during follow-up were excluded from analysis. Treatment consisted of a 
single dose of SP (25/1.25 mg/kg, Fansidar, Roche, Switzerland). Children were 
observed for at least 30 minutes. If vomiting occurred, treatment was repeated. 
Paracetamol was given on days 0, 1, and 2 if the axillary temperature was 
>38°C. Patients were examined clinically and parasitologically on days 0, 1 (only 
clinically), 2, 3, 7, 14, 21, 28, and at unscheduled visits in case of fever.  
Therapeutic outcome during four weeks of follow-up was classified into 
early treatment failure (ETF), late clinical failure (LCF), late parasitological failure 
(LPF) or adequate clinical and parasitological response (ACPR)20. Mefloquine 
(Lariam, Roche, Switzerland; 15 mg/kg on first day and 10 mg/kg on second 
day) was given in case of treatment failure.  
Venous blood was collected. Asexual parasites and gametocytes (only 104 
samples available for this purpose on day 7) were counted per ≥200 and 500 
white blood cells, respectively, on Giemsa-stained thick blood films, and 
densities were calculated based on a putative mean WBC count of 8,000/μL. Pre-
treatment levels of CQ and pyrimethamine in blood were assessed by ELISA 
assays with lower limits of detection of 10 ng/mL and 25 ng/mL, respectively 
21,22. Hb concentrations were measured by a HemoCue photometer (Ångelholm, 
Sweden). DNA was extracted by commercial kits (QIAmp, Qiagen, Germany). 
Differentiation of recrudescence from new infection was achieved by comparing 
PCR-generated msp1 and msp2 genotype patterns in matched pairs of isolates 
obtained on admission and on the day parasitemia reappeared 23.  
P. falciparum dhfr and dhps alleles were identified by restriction fragment 
length polymorphisms of PCR-generated amplicons 24. Genotyping included: 
dhfr: Ser-108 → Asn-108, Ser-108 → Thr-108, Asn-51 → Ile-51, Cys-59 → Arg-
59, Ala-16 → Val-16, Ile-164 → Leu-164; dhps: Ser-436 → Ala-436, Ala-437 → 
Gly-437, Lys-540 → Glu-540, Ala-581 → Gly-581, and Ala-613 → Ser-613. 
Frequencies were compared by χ2-tests or Fisher's exact tests, and 
continuous variables by Student’s t-tests, Mann-Whitney U-tests, or Kruskal-
Wallis tests as applicable. To estimate the risk of treatment failure, mixed alleles 
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(both wildtype and mutant allele present) were considered mutant. A p-value < 
0.05 was considered statistically significant. 
 
 
Results 
The baseline characteristics of the 126 patients are shown in Table 4.1 and the 
distribution of dhfr and dhps alleles in Figure 4.1. Dhfr Thr-108, Val-16, and Leu-
164 were not detected. Assigning mixed alleles as mutant, Ile-51, Arg-59, and 
Asn-108 occurred in 56% (70/126), 65% (82/126), and 72% (91/126) of the 
isolates, respectively. Figure 4.2 illustrates the grouping of dhfr alleles for 
further analysis. Isolates with the dhfr triple mutation were seen in 47% 
(59/126), and quadruple (dhfr triple + dhps Gly-437) and quintuple (dhfr triple 
+ dhps Gly-437 + Glu-540) variants in 44% (55/126), and 0.8% (1/126), 
respectively. 
 
Table 4.1. Baseline characteristics of 126 Ghanaian children with uncomplicated malaria 
Parameter  Value 
No.  126 
Female : male  68 : 58 
Age in months, median(range)  28.5 (6-59) 
Weight in kg, median (range)  10.4 (5.5-19.1) 
Axillary temperature, median in °C (range) 38.8 (37.5-41.0) 
Haemoglobin level, median in g/dL (range) 8.0 (5.0-12.9) 
Geometric mean parasite density/µL (range) 36,358 (2,068-175,333) 
Pre-treatment gametocytes   
 Prevalence, % (n/N) 19 (24/126) 
 Geometric mean density/µL (range) 50 (16-1,120) 
Pre-treatment chloroquine   
 Prevalence, % (n/N) 66 (83/126) 
 Median concentration, ng/mL (range) 32 (10-718) 
Pre-treatment pyrimethamine   
 Prevalence, % (n/N) 1.6 (2/126) 
 Concentrations, ng/mL 78 & 326 
PCR-corrected treatment outcome within 4 weeks  
 Early treatment failure, % (n/N) 5.6 (7/126) 
 Late clinical failure, % (n/N) 3.2 (4/126) 
 Late parasitological failure, % (n/N) 19 (24/126) 
 Adequate clinical and parasitological response, % (n/N) 72.2 (91/126) 
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SP treatment failure was strongly associated with the dhfr mutations. The mere 
presence (as compared to absence) of the core mutation Asn-108 and of the 
triple dhfr mutation effected ORs (95%CIs) for treatment failure of 4.0 (1.2-
16.9) and 2.9 (1.2-7.2), respectively. The risk estimate improved when 
comparing triple mutant strains to dhfr wildtype parasites (Table 4.2; positive 
predictive value, 39%; 95%CI, 32-42%; negative predictive value, 94%; 
95%CI, 81-99%).  
Figure 4.1. Prevalence of dhfr and dhps alleles in 126 Ghanaian children.  
 
 
  dhfr codon  No.    
  51 59 108      
          
dhfr wildtype      32    
dhfr single/double mutation      3    
      1    
      8    
      23   mutation 
dhfr triple mutation      59   wildtype 
 
Figure 4.2. Scheme of grouping dhfr alleles. 
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Table 4.2. Associations between dhfr/dhps alleles and sulfadoxine-pyrimethamine 
treatment failure in 126 Ghanaian children 
No. No.  
Mutation Failure  ACPR  
 
OR (95%CI) 
 
P 
Sensitivity  
(95%CI) 
Specificity  
(95%CI) 
dhfr        
 WT  2 30 1    
 S or D 10 25 6.0 (1.1-59.9) 0.02 83 (54-97) 55 (48-58) 
 T 23 36 9.6 (2.0-88.7) 0.0008 92 (75-99) 46 (39-48) 
       
dhps¥        
 WT 4 12 1    
 S (Gly-437) 31 77 1.2 (0.3-5.5) 1.0 89 (77-96) 14 (9-16) 
       
dhfr/dhps combinations       
 dhfr WT 2 30 1    
 dhfr S/D + dhps S  8 21 5.7 (1.0-58.9) 0.04 80 (47-96) 59 (52-62) 
 dhfr T + dhps S 22 31 10.7 (2.2-98.9) 0.0005 92 (74-99) 49 (42-52) 
APCR = adequate parasitological and clinical response within four weeks of follow-up; OR = odds 
ratio; 95%CI = 95% confidence interval; WT = wildtype; S = single mutation; D = double 
mutation; T = triple mutation. ¥dhps WT, wildtype alleles at codons 437, 540, 581, codons 436, 
613 disregarded; dhps S, Gly-437, codons 540, 581 WT, codons 436, 613 disregarded 
 
Adjusting for sex, pre-treatment CQ, pyrimethamine and parasite density (all not 
associated with treatment outcome) in a logistic regression model did not 
change these associations substantially (data not shown). After adjusting for age 
(in months, odds ratio (OR), 1.05; 95%CI, 1.02-1.08), the risk of treatment 
failure was increased nine-fold (OR, 8.6; 95%CI, 1.6-46.0; P = 0.01) and 
fifteen-fold (OR, 14.9; 95%CI, 3.0-74.0; P = 0.001) in children harbouring 
strains with dhfr single/double mutations and with the dhfr triple mutation, 
respectively, as compared to dhfr wildtype infections. When considering only 
failures occurring within the first two weeks of follow-up in this model (n = 19), 
the risk estimates were similar (single/double mutation, OR, 9.3; 95%CI, 1.0-
86.8; P = 0.05; triple mutation; OR, 11.9; 95%CI, 1.4-101.7; P = 0.02). ETF 
was not predicted by any of the dhfr variants, the prevalence of isolates with the 
dhfr triple mutation in this group being 43% (3/7) compared to 40% (36/91) in 
ACPR (late failures, 71%, 20/28). The impact of dhfr mutations on parasite 
clearance is shown in Figure 4.3. Parasitaemia following SP treatment was more 
common in case of dhfr mutant parasites than with wildtype infections for all but 
one day of follow-up. 
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Figure 4.3. Proportion of parasitaemic children following treatment according to dhfr 
genotype of infecting parasite strains. Triangles indicate dhfr triple mutation, squares 
single/double mutation and circles wildtype. Four re-infections were not considered. *wildtype vs. 
single/double mutant, P < 0.05; †wildtype vs. triple mutant, P < 0.05 
 
None of the dhps alleles was associated with treatment outcome 
(presence vs. absence, OR (95%CI), Ala-436, 1.3 (0.2-5.4); Gly-437, 1.2 (0.3-
5.4); Ser-613, 0.2 (0-1.6)). Glu-540 and Gly-581 were too rare (one each) for 
sensible analysis. None of the dhps mutations significantly affected parasite 
clearance or substantially improved the predictive value of the dhfr alleles; 
results for Gly-437 are shown in Table 4.2. Albeit, Gly-437 was found at a 
significantly higher frequency in isolates obtained at treatment failure comparing 
to all recruitment isolates (P = 0.02) as was the case for all dhfr variants. 
Comparing the 35 pairs of recruitment and failure isolates, the increase in 
prevalence of Gly-437 was at borderline significance (P = 0.07; Figure 4.4).  
Pre-treatment gametocyte carriage was associated with dhfr mutations, 
the highest prevalence of 29% occurring in children harbouring strains with 
triple mutations (Table 4.3). Gametocytaemia on day 7 after treatment was seen 
in 63% of the individuals and was also associated with dhfr variants, adjusting 
for the presence of gametocytes at enrolment (Table 4.3). Age, asexual 
parasitaemia at enrolment and previous drug use did not confound this relation. 
No associations between dhfr alleles and gametocyte density was observed. 
Dhps alleles were not associated with gametocyte prevalence or density at any 
time (data not shown). 
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Figure 4.4 Prevalence of Plasmodium falciparum dhfr/dhps mutations in isolates 
obtained at recruitment and at treatment failure in 35 children. *P = 0.02 (McNemar paired 
test, exact significance probability)  
 
 
Table 4.3. Associations of dhfr alleles with gametocyte prevalence at enrolment and one 
week following treatment 
 
Enrolment (n = 126)  Day 7 after treatment (n = 104) 
dhfr 
mutation 
Gametocyte 
prevalence (%) 
OR (95%CI) P  
Gametocyte 
prevalence (%) 
OR  
(95%CI)† 
P 
wildtype 9.4  
(3/32) 
1 -  43.3  
(13/30) 
1 - 
        
single or 
double 
11.4  
(4/35) 
1.3  
(0.2-9.2) 
1  80.8  
(21/26)* 
5.7  
(1.7-19.4) 
0.006 
        
triple 28.8  
(17/59) 
3.9  
(1.0-22.4) 
0.03  66.7  
(32/48)* 
2.1  
(0.8-5.7) 
0.12 
OR = odds ratio; 95%CI = 95% confidence interval; *P < 0.05 (univariate analysis); †adjusted for 
enrolment gametocytaemia (OR, 4.1; 95%CI, 1.0-22.9). 
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Discussion 
In this study in northern Ghana, we show that the mere presence of the dhfr 
triple mutation confers a three-fold increased risk of treatment failure. In 
comparison to dhfr wildtype parasites, this risk is increased ten-fold. The 
relatively low specificity points to additional factors involved in treatment 
success, e.g. drug absorption, immunity, folate levels 25,26, parasite density 27, 
and impairs a reliable prediction of the individual treatment outcome. Inclusion 
of the above named and further factors in analysis would increase the precision 
of predicting resistance. However, in practice, moleculars marker need to be 
simple and easy to apply. Also for feasibility, we categorized mixed genotypes 
(both wildtype and mutant alleles present) as mutant. Essentially, for mapping 
SP resistance in simple cross-sectional surveys in this area, the ratio between 
the prevalence of the dhfr triple mutation and the treatment failure rate might 
serve as crude tool. Yet, it needs to be evaluated whether this index is similar in 
different locations and remains stable over time. Our findings also highlight the 
necessity to locally establish a relation between molecular markers and 
treatment outcome. In Malawi and Uganda 28,29, dhfr Arg-59/dhps Glu-540 
strongly predicted treatment failure. In our study population this combination 
was seen only once rendering it inapplicable. One reason for this difference may 
be the quasi omnipresence of resistant dhfr alleles in the East African sites 
whereas in Tamale, roughly a third of the dhfr codons 51, 59, and 108, 
respectively, were wildtype.  
 Nevertheless, almost half of the isolates and thus substantially more than 
the one third observed in southern Ghana30 exhibited the dhfr triple mutation. 
This was an unexpected finding because in Ghana, SP has been used as a 
second-line antimalarial so far and rarely in the study area which is corroborated 
by the very low prevalence of pyrimethamine in blood. Even considering that the 
ELISA assay applied can detect the drug for only two weeks after therapeutical 
SP intake 21 this renders exclusive selection by previous or home-treatment with 
SP unlikely. Trimethoprim-sulfamethoxazole is a cheap and widely used 
antibiotic. Cross-resistance between pyrimethamine and trimethoprim has been 
observed in vitro and on the molecular level 31-33. Although one small-scale study 
reported opposite results34, selection of dhfr variants by widespread use of 
trimethoprim-sulfamethoxazole might partially explain the abundance of the dhfr 
triple mutation in our study population. This notion is supported by a recent 
study from Guinea-Bissau35. Likewise, the use of sulfa drugs in bacterial 
infections has been suggested to contribute to a high prevalence of the dhps 
variants Ala-436 and Gly-437 in Brazil 36. However, so far, there are no data to 
substantiate this hypothesis. 
A minor role of dhps mutations in SP treatment failure has been reported 
from various sites 13,37-40. In Cameroon, the dhps genotype did not affect the 
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efficacy of SP 39. Similarly, in the present study, dhps alleles had no influence on 
treatment outcome, parasite clearance or gametocyte carriage. This contrasts 
with findings from East Africa where dhps variants increased the likelihood of 
treatment failure in the presence of dhfr triple mutants 28,29,41. The reason for the 
complete independence of SP efficacy from dhps alleles, particularly from the 
key mutation Gly-437, in northern Ghana is unclear. A major role of exogenous 
folate in determining sulfadoxine resistance has been observed in vitro 42 but 
respective blood concentrations were not measured in our patients. Omar et al.13 
suggested that in highly endemic areas, immunity may mask the impact of the 
presumably less important dhps mutations to a larger extent than the one of 
dhfr alleles. In essence, our observations fit the concept that SP resistance is 
mediated only secondarily by dhps variants once dhfr triple mutant parasites 
predominate 38,41. In the present study, only one isolate exhibited the highly 
resistant quintuple dhfr/dhps mutation 28. The role of dhps variants may change 
once further mutations, particularly Glu-540, emerge under drug pressure. 
Selection of Gly-437 was observed in this trial. Of course, we cannot state 
whether this and resistant dhfr alleles emerged from below detection level or 
were induced by SP. Albeit, findings from Kenya suggest that selection for dhps 
mutants occurs more easily the more frequent dhfr mutations are43.  
Gametocyte carriage one week following treatment was increased in 
children harbouring dhfr mutant parasites. Irrespective of the notorious 
difficulties in microscopically detecting low density gametocytaemia44 dhfr 
mutations influenced gametocyte prevalence rather than density, which was 
reported previously 17. Even though this association held true after correcting for 
pre-treatment gametocytaemia, gametocytes observed on day 7 are likely to 
comprise portions formed before as well as during treatment. Prolonged 
clearance of resistant strains under drug pressure may increase the chance of 
parasites committed to gametocyte formation to progress. This has been 
suggested for both SP and CQ resistant infections 17,45. Though infectivity of the 
gametocytes observed was not assessed. Increased gametocyte carriage 
following treatment of dhfr mutant strains will likely contribute to spreading 
resistance. Likewise, following CQ treatment, P. falciparum initially exhibiting the 
chloroquine resistance transporter key mutation were found to produce 
approximately 40-fold higher oocyst numbers in Anopheles than did sensitive 
strains45. 
Due to the methodology applied, it is impossible to separate dhfr 
genotypes in gametocytes and asexual parasites. Increased gametocytaemia at 
enrolment has also been observed for subsequently CQ resistant infections 46-48. 
Previous drug use could have selected for mutant parasite strains with 
gametocytes persisting for a longer period than drug pressure being 
demonstrable. As mentioned before it seems unlikely that such selection can be 
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attributed exclusively to SP usage. In any case, the observation of dhfr 
mutations being associated with both pre- and post-treatment gametocyte 
carriage is worrying since it supports similar findings on CQ resistance45 pointing 
to a transmission advantage of resistant parasites.  
 In conclusion, despite a lack of complete agreement, P. falciparum dhfr 
mutations predict treatment failure to SP in the study area of northern Ghana, 
and are associated with prolonged parasite clearance and increased gametocyte 
carriage. Dhps alleles show no such features. For now, the dhfr triple mutation 
may serve to monitor the distribution, emergence, and development of SP 
resistance in this region. 
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Summary 
The effects of drugs on Plasmodium falciparum transmission stages may reduce 
the spread of parasites in the population and contribute to malaria control. 
Detailed quantitative studies on (sub)microscopic gametocytaemia have become 
feasible with the availability of real-time Pfs25 quantitative Nucleic Acid 
Sequence-based Amplification (QT-NASBA), which can be used to detect 
gametocyte densities above 20 gametocytes/mL from in vitro cultures.  
Gametocyte dynamics were investigated in children with uncomplicated P. 
falciparum malaria after treatment with sulphadoxine-pyrimethamine (SP) or a 
combination of SP and artesunate (SP+AS), in a 28-days drug efficacy study.  
This study demonstrated that gametocyte prevalence in 873 samples from 
symptomatic Kenyan children was 2.8 times higher by QT-NASBA compared to 
microscopy. Microscopy-positive cases showed a significant correlation with QT-
NASBA for gametocyte density. At enrolment, gametocyte prevalence was 86% 
by QT-NASBA compared to 22% by microscopy. Gametocytes were detected in 
97% of children in at least one blood sample and in 38% of children in all 
samples obtained during the 28-days follow-up. Both the risk of gametocyte 
carriage and gametocyte density were considerably higher after treatment with 
SP compared to SP+AS. Gametocyte prevalence and density decreased with 
time in the SP+AS group, but not in the SP-treated children.  
Our data suggest that the potential of malaria transmission remains high 
even after treatment with artemisinin combination therapy, although prevalence 
and density of gametocytes is lower after SP+AS.  
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Introduction  
Clinical symptoms of malaria are caused by cyclical proliferation of asexual 
Plasmodium parasites in the patient’s red blood cells. Spread of the disease 
depends on the presence of mature sexual stage parasites (gametocytes), which 
do not replicate or cause clinical symptoms, but are essential for transmission 
from humans to the mosquito vector.  
As measures to prevent malaria are not completely efficient, early 
treatment of symptomatic infections is a major component of malaria control 
strategies. Drugs are designed to cure clinical symptoms and therefore mostly 
target asexual stages; the impact of drug treatment on gametocytes and 
transmission has long been neglected. Some drugs increase (e.g. chloroquine 
and sulphadoxine-pyrimethamine) or decrease (e.g. artemisinin derivatives) 
gametocyte prevalence 1-4. Due to increasing resistance to most affordable 
antimalarial drugs, many countries are forced to revise drug treatment 
strategies. Generally, artemisinin combination therapies (ACT) are recommended 
to replace current first line drugs such as chloroquine and sulphadoxine-
pyrimethamine (SP).  
Combination of artemisinin derivatives with other antimalarial drugs may protect 
the other drug from development of resistance. The benefit of better cure rates 
induced by ACT combined with its effect on transmission due to its alleged 
gametocytocidal effects 5 may justify increased costs for treatment. 
The key factors that trigger sexual stage development are not yet 
understood. Gametocytes are derived only from a small subset of asexual 
parasites and only a fraction of patients develop patent gametocytaemia 6. 
However, the apparently low prevalence of gametocytes contrasts with the 
successful spread of malaria and the difficulties to control malaria transmission 7. 
Recently, a number of studies have addressed the effect of antimalarial drug 
treatment on gametocytes 3,8-13. Most of these studies used microscopy for 
detection and quantification of gametocytes, but it has been shown that patients 
without microscopically detectable gametocytes can infect mosquitoes 14,15 and 
submicroscopic gametocytaemia can be common 16-19. Detailed quantitative 
studies on submicroscopic gametocytes are now possible with the recently 
developed gametocyte-specific Pfs25 quantitative Nucleic Acid Sequence-Based 
Amplification (QT-NASBA) 20. The assay is performed in real-time, and quantifies 
mature Plasmodium falciparum gametocytes in blood samples with a lower 
detection limit of 20-100 gametocytes per millilitre of blood. The objective of this 
study was to investigate the effect of SP and of SP plus artesunate (SP+AS) 
treatment on P. falciparum gametocyte dynamics using Pfs25 real-time QT-
NASBA. 
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Methods 
Real-time Pfs25 QT-NASBA and nucleic acid extraction 
Nucleic acids were extracted from blood samples using the 
Guanidiumisothiocyanate (GuSCN)/silica procedure as described by Boom et al. 
(1990). Total parasite load was quantified by real-time 18S rRNA QT-NASBA as 
previously described 21. Pfs25 mRNA QT-NASBA was performed as described by 
Schneider et al. 20 with some adjustments to enable real-time detection. Briefly, 
real-time QT-NASBA for Pfs25 mRNA (Genbank accession number AF193769.1) 
was performed on a NucliSens EasyQ analyser (bioMérieux) using the NucliSens 
Basic Kit for amplification according to manufacturer’s manual at a KCl 
concentration of 80mM. Reactions were carried out in a total reaction volume of 
10μL per reaction. Forward primer: 5’-gac tgt aaa taa acc atg tgg aga-3’ 
(nucleotides 204-227); reverse primer: 5’-aat tct aat acg act cac tat agg gag 
aag gca ttt acc gtt acc aca agt ta-3’ (T7 promoter sequence, linker and 
nucleotides 338-359); Pfs25 molecular beacon: 5’-TexasRed-cga tcg ccc gtt tca 
tac gct tgt aac gat cg-DABSYL-3’ (molecular beacon stem of 6 paired nucleotides 
and nucleotides 259-278). The time point during amplification at which the 
fluorescence, resulting from detection of target amplicons, exceeded the mean 
fluorescence of three negative controls + 20 standard deviations (SD) was 
calculated (time to positivity). The use of a standard gametocytes stage V 
dilution series allowed calculation of the number of gametocytes present in test 
samples 20. 
 
Detection limit and interassay variability 
Blood samples of in vitro parasite culture of P. falciparum NF54 22 were collected 
as described by Schneider et al. 20, with the exception that internal controls for 
quantification were not added to the samples. Ten-fold dilution series of 
gametocytes ranging from 106 to 10 gametocytes per millilitre of blood were 
made, nucleic acids extracted using the GuSCN/silica procedure23 and the 
number of gametocytes was quantified by real-time Pfs25 QT-NASBA.  
 
Field study 
A drug efficacy study was performed from October to December 2003 in Mbita, 
Western Kenya (0° 25'S, 34° 13'E), according to the WHO protocol (WHO, 
2002). Mbita is a rural region on the shores of Lake Victoria experiencing 
endemic malaria with seasonal variation in transmission intensity. A description 
of the study site can be found in Chapter 2 24,25. Study approval was obtained 
from the ethical and scientific review boards of the Kenya Medical Research 
Institute (SSC 791).  
In total, 245 children aged 6 months to 10 years with uncomplicated 
clinical P. falciparum malaria confirmed by microscopy (500-100,000 
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parasites/µL) were included in the study after their guardians gave informed 
consent. Children were randomised to receive either SP (Fansidar, Roche, 
Switzerland; 125mg sulphadoxine and 6.25mg pyrimethamine/ 5kg as a single 
dose) or SP+AS (Arsumax, Sanofi, France; 20mg/ 5kg daily for 3 days) 
treatment. Details of randomisation and treatment procedures are described 
elsewhere (Chapter 6) 26. Follow-up was performed by the study clinician on 
days 1, 2, 3, 7, 14 and day 28 post-treatment and at any time the child showed 
symptoms of disease. At all sampling points, a blood smear for microscopic 
detection of parasites was made and stained with 10% Giemsa. Asexual 
parasites were counted against 200 leucocytes, gametocytes against 500 
leucocytes and converted to number of parasites per volume assuming 8,000 
white blood cells/µL blood. Slides were considered negative when no parasites 
were detected after viewing 100 microscopic fields at a 10x100 magnification. 
Additional to the standard protocol (microscopy), at all sampling times, a small 
blood sample on filter paper was collected for genotyping. A blood sample (50 
µL) for QT-NASBA, stored in GuSCN lysis buffer until further analysis, was 
collected on the same days except for day 2. Samples for all methods were 
obtained from the same finger prick.  
 
Statistical analysis 
Statistical analyses were performed in SPSS version 12.0.1 and STATA 7.0. 
Mann-Whitney U test was used for comparisons between groups for continuous 
variables and Chi-square test for dichotomous variables. Results of microscopy 
and QT-NASBA were compared by Spearman correlation and paired t-test. 
Gametocyte prevalence and density after treatment were assessed by use 
of QT-NASBA in a random subset of 118 children, aged 6 months to 5 years, 
who completed at least 7 days of follow-up (age groups of 1, 2, 3, 4 and 5 years 
consisted of 32, 23, 20, 21 and 22 children respectively). This group was 
representative for the entire study group regarding gender (50% male), mean 
weight (13.3 kgs) and mean age (2.8 years). Gametocyte prevalence at 
enrolment was not statistically different between the two treatment groups (Chi 
square tests, P=0.770 for microscopy and P=0.421 for QT-NASBA), neither were 
total parasite and gametocyte densities at enrolment (Mann-Whitney U tests, 
total parasite density P=0.345 and 0.516; gametocyte density P=0.732 and 
0.538 for microscopy and QT-NASBA, respectively). Logistic regression was used 
to determine the relation between gametocyte prevalence and time after 
treatment and type of drug treatment (SP or SP+AS), adjusting for age in years 
and outcome of drug treatment (adequate clinical response or late treatment 
failure 27). Odds Ratios (OR) were calculated with 95% confidence intervals 
(95% CI). For gametocyte density, linear regression was used with inclusion of 
the same parameters, but only gametocyte-positive samples were used in the 
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analysis. In case of multiple observations per individual, Generalised Estimating 
Equations28 models (STATA 7.0) were used to allow for correlation of 
observations from the same individual. 
 
Results 
Detection limit and interassay variation of real-time Pfs25 QT-NASBA 
Eighteen independent gametocyte series from in vitro parasite culture were 
collected and processed over a period of 2 months. Gametocyte densities from 
102 to 106 gametocytes/mL could be detected consistently with 10 
gametocytes/ml being close to the detection limit of 20-100 gametocytes/mL of 
blood. Interassay variability (SD/mean*100%), including variations in culture 
material and nucleic acid extractions, is below 10% for all measured gametocyte 
densities and is highest for the lower densities (table 5.1). Regression analysis 
on the 10log number of parasites present in the control samples and the resulting 
time to positivity showed a consistently significant correlation (P<0.001) with a 
correlation coefficient of on average 0.98 (range 0.92-0.99). 
For negative controls, blood samples (50 µL) were obtained from 20 
malaria-naïve blood donors in Nijmegen, the Netherlands and from 10 healthy 
volunteers at Kenya Medical Research Institute, Nairobi, Kenya with no recent 
history of malaria. The 30 blood samples were all confirmed negative by Pfs25 
QT-NASBA.  
 
Table 5.1 Interassay variability (SD/mean*100%) for real-time Pfs25 QT-NASBA in 18 
independent dilution series from in vitro cultured gametocytes. 
Log gct/ml TTP SD Interassay variability 
6 46.60 1.95 4.2% 
5 53.48 3.32 6.2% 
4 64.56 4.26 6.6% 
3 72.70 5.03 6.9% 
2 84.06 6.29 7.5% 
1¥ 89.85 8.33 9.3% 
Log gct/mL = 10log of the number of gametocytes/ ml of blood originally determined by 
microscopy and diluted. TTP = Average time to positivity for Pfs25 QT-NASBA for each gametocyte 
concentration. SD = standard deviation. ¥Calculations for 8 measurements only, 10/18 were below 
the detection limit and excluded from the analysis 
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Field study, comparison microscopy and QT-NASBA for gametocyte 
quantification 
In total, 873 samples obtained during the drug efficacy study in Mbita were 
quantified for P. falciparum gametocytes both by microscopy and by Pfs25 QT-
NASBA. Of these samples, 72% were positive for gametocytes by QT-NASBA, 
while gametocytes were detected in only 26% of the blood smears by 
microscopy. The Pfs25 QT-NASBA confirmed 92% of the microscopically positive 
samples; 65% of the microscopically gametocyte negative samples was positive 
in the QT-NASBA with a geometric mean of 6.0*102 gametocytes/mL (IQR 
1.7*102–2.1*103), which is well below the detection limit of microscopy (1.6*104 
gametocytes/mL). In total, inconsistent results between Pfs25 QT-NASBA and 
microscopy were shown in 33/873= 3.7% of the samples. Quantification of 
gametocytes by Pfs25 QT-NASBA and microscopy showed a statistically 
significant correlation (Spearman correlation, ρ=0.452, P<0.001). However, for 
samples with microscopically detected gametocytes, quantification by QT-NASBA 
was slightly lower than quantification by gametocyte microscopy (paired t-test, 
P<0.01). 
 
Gametocyte dynamics after SP and SP+AS treatment 
Of the 245 children included in the study comparing treatment efficacy of SP 
alone versus SP+AS (Chapter 6) 26 a random subset of 118 children was included 
for QT-NASBA analysis. Gametocyte prevalence at enrolment was 22% as 
detected by microscopy and 86% by Pfs25 QT-NASBA. Gametocytes were 
detected in 97% of all children at some time point and in 38% at all time points 
during the 28-days follow-up period by Pfs25 QT-NASBA. 
The SP+AS treated group (n=55) showed a significantly lower risk of 
gametocyte carriage (OR 0.137; 95% CI 0.065 - 0.288) and a reduced 
gametocyte density (β -0.395; 95% CI -0.652 – -0.139) compared to the SP 
treated group (n=63) in the Pfs25 QT-NASBA analysis. Microscopic analysis 
showed a less pronounced effect of treatment on prevalence (OR 0.322; 95% CI 
0.185, 0.561) and no statistically significant effect on gametocyte density.  
Since SP and SP+AS showed different effects on gametocytes, data were 
further analysed separately for each treatment group. Gametocyte prevalence by 
QT-NASBA decreased significantly with time after SP+AS treatment in days (OR 
0.905; 95% CI 0.877 – 0.934) but not after SP treatment (Fig. 5.1). Similar 
results were obtained with microscopy. However, microscopy data show a peak 
in gametocyte prevalence at day 7 after SP treatment that was not detected by 
Pfs25 QT-NASBA (Fig. 5.1). Gametocyte density decreased significantly (β -
0.032; 95% CI -0.048 – -0.017) after treatment with SP+AS but not after 
treatment with SP, where gametocyte densities peaked at day 7. This is shown 
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Figure 5.1. Gametocyte prevalence from day 0 to 28 after treatment, calculated by 
microscopy (shaded bars) and Pfs25 QT-NASBA (black bars) for SP monotherapy and 
SP+AS combination therapy. Error bars indicate the upper limit of the 95% confidence 
intervals. 
 
 
 
 
 
 
 
 
 
 
Figure 5.2. Median QT-NASBA total parasite (shaded bars) and gametocyte (black bars) 
densities relative to day 0. Figures are given for SP monotherapy and SP+AS combination 
therapy.  
 
 
Discussion 
The real-time Pfs25 QT-NASBA is more sensitive for quantification of P. 
falciparum gametocytes compared to standard microscopy (detection limits of 
20-100 and 16,000 gametocytes/mL of blood, respectively). Inconsistent results 
between gametocyte detection by microscopy or Pfs25 QT-NASBA, including 
both false positive and false negative results, occurred in 3.7% of all samples. 
Similar low percentages of inconsistent results were found during a cross-
sectional study in Burkina Faso (Ouédraogo et al. unpublished). The observation 
that QT-NASBA results in lower gametocyte densities compared to microscopy 
may be explained by an overestimation of gametocyte densities by microscopy. 
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Counting of gametocytes against 500 leucocytes was started only after the first 
gametocyte has been detected, which introduces a positive bias in quantification. 
 
Over 50% of the microscopically gametocyte-positive in vivo samples 
from the study in Kenya contained only 1 gametocyte/500 white blood cells, a 
density just above the detection limit of microscopy. The increased sensitivity of 
gametocyte detection by Pfs25 QT-NASBA revealed high prevalences of 
submicroscopic levels of gametocytes at enrolment and during the 28-days 
follow-up period. This confirms previous studies showing submicroscopic 
gametocytaemia in endemic samples 15,18,19,29,30. Almost all children harbour 
gametocytes at some time point during the study and 38% show persistent 
gametocytaemia during follow-up. This suggests that the majority of children 
with uncomplicated symptomatic P. falciparum infection contribute to the 
infectious reservoir both before and after treatment with antimalarial drugs. 
Our data further show that the gametocyte reservoir in symptomatic 
children may be much larger than previously indicated by microscopic analyses. 
Many gametocyte carriers carry very low densities of gametocytes (geometric 
mean 600/mL) in the circulation. Data suggest that gametocyte densities below 
the microscopy detection limit can infect Anopheles stephensi mosquitoes in 
membrane feeding experiments (Chapter 7)31. Therefore, low gametocyte 
densities in vivo may infect mosquitoes, especially when taking into account that 
P. falciparum gametocytes in the peripheral blood may not be homogeneously 
distributed 32,33. 
Both gametocyte carriage and higher gametocyte densities are 
considerably more prevalent in the SP group compared to SP+AS. A post-
treatment reduction of gametocyte prevalence and density over time was 
present in the SP+AS but not in the SP treatment group. The peak gametocyte 
prevalence at day 7 after SP treatment observed by microscopy confirms data 
from previous studies 1,8,34 but was not confirmed by QT-NASBA. In contrast, QT-
NASBA showed a peak in gametocyte density in the SP group at day 7. This 
difference may be explained as higher gametocyte densities being more likely to 
be detected by microscopic analysis. The peak of gametocyte density at day 7 
after SP treatment cannot be the result of de novo induction under drug 
pressure, as gametocyte development takes longer than 7 days. This peak may 
reflect the slower clearance of immature gametocytes after SP treatment 
compared to SP+AS treatment. These results show that data on gametocyte 
prevalence are highly dependent on the sensitivity of the detection method and 
microscopy is inferior for this purpose. In conclusion, the Pfs25 QT-NASBA is the 
preferred technique to detect and quantify P. falciparum gametocytes. The use 
of Pfs25 QT-NASBA in transmission studies provides more detailed data and 
makes studies, especially those with small sample sizes, more efficient. 
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Summary 
Artemisinin-based combination therapy (ACT) reduces microscopically confirmed 
gametocytaemia and mosquito infection. However, molecular techniques have 
recently revealed high prevalences of submicroscopic gametocytemia. Our 
objective here was to determine the effect of sulphadoxine-pyrimethamine (SP) 
monotherapy and treatment with SP plus amodiaquine (AQ), SP plus artesunate 
(AS), and artemether-lumefantrine (AL; Coartem) on submicroscopic 
gametocytaemia and infectiousness. 
Kenyan children (n = 528) 6 months–10 years of age were randomized to 
4 treatment arms. Gametocytaemia was determined by both microscopy and 
Pfs25 RNA–based quantitative nucleic acid sequence–based amplification (Pfs25 
QT-NASBA). Transmission was determined by membrane-feeding assays.  
Gametocyte prevalence, as determined by Pfs25 QT-NASBA, was 89.4% 
(219/245) at enrollment and decreased after treatment with SP plus AS, SP plus 
AQ, and AL. Membrane-feeding assays for a group of randomly selected children 
revealed that the proportion of infectious children was as much as 4-fold higher 
than expected when based on microscopy. ACT did not significantly reduce the 
proportion of infectious children but did reduce the proportion of infected 
mosquitoes. 
Submicroscopic gametocytemia is common after treatment and 
contributes considerably to mosquito infection. Our findings should be interpreted 
in the context of transmission intensity, but the effect of ACT on malaria 
transmission appears to be moderate and restricted to the duration of 
gametocyte carriage and the proportion of mosquitoes that are infected by 
carriers. 
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Introduction 
Antimalarial drug treatment targets the asexual blood stages of Plasmodium 
falciparum, which are responsible for clinical disease and death. Sexual-stage 
parasites—that is, gametocytes—do not cause clinical disease, and they can also 
be found in the circulation of infected persons and can infect mosquitoes taking a 
blood meal. After fertilisation and further sporogonic development, infectious 
parasites appear in the mosquito salivary gland. With each subsequent blood 
meal, parasites are transmitted to a new person, resulting in the spread of 
malaria among the human population. The majority of the currently used 
antimalarial drugs do not kill gametocytes, and the effects of drugs on these 
stages are often ignored during the development of antimalarial drugs and 
policies.  
The resistance of P. falciparum to such antimalarial drugs as chloroquine 
and sulfadoxine-pyrimethamine (SP) is rapidly increasing in many areas of sub-
Saharan Africa. This has forced many African countries to abandon monotherapy 
with these drugs as first-line antimalarial treatment 1. Because drug resistance is 
less likely to develop when combination therapy is used 2,3, there is increasing 
acceptance that it, rather than monotherapy, is the way forward, with artemisinin 
being one of the preferred components 1,2,4. Compared with monotherapy, 
artemisinin-based combination therapy (ACT) provides higher clinical efficacy 5,6 
in the absence of drug resistance. An additional advantage of ACT is its effect on 
sexual stages—it lowers the prevalence and density of posttreatment 
gametocytemia 5,7,8 and, subsequently, the prevalence of mosquito infection 7,9,10. 
ACT may reduce malaria transmission at the population level 8,11, and the specific 
reduction in the transmission of resistant strains 8,11,12 further suggests that ACT 
may counteract the spread of drug resistance.  
In contrast to asexual parasites, gametocytes often circulate at such low 
densities that they may not be detected by standard microscopy 13-15. Indeed, 
Pfs25 RNA–based quantitative nucleic acid sequence–based amplification (Pfs25 
QT-NASBA) 16 recently revealed that a large proportion of children with 
symptomatic malaria had submicroscopic gametocytemia (Chapter 5) 17.  
Our objective here was to determine, in Kenyan children treated for 
uncomplicated malaria, the clinical efficacy of drug regimens that are currently in 
use or are being considered for inclusion in national guidelines in different African 
countries; gametocyte prevalence by Pfs25 QT-NASBA 16; and posttreatment 
infectiousness to Anopheles gambiae mosquitoes. The regimens analyzed were 
SP monotherapy and 3-day courses of SP plus amodiaquine (AQ), SP plus 
artesunate (AS), and artemether-lumefantrine (AL) 1,6.  
 
Chapter 6 
 72
Methods 
The present study was conducted from October to December in 2003 and 2004 in 
Mbita, a rural village on the shores of Lake Victoria in Suba District, western 
Kenya. The main malaria vectors in the area are A. gambiae, A. funestus, and A. 
arabiensis. Malaria transmission is high and perennial, with parasite prevalences 
in the human population ranging from 24.4% to 99.0% 18. Generally, the rainfall 
pattern is bimodal, with a long rainy season between March and May and a short 
rainy season between October and December. The study protocol (SSC 791) was 
approved by the Scientific Steering Committee and the Ethical Review Committee 
of the Kenya Medical Research Institute. Written informed consent was obtained 
from a parent or guardian of the participating children.  
   
Study population and treatment   
Subjects were recruited at the clinic of the International Centre of Insect 
Physiology and Ecology (ICIPE) Mbita Point Field Station and came from an area 
of ~10 km around the ICIPE compound. Children 6 months–10 years of age with 
either a temperature of >37.5°C or a history of fever and with P. falciparum 
monoinfection at an asexual parasite density of ≥500 parasites/μL were eligible 
for recruitment. Exclusion criteria were the inability to take drugs orally, known 
hypersensitivity to any of the drugs given, reported treatment with antimalarial 
chemotherapy during the previous 2 weeks, evidence of chronic disease or of an 
acute infection other than with a malarial parasite, residence outside of the study 
area, and signs of severe malaria. Children were randomly allocated to receive 
one of the four following treatment regimens: (i) SP monotherapy, which 
consisted of 25 mg/kg sulfadoxine and 1.25 mg/kg pyrimethamine as a single 
dose (Fansidar; Roche) plus placebo once daily for 3 days; (ii) SP plus 4 mg/kg 
AS (Arsumax; Sanofi) once daily for 3 days; (iii) SP plus 10 mg/kg AQ 
(Camoquine; Pfizer) once daily for 3 days; and (iv) AL (Coartem; Novartis 
Pharma), administered as half a tablet (20 mg of artemether and 120 mg of 
lumefantrine) per 5 kg of body weight in a 6-dose regimen (at enrollment and 8, 
20, 32, 44, and 56 h (±90 min) after the initiation of treatment).  
Children were randomized to the SP monotherapy and the SP plus AS arms 
in 2003 and to the SP monotherapy, SP plus AS, SP plus AQ, and AL arms in 
2004. The sizes of the arms were not equal, for several reasons. At the time of 
the study, AL was not recommended for children who weighed <10 kg. In 
addition, the 6-dose AL regimen required treatment to be administered at the 
child's home. Therefore, only those children who weighed ≥10 kg and resided <5 
km from the clinic (to allow supervised treatment at home) were eligible for 
randomization to the AL arm. This resulted in a smaller number of children in this 
treatment arm. The numbers of children in the SP monotherapy arm and the SP 
plus AS arm were highest because the relevance of the random-feeding assays 
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became evident during the latter part of data collection in 2004. For these 
assays, an additional number of children had to be randomized to the SP 
monotherapy and the SP plus AS arms. Therefore, to supplement the number of 
children who received these regimens in 2003 (n = 245), 81 children were 
randomized to the SP monotherapy and the SP plus AS arms at a 1 : 2 ratio in 
2004. This ratio was chosen to facilitate comparison between the SP plus AS arm 
and the AL arm, for which parasitological differences were expected to be 
smallest.  
For SP monotherapy and treatment with SP plus AQ and SP plus AS, 
treatment was administered by staff at the recruitment clinic; for treatment with 
AL, the first dose was administered by staff at the recruitment clinic, and 
subsequent doses were administered by field assistants at the child's home. All 
medication was given with a local fatty food (mandazi), to facilitate absorption. 
Each child was observed for 20 minutes after administration of treatment, and a 
replacement dose was given if vomiting occurred. Repeated vomiting led to 
exclusion from the study; paracetamol (10 mg/kg) was given until symptoms had 
subsided.  
Children were encouraged to return to the recruitment clinic on days 1, 2, 
3, 7, 14, and 28 after initiation of treatment and at any time the child became ill. 
Field assistants visited the homes of children who failed to appear at the clinic, to 
collect additional samples. Other than those administering medication, all staff 
engaged in the trial were blinded to the treatment arm of each child.  
 
Microscopy and Pfs25 QT-NASBA 
Blood smears were stained with 10% Giemsa for 10 min and then screened for 
asexual parasites and gametocytes at enrollment and on days 3, 7, 14, and 28. 
Slides were considered to be negative if no parasites were observed in 100 
microscopic fields, resulting in a sensitivity of ~5 gametocytes/μL of blood. 
Asexual parasites and gametocytes were counted against 200 and 500 white 
blood cells (WBCs), respectively, and the counts were converted to parasites per 
microliter on the assumption of a density of 8,000 WBCs/μL. For quality control, 
10% of the slides were reread. Parasite detection by Pfs25 QT-NASBA was done 
as described elsewhere 16,19, using a NucliSens EasyQ analyser (bioMérieux) as 
described elsewhere for Pfs25 mRNA 16. Nucleic acid was extracted from 50 μL 
blood samples as described by Boom et al. 20. The Pfs25 QT-NASBA technique is 
gametocyte specific and has a detection limit of 20–100 gametocytes/mL. 
NucliSens Basic kits were used for amplification, in accordance with the 
manufacturer's instructions. A standard dilution series of mature, in vitro 
cultured NF54 gametocytes 21 was included in each run. Detection by Pfs25 QT-
NASBA was done for a random selection of children from each treatment arm and 
for all of the samples included in the membrane-feeding assays.  
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Mosquito membrane feeding and dissection 
Membrane-feeding assays were conducted on day 14, when the gametocytes 
that develop after treatment are expected to be mature 22. Children >2 years of 
age whose parent or guardian gave specific consent for the procedure were 
eligible for the membrane-feeding assays. Two groups of subjects were selected: 
(i) children with microscopically confirmed gametocytemia on day 7, which has 
been shown to be the time when the peak prevalence after treatment occurs 7,23; 
and (ii) a random selection of children from each treatment arm (including 
children with and without gametocytemia by both microscopy and Pfs25 QT-
NASBA).  
For all membrane-feeding assays, 3 mL venous blood samples were 
obtained and fed to ~150 locally reared 24 4 to 5-day-old female A. gambiae 
sensu stricto mosquitoes via an artificial membrane attached to a water-jacketed 
glass feeder maintained at 37°C. After 10–15 min, fully fed mosquitoes were 
selected and kept on glucose for 7 days at 27°C–29°C, at which time midguts 
were dissected in 2% mercurochrome. Midguts were examined microscopically 
for oocysts, with a second microscopist confirming their presence if observed. 
Assay results were considered to be valid if a minimum of 20 mosquitoes were 
dissected. For the randomly selected children, exactly 30 mosquitoes were 
dissected per child.  
 
Molecular genotyping   
For DNA analyses, blood was collected as dry blood on Whatman glass microfiber 
filter papers. DNA was extracted using a chelex-based method. Alleles of the 
polymorphic locus msp2 were compared between pretreatment and 
posttreatment parasite isolates by polymerase chain reaction, as described 
elsewhere 10. The procedure of Cattamanchi et al. 25 was followed in that 
indeterminate samples for which a majority of novel bands appeared for the 
posttreatment infection were scored as new infections.  
 
Statistical analyses 
Treatment outcome was classified as early treatment failure, late treatment 
failure, reinfection, or adequate clinical response 26. In the event of treatment 
failure, rescue treatment was administered in accordance with Kenyan national 
guidelines. Statistical analyses were done using SPSS for Windows (version 12.0; 
SPSS) and Stata (version 7.0; Stata Corporation). Percentages were compared 
using the 2 test, and trends in percentages were analyzed using the Cochran-
Armitage test for trend. Parasite densities were analyzed after log 
transformation. Normally distributed continuous variables were compared using 
analysis of variance or Student's t test. Variables that were not normally 
distributed were compared using the Kruskal-Wallis or Wilcoxon rank-sum test. 
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For analyses of gametocyte prevalence during follow-up, multiple logistic 
regression models and generalized estimating equations were used, to allow for 
autocorrelation. Regression coefficients (β) were calculated.  
The results of the membrane-feeding assays were analyzed on two 
outcomes. The percentage of the population that was infectious was estimated by 
multiplying the percentage of children with gametocytemia on day 7 and the 
percentage of these children who infected at least one mosquito; this method 
was used because it is in accordance with that of previous studies of malaria 
transmission after antimalarial drug treatment 7,9,10 and, hence, allowed 
comparison of results. In addition, the percentage of infectious children and the 
percentage of infected mosquitoes were directly determined for the randomly 
selected children. Relative risks and 95% confidence intervals were calculated 
using the SP monotherapy arm as the reference group.  
 
Results 
Clinical efficacy 
A total of 528 children were randomized to the four treatment arms (figure 6.1). 
Two children died within one day of enrollment, as a result of factors other than 
malaria. Of the remaining children, 6.3% (33/526) were lost for evaluation 
during the 28-day follow-up period. Asexual parasite density, gametocyte 
prevalence, and frequency of fever at enrollment were not significantly different 
among the four treatment arms (table 6.1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1 Profile of the study. 
 2654 screened 2126 not  included 
1878 not malaria 
173 <500 parasites/μL 
11 severe malaria 
51 malariae mixed or  
mono-infection 
5 refused consent 
8 not from study area 528 randomized 
152 SP 
0 deceased 
2 withdrew  
consent 
0 incomplete  
treatment 
7 did not attend 
follow-up 
143 SP 
day 28 outcome 
127 SP + AQ 
2 deceased 
1 withdrew  
consent 
1 incomplete  
treatment 
8 did not attend 
follow-up 
115 SP + AQ 
day 28 outcome 
174 SP + AS 
0 deceased 
1 withdrew  
consent 
4 incomplete  
treatment 
9 did not attend 
follow-up 
160 SP + AS 
day 28 outcome 
75 AL 
0 deceased 
0 withdrew  
consent 
0 incomplete  
treatment 
0 did not attend 
follow-up 
75 AL 
day 28 outcome 
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The median age (P = 0.03), weight (P = 0.03), and age-associated hemoglobin 
level (P = 0.01) were slightly higher for the children in the AL arm than for the 
children in the other arms, because only subjects who weighed ≥10 kg were 
included in the AL arm. This imbalance was accounted for in the statistical 
analyses and did not confound any of the observed relationships. During follow-
up, SP monotherapy produced an adequate clinical response in 44.1% (63/143) 
of the children, and early treatment failure was observed in 9.8% (14/143) of the 
children in this arm (table 6.2). The combination regimens resulted in fewer 
treatment failures, and adequate clinical response was observed in 87.0% 
(100/115), 81.9% (131/160), and 96.0% (72/75) of the children in the SP plus 
AQ, SP plus AS, and AL arms, respectively.  
 
Table 6.1. Characteristics of the study population at enrolment 
 SP  SP+AQ SP+AS AL 
N 152 127 174 75 
Age, median  
(IQR) 
3.5  
(2.0–5.3) 
2.6  
(1.4-4.9) 
3.1  
(1.8-5.1) 
4.1  
(2.0-6.4) 
Sex, % male  
(n/N) 
50.7  
(77/152) 
52.8  
(67/127) 
49.4  
(86/174) 
53.3  
(40/75) 
Weight, median (IQR) 14.0  
(11.0-18.4) 
13.0  
(10.0–16.1) 
13.5  
(10.0–18.0) 
16.0  
(12.0-20.2) 
Temperature, % 
>37.5ºC (n/N) 
66.2  
(100/151) 
53.5  
(68/127) 
64.7  
(112/173) 
54.7  
(41/75) 
Hemoglobin, median 
(IQR) 
9.4  
(7.9-10.7) 
9.3  
(8.0-10.7) 
9.4  
(7.8-10.6) 
10.4  
(8.6 – 11.8) 
Asexual parasite 
density, GM (IQR) 
10,122  
(3,680-29,593) 
11,452  
(5,040-31,679) 
12,355  
(5,417-28,521) 
11,887  
(3,680-32,161) 
Gametocyte prevalence, 
% (n/N) 
20.9  
(31/148) 
22.3  
(27/121) 
24.4  
(42/172) 
24.6  
(17/69) 
IQR = interquartile range; GM = geometric mean 
 
Table 6.2. Treatment outcome for the different treatment regimens on day 28. 
 SP SP+AQ SP+AS AL 
Number evaluated 143 115 160 75 
Treatment outcome, %      
 ACR 44.1 87.0 81.9 96.0 
 ETF 9.8 0.9 0.6 0.0 
 LTF 44.8 7.8 13.8 2.0 
 Re-infection 1.4 4.3 3.8 2.0 
ACR = adequate clinical response, ETF = early treatment failure, LTF = late treatment failure 
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Figure 6.2 Gametocyte prevalence by microscopy (A) and Pfs25 QT-NASBA (B) after 
sulphadoxine-pyrimethamine (SP) monotherapy (black diamonds), SP plus amodiaquine 
(AQ) (white triangles), SP plus artesunate (AS) (white squares), and artemether-
lumefantrine (AL) (black triangles).  
Bars indicate the 95% confidence intervals around the proportions.  
6.2A: Differences in microscopic gametocyte prevalence were statistically significant for the 
comparison between SP and SP+AS (β=-0.78, se=0.17, p<0.001) and AL (β=-1.14, se=0.26, 
p<0.001); between SP+AQ and SP+AS (β=-0.70, se=0.19, p<0.001) and AL (β=-1.06, se=0.27, 
p<0.01). Differences in gametocyte prevalence were not statistic ally significant for the 
comparison between SP and SP+AQ (β=-0.08, se=0.18, p=0.67) and between SP+AS and AL (β=-
0.35, se=0.27, p=0.18).  
6.2B:Differences in Pfs25 QT-NASBA gametocyte prevalence were statistically significant for the 
comparison between SP and SP+AQ (β=-1.31, se=0.38, p=0.001); SP+AS (β=-2.14, se=0.33, 
p<0.001) and AL (β=-2.44, se=0.37, p<0.001); between SP+AQ and SP+AS (β=-0.83, se=0.30, 
p=0.007) and AL (β=-1.12, se=0.34, p=0.001). There was no statistically significant difference in 
gametocyte prevalence between SP+AS and AL (β=-0.30, se=0.27, p=0.27).  
 
 
Gametocyte prevalence by Pfs25 QT-NASBA  
During follow-up, gametocyte prevalence by microscopy was significantly lower 
among the children in the SP plus AQ, SP plus AS, and AL arms than among the 
children in the SP monotherapy arm (figure 6.2A). Gametocyte prevalence by 
Pfs25 QT-NASBA was much higher than by microscopy (figure 6.2B). The overall 
gametocyte prevalence was 22.9% (117/510) at enrollment by microscopy, 
compared with 89.4% (219/245) by Pfs25 QT-NASBA (χ2 = 295.9; P < 0.001).  
Although gametocyte prevalence by Pfs25 QT-NASBA was almost universal at 
enrollment (range for the treatment arms, 85%–92%), it decreased gradually 
during the follow-up period for the SP plus AQ (β= -0.060, se= 0.014; P < 
0.001), SP plus AS (β= -0.090, se= 0.012; P < 0.001), and AL (β= -0.099, se= 
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0.015; P < 0.001) arms but not for the SP monotherapy arm (β= -0.0032, se= 
0.15; P = 0.83).   
During the entire study period, gametocyte prevalence by Pfs25 QT-NASBA was 
lower in the SP plus AQ, SP plus AS, and AL arms than in the SP monotherapy 
arm. The children treated with AL had the lowest gametocyte prevalence by Pfs25 
QT-NASBA, although the difference between the prevalence in this arm and that 
in the SP plus AS arm was not statistically significant (figure 6.2B).  
 
Infectiousness of children in different treatment arms 
A total of 118 successful membrane-feeding assays were conducted for children 
who had microscopically confirmed gametocytemia on day 7 and were >2 years 
of age. Three assays were not included in the analyses because <20 mosquitoes 
were dissected. A high percentage of the gametocyte carriers were infectious to 
mosquitoes (table 6.3). The estimated percentage of the population who were 
infectious to mosquitoes was significantly lower after treatment with either SP 
plus AS or AL, compared with that after SP monotherapy. No statistically 
significant difference was observed between SP monotherapy and treatment with 
SP plus AQ. However, the high gametocyte prevalence by Pfs25 QT-NASBA 
prompted us to randomly test blood samples from treated children by the 
membrane-feeding assay. Across treatment arms, the percentages of the 
randomly selected children who were infectious to mosquitoes were consistently 
higher than the estimated percentages of the children with microscopically 
confirmed gametocytemia (table 6.3). Although this result was observed for SP 
monotherapy (64.0% vs. 48.4%), the relative increase was most evident for the 
combination therapies, for which the infectious proportion increased 2-fold for SP 
plus AQ treatment (80.0% vs. 37.9%), 3-fold for SP plus AS treatment (44.0% 
vs. 14.7%), and 4-fold for AL treatment (60.0% vs. 14.0%). Among the 
randomly selected children themselves, there were no statistically significant 
reductions in the infectious proportion for treatment with SP plus AQ, SP plus AS, 
or AL, compared with that for SP monotherapy (table 6.3).  
The force of malaria infection in the natural situation is determined by the 
infectious mosquito reservoir. This reservoir is related to the infectious proportion 
of the human population but also to the percentage of mosquitoes that become 
infected when feeding on humans. Among the randomly selected children, the 
percentage of mosquitoes that became infected was quantified for each 
treatment arm and was found to be 6.9% for SP monotherapy, 5.5% for SP plus 
AQ treatment, 2.3% for SP plus AS treatment, and 3.6% for AL treatment (table 
6.4). Compared with that for SP monotherapy, the probability of a mosquito 
becoming infected was significantly lower for treatment with SP plus AS and with 
AL but not for treatment with SP plus AQ.  
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Table 6.3. The estimated proportion of infectious children per treatment arm in 
membrane feedings in microscopically confirmed gametocyte carriers (A) and a random 
selection of patients (B)  
A. Microscopically confirmed gametocyte carriers 
 Gametocytaemic 
children, % (n/N) 
Infectious 
gametocyte 
carriers, % (n/N) 
Proportion 
infectious 
children, %* 
RR (95% CI)† 
SP 61.5 (83/135) 78.7 (48/61) 48.4 1 
SP+AQ 46.2 (55/119) 82.1 (23/28) 37.9 0.79 (0.59–1.05) 
SP+AS 23.8 (39/164) 61.9 (13/21) 14.7 0.30 (0.20–0.46) 
AL 16.0 (12/75) 87.5 (7/8) 14.0 0.30 (0.17–0.53) 
B. Random selection of patients 
SP n.a. n.a. 64.0 (16/25) 1 
SP+AQ n.a. n.a. 80.0 (20/25) 1.25 (0.88–1.78) 
SP+AS n.a. n.a. 44.0 (11/25) 0.69 (0.40–1.17) 
AL n.a. n.a. 60.0 (15/25) 0.94 (0.61–1.45) 
RR = relative risk; 95% CI = 95% confidence interval; n.a.= not applicable. The median number 
of dissected mosquitoes per experiment was 31.0 (IQR 30-48) for table 6.3A and not different 
between the treatment groups (Kruskal-Wallis χ2 =0.88; p=0.83). The number of dissected 
mosquitoes for table 6.3B was exactly 30 for each experiment.*The proportion of infectious 
children was estimated for table 6.3A by multiplying the gametocytaemic proportion of children 
with the proportion of infectious gametocyte carriers. The number of children who were included in 
the membrane feedings was smaller than the number of gametocytaemic children because only 
children above 2 years of age were eligible for membrane feedings. For table 6.3B, this proportion 
was determined directly. †The relative risk for the proportion of infectious children with SP as 
reference group. 
 
 
Table 6.4 The average number of infected mosquitoes in different treatment arms  
 No. of children  Proportion infected 
mosquitoes, % (n/N)  
RR (95% CI)† 
SP 25 6.9 (52/750) 1 
SP+AQ 25 5.5 (41/750) 0.79 (0.53 – 1.17) 
SP+AS 25 2.3 (17/750) 0.33 (0.19 – 0.56) 
AL 25 3.6 (27/750) 0.52 (0.33- 0.82) 
†The relative risk for the probability of mosquito infection with SP as reference group. 
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Discussion 
The present study shows that the effect of ACT on the infectiousness of young 
children to mosquitoes is moderate in an area of Kenya where malaria is highly 
endemic. Although ACT reduces the density of gametocytemia and the proportion 
of infected mosquitoes, submicroscopic gametocytemia appears to be sufficient 
to drive posttreatment malaria transmission.  
 
Our microscopy findings on posttreatment gametocyte prevalence are similar to 
those of other studies of SP monotherapy 7,23 and of treatment with SP plus AS 
7,23,27,28, SP plus AQ 6,23,27, and AL 6,10. The infectiousness of gametocyte carriers 
was somewhat higher in our study than in the studies by Targett et al. 7 and 
Sutherland et al. 10, possibly because the membrane-feeding assays were 
conducted on different days. We conducted ours on day 14 after initiation of 
treatment, whereas Targett et al. and Sutherland et al. conducted theirs on day 
7, when gametocytes may not be fully mature 22 or may be less infectious as a 
result of residual drug concentrations 29. We nevertheless consider this possibility 
to be unimportant for interpretation of our data, because our findings on 
infectiousness by microscopy are comparable with those of these two previous 
studies and lead to the same conclusions. We observed a clear reduction in 
malaria transmission after administration of ACT (i.e., treatment with SP plus AS 
7 or with AL 10). No estimate for infectiousness has been given previously for SP 
plus AQ treatment, which appears to be similar to SP monotherapy with respect 
to its effect on posttreatment malaria transmission.  
The results of the membrane-feeding assays for the randomly selected 
children, however, lead to very different conclusions. The most likely explanation 
for this is that detection of gametocytes by microscopy represents only the tip of 
the iceberg. The results for the randomly selected children suggest that relying 
on microscopy to select gametocyte carriers may lead to an overestimation of the 
effects of treatment regimens on malaria transmission. This was evident for all 
tested regimens and is attributable to low-density gametocytemia. The 
proportion of gametocyte carriers among children presenting with clinical malaria 
was as much as 4-fold higher when based on Pfs25 QT-NASBA than when based 
on microscopy, and certainly this estimate is closer to the truth. This proportion 
decreased markedly after administration of ACT, suggesting a direct negative 
effect of artemisinin derivatives on gametocyte survival 10,30. In contrast to SP 
monotherapy, ACT seemed to limit the period of infectiousness. Despite the 
evident reduction in gametocytemia after the administration of ACT, during the 
first two weeks after treatment, the majority of children harbored gametocytes at 
a density that was at or below the microscopic limit of detection, and a large 
proportion of these carriers were capable of infecting mosquitoes. The 
observation of infectiousness in children with gametocytemia below the 
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microscopic threshold is not unexpected 31-33, but the relative contribution made 
by these carriers to posttreatment malaria transmission in the present study is 
remarkable. Although a recent study concluded that AL treatment is highly 
effective in preventing posttreatment malaria transmission 10, we found here that 
60% of children treated with AL were capable of infecting mosquitoes. The 
present study shows that ACT does not substantially reduce the proportion of 
infectious children but results in a significantly lower proportion of infected 
mosquitoes. In this manner, ACT is likely to have beneficial effects on 
transmission.  
Submicroscopic gametocytemia is a relevant factor in mathematical 
models of general malaria transmission 34 and the development and spread of 
drug resistance 35. Resistance of malarial parasites to SP is common in our study 
area, with more than half of the children experiencing treatment failure during 
follow-up. This finding is similar to those of recent studies in Kenya and Uganda 
27,36,37. The efficacy of SP combination therapy is high, as has been previously 
reported for SP plus AQ treatment 27,38 and SP plus AS treatment 27. Here, we 
found that AL treatment provides the best clinical response, with only 2% 
treatment failure; this is identical to recent findings from Uganda and Tanzania 
6,39.  
Transmission intensity varies significantly in Africa and is determined by 
the local reservoir of infectious mosquitoes and the gametocyte prevalence in a 
population. We dissected ~30 fully fed mosquitoes per child, which is 
approximately equivalent to 1 week of exposure to mosquito bites in our study 
area 40. Considering a person's infectious period, this makes our estimates 
reasonable for the local situation, but our results clearly need to be interpreted in 
the context of biting rates in areas with other levels of endemicity. In our study 
area, the gametocyte prevalence at enrollment was ~90%. In a previous study of 
malaria transmission after AL treatment in the Gambia 10, where transmission 
intensity is much lower and highly seasonal, a number of children without 
microscopically detectable gametocytemia before or after treatment were 
included in membrane-feeding assays. Only 3.2% (1/31) of these assays resulted 
in mosquito infection (G. Targett, R. Ord, M. Jawara, and C. Sutherland, 
unpublished data), which is much lower than our present findings, despite 
comparable levels of infectiousness among children with microscopically 
confirmed gametocytemia. This suggests that infectious submicroscopic 
gametocyte densities may be less common in the Gambia. Findings from an area 
of low endemicity in Sudan, on the contrary, suggested a high prevalence (12%–
45%) of submicroscopic gametocyte densities, although infectiousness was not 
assessed 41. Future studies conducted in the general populations of areas with 
different transmission intensities and seasonalities should determine the 
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relationships among the level of endemicity, the prevalence of submicroscopic 
gametocytemia, and infectiousness to mosquitoes.  
Although Pfs25 QT-NASBA is much more sensitive than microscopy and 
may prove to be very valuable in estimating gametocyte prevalences, some 
reservations should be considered. It is not the mere presence of gametocytes 
but their capacity to infect mosquitoes that is relevant for transmission. For this, 
the accepted assay is measurement by membrane feeding. In addition, the 
sensitivity of Pfs25 QT-NASBA is 20–100 gametocytes/mL (i.e., 0.02–0.1 
gametocytes/μL). The average size of a blood meal of a mosquito is 2μL, and, to 
result in mosquito infection, it should contain a minimum of 1 male and 1 female 
gametocyte. Therefore, the lowest densities detected by Pfs25 QT-NASBA may be 
too low to be relevant for malaria transmission.  
In conclusion, our findings need to be interpreted in the context of 
transmission intensity but indicate that none of the tested drug regimens can 
clear gametocytes from all children during the month after treatment. ACTs in 
general, and AL in particular, are efficacious as treatments for uncomplicated 
malaria and are able to limit the period of posttreatment gametocyte carriage. 
However, because of the contribution made by submicroscopic gametocytemias, 
infectiousness appears to be the rule rather than the exception after treatment. 
These findings highlight the possible limitations of interventions that aim to 
reduce transmission by use of antimalarial drugs and indicate that gametocyte 
detection by microscopy is insufficient for future studies of malaria transmission.  
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Summary 
Submicroscopic Plasmodium falciparum gametocytaemia (<5,000 gametocytes/ 
mL) is common and may result in mosquito infection. We assessed the relation 
between gametocyte density and mosquito infection under experimental and 
field conditions using real-time quantitative nucleic acid sequence-based 
amplification (QT-NASBA) for gametocyte quantification.  
Serial dilutions of NF54 P. falciparum gametocytes showed a positive 
association between gametocyte density and the proportion of infected 
mosquitoes (β= 6.1, 95% CI 2.7 – 9.6, p=0.001). Successful infection became 
unlikely below an estimated density of 250-300 gametocytes/mL. In the field, 
blood samples of 100 naturally infected children showed a positive association 
between gametocyte density and oocyst counts in mosquitoes (β = 0.38, 95% 
CI 0.14 – 0.61, p = 0.002). The relative contribution to malaria transmission 
was similar for carriers with submicroscopic and microscopic gametocytaemia.  
Our results show that transmission occurs efficiently at submicroscopic 
gametocyte densities and that carriers harbouring submicroscopic 
gametocytaemia constitute a considerable proportion of the human infectious 
reservoir. 
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Introduction 
Transmission of Plasmodium falciparum from man to mosquito depends on the 
presence of infectious sexual stage parasites (gametocytes) that are ingested by 
mosquitoes taking a blood meal. The likelihood of mosquito infection can be 
expected to increase proportionally with increasing gametocyte density. 
However, this relation remains equivocal. A positive relation between 
gametocyte density and the proportion of infected mosquitoes was detected in 
experimental 1-3 and natural 2,4-6 P. falciparum infections but this relation was 
weak or non-existing in other studies 7-11. Several studies show that mosquitoes 
can become infected with gametocyte densities below the detection level of 
standard microscopy 3,6,8,9,12-14.  
Importantly, the recent application of molecular techniques for the 
detection 15,16 and quantification (Chapter 5) 17,18 of gametocytes indicated that 
submicroscopic gametocyte densities are common (Chapter 5) 18-20. In a 
previous study we have shown that submicroscopic gametocyte densities appear 
sufficient to drive post-treatment malaria transmission (Chapter 6) 21. It is 
important to quantify this potential reservoir and to determine the relation 
between submicroscopic gametocyte densities and the infectiousness to 
mosquitoes in order to plan and evaluate transmission reducing interventions 22. 
This can be done in natural infections and under laboratory conditions where the 
use of cultured, synchronized gametocytes excludes potential confounders such 
as gametocyte maturity and host immune factors.  
In this study we used quantitative nucleic acid sequence-based 
amplification (QT-NASBA) to determine the relation between P. falciparum 
gametocyte density and the infectiousness to mosquitoes under field and 
laboratory conditions.  
 
 
Methods 
The infectiousness of cultured gametocytes.  
Plasmodium falciparum NF54 gametocytes were obtained from in vitro culture 23. 
Experiments were performed with mature gametocytes. Serial dilutions were 
made in whole blood to obtain gametocyte dilutions at approximately 50% 
haematocrit ranging from 102 to 106 gametocytes/mL. Gametocyte density in 
serially diluted suspensions was calculated from the number of gametocytes 
present in the original sample. Of all dilutions, a 50 µL sample was stored at -
70ºC for subsequent quantification of gametocytes by real-time Pfs25 QT-
NASBA. All dilutions were fed through a membrane feeding system to 50-100 
female Anopheles stephensi mosquitoes 24 that were 3-5 days old and starved 
for 1-2 hours prior to feeding. After feeding, mosquitoes were kept at 26ºC, 
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80% relative humidity, on glucose until dissected in 1% mercurochrome for 
microscopical assessment of oocyst infection on days 7-9.  
 
Infectiousness of naturally infected children  
Membrane feedings were conducted on samples from children naturally infected 
with P. falciparum malaria in Mbita, Suba district, western Kenya. Details of the 
study can be found elsewhere (Chapter 6). The study protocol was approved by 
the scientific steering committee and ethical review committee of the Kenya 
Medical Research Institute (SSC No. 791). Children were treated for 
uncomplicated P. falciparum malaria with sulphadoxine-pyrimethamine (SP), SP 
plus artesunate, SP plus amodiaquine or artemether-lumefantrine. All children 
older than 2 years who attended the clinic for their day 14 post-treatment visit 
in November-December 2004 were invited for membrane feeding experiments, 
regardless of microscopic gametocytaemia. We enrolled 25 children 
consecutively per treatment arm, giving a total of 100 membrane feeding 
experiments. 
Venous blood samples of 3 mL were obtained from children whose parent 
or guardian gave specific consent for the procedure. Samples were fed to 
approximately 150 locally reared 4 to 5-day-old female Anopheles gambiae s.s. 
mosquitoes via an artificial membrane attached to a water-jacketed glass feeder 
maintained at 37ºC. After 10 to 15 minutes, fully fed mosquitoes were selected 
and kept at 27-29ºC for 7 days on glucose (10%) until midguts were dissected 
in 2% mercurochrome. The midguts were examined microscopically for oocysts 
with a second microscopist confirming their presence if observed. For each 
experiment, exactly 30 randomly selected mosquitoes were dissected. From 
each blood sample included in the membrane feedings, 50μL was used for 
quantification of gametocytes by real-time Pfs25 QT-NASBA.  
 
Gametocyte detection by Pfs25 QT-NASBA  
Quantification of gametocytes by real-time Pfs25 mRNA QT-NASBA was 
performed as described elsewhere (Chapter 5)18. Briefly, nucleic acids were 
extracted from the blood samples using the guanidium isothiocyanate/silica 
procedure 25. QT-NASBA was performed on a NucliSens EasyQ analyser 
(bioMérieux) using the NucliSens Basic Kit for amplification according to 
manufacturer’s manual at a KCl concentration of 80mM in a total reaction 
volume of 10 μL per reaction. The number of gametocytes was calculated in 
relation to a standard gametocyte stage V dilution series, using the time point of 
amplification at which the fluorescence detecting target amplicons exceeded the 
mean fluorescence of three negative controls + 20 standard deviations. A similar 
protocol was used for the 18S rRNA QT-NASBA 17 to confirm the presence of P. 
falciparum parasites. 
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Data analyses  
Statistical analyses were carried out in SPSS version 12.0 and STATA 8.0. Pfs25 
QT-NASBA gametocyte density was analyzed on a log-scale with negative 
samples included as zero’s. The relation between gametocyte density and 
mosquito infection rates was fitted to linear, logistic and exponential functions. 
The best results were presented based on r2. For field samples, the relation 
between gametocyte density and oocyst counts in individual mosquitoes was 
determined using negative binomial models. Uninfected mosquitoes were 
included in these analyses and a random effect was added to allow for the 
correlation between observations from the same individual. Regression 
coefficients β with 95% confidence intervals (95% CI) were presented. 
Proportions were compared using odds ratio’s (OR), the trend in proportions with 
the Cochran-Armitage test for trend. Normally distributed continuous variables 
were compared using the Student t-test and the correlation between continuous 
normally distributed variables was quantified with the Pearson correlation 
coefficient.  
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Results 
Infectiousness of cultured gametocytes 
The percentage of infected mosquitoes was positively associated with 
gametocyte density from in vitro culture (β = 6.1, 95% CI 2.7-9.6) and was 
described by a linear function (r2 = 0.39, p = 0.001)(figure 7.1). Non-linear 
functions did not improve the fit. Infected mosquitoes harboured 1-4 oocysts 
and only 14% of the infected mosquitoes had more than one oocyst, making 
analyses on oocyst counts uninformative. An estimated 7.6% of the feeding 
mosquitoes was infected at the microscopic detection limit of 5 gametocytes/μL. 
The trendline crossed the Y-axis at 250-300 gametocytes/mL, indicating that 
mosquito infection under the used conditions is unlikely below this threshold. 
There was a good consensus between the gametocyte density measured in the 
Pfs25 QT-NASBA and the estimated density from diluted starting concentrations 
(Pearson correlation coefficient = 0.88, p < 0.001).  
 
 
 
Figure 7.1 Mosquito infection rates against log gametocyte density for feeding 
experiments on serial dilutions of in vitro cultured P. falciparum gametocytes. Results are 
shown from three membrane feeding experiments with serial dilutions of non-synchronised (open 
circles) and synchronized (filled circles) gametocytes. Gametocyte density was determined by 
Pfs25 QT-NASBA; mosquito infection rates by examination of 50-100 dissected mosquitoes per 
sample. The curve represents the linear relation between log gametocyte density and mosquito 
infection rates (y = 6.13 x – 15.06; r2 = 0.39, p = 0.001). 
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Infectiousness of naturally infected children 
A total of 100 membrane feedings were successfully carried out in children with 
a median age of 2.8 (interquartile range 2-4) years. At the time of membrane 
feedings 25.0% (25/100) of the children harboured microscopically detectable 
gametocytes and 75.0% (75/100) were gametocyte positive by Pfs25 QT-
NASBA. A total of 62.0% (62/100) of the children was infectious to mosquitoes, 
of whom 69.4% (43/62) had no microscopically detectable gametocytes. There 
was a positive association between gametocyte density and the percentage of 
infected mosquitoes, described by an exponential function (r2 = 0.48, p = 
0.026)(figure 7.2).  
 
 
 
Figure 7.2. Mosquito infection rates against log gametocyte density for feeding 
experiments on venous blood samples of naturally infected Kenyan children. Results are 
shown for individual venous blood samples; microscopically confirmed gametocyte carriers are 
indicated with filled circles. Gametocyte density was determined by Pfs25 QT-NASBA; mosquito 
infection rates by examination of 30 dissected mosquitoes per sample. The curve represents the 
exponential relation between log gametocyte density and mosquito infection rates (y = 1.93 e0.31 x; 
r2 = 0.48, p = 0.026). 
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Infectiousness of children with submicroscopic gametocytaemia  
Successful mosquito infection was observed in children with microscopic and 
submicroscopic gametocyte densities (table 7.1). Compared to children with 
microscopically detectable gametocytes, the proportion of infectious children was 
lower in children with submicroscopic gametocytaemia and lowest in children 
who were negative in both microscopy and Pfs25 QT-NASBA (Cochran-Armitage 
test for trend, p = 0.001). The same trend was observed for the proportion of 
infected mosquitoes (Cochran-Armitage test for trend, p < 0.001). Importantly, 
70.0% (35/50) of the children with submicroscopic gametocytaemia were 
capable of infecting at least one mosquito.  
Infected mosquitoes harboured 1-13 oocysts and 26% of the infected 
mosquitoes had more than one oocyst. We observed a positive association 
between gametocyte density and oocyst counts in mosquitoes (β = 0.38, 95% 
CI 0.14-0.61, p = 0.002) and an independent borderline significant positive 
association between age and oocyst counts (β = 0.11, 95% CI -0.01-0.23, p = 
0.075). Eight children were infectious to mosquitoes with no gametocytes 
detected in their samples by Pfs25 QT-NASBA. P. falciparum 18S ribosomal RNA 
was detected in all these samples (8/8), indicating that RNA extraction had been 
successful and that P. falciparum parasites were present. Of those children who 
were gametocyte negative in both microscopy and Pfs25 QT-NASBA, 32.0% 
(8/25) were infectious to mosquitoes. In general, the association between 
gametocyte prevalence and the proportion of infectious children in the random 
feeds was weak for microscopy (OR = 2.36, 95% CI 0.85-6.57) and much 
stronger for the Pfs25 QT-NASBA (OR = 5.46, 95% CI 2.05-14.56).  
The contribution to malaria transmission of children with microscopically 
confirmed gametocytes and children with submicroscopic gametocytaemia was 
estimated by determining the proportion of the total number of infected 
mosquitoes that they infected. Although individual submicroscopic gametocyte 
carriers infected fewer mosquitoes, submicroscopic gametocytaemia was more 
common than microscopic gametocytaemia, resulting in an estimated 
contribution to transmission of 45.3% for both groups (table 7.1). 
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Table 7.1. Gametocyte carriage detected by microscopy and Pfs25 QT-NASBA and 
infection of mosquitoes after membrane feeding. 
 Gametocyte carriage p-value 
Microscopy - - +  
Pfs25 QT-NASBA - + +  
Number of samples 25 50 25  
Density, GM (IQR) * - 592.5  
(42-2487) 
4058.1  
(301-34798) 
0.007† 
Infectious children, % (n/N) 32.0 (8/25) 70.0 (35/50) 76.0 (19/25) 0.001‡ 
Infected mosquitoes, % (n/N) 1.7 (13/750) 4.1 (62/1500) 8.3 (62/750) <0.001‡ 
Contribution to transmission,%§ 9.5 45.3 45.3  
 
- = gametocyte negative; + = gametocyte positive; GM = geometric mean. IQR = interquartile 
range; *Geometric mean density of gametocytes per mL of blood in the Pfs25 QT-NASBA for 
positives only; †P-value for the Student t-test on log-transformed gametocyte density; ‡P-value for 
the Cochran-Armitage test for trend; § The contribution of each group to transmission was 
estimated by dividing the number of mosquitoes infected by this group by the total number of 
mosquitoes infected by all 100 children. Equal mosquito exposure of all groups is assumed. 
 
Discussion 
In this study, we show that submicroscopic gametocyte densities can efficiently 
infect mosquitoes under both laboratory and field conditions. Although it has 
previously been suggested that submicroscopic gametocyte densities can infect 
mosquitoes, 3,6,8,9,12-14 this is the first study that actually quantifies 
submicroscopic gametocytaemia in relation to mosquito infection. We found that 
the contribution of submicroscopic gametocytaemia to malaria transmission can 
be similar to that of microscopically confirmed gametocyte carriers.  
 
Data from cultured gametocytes show a clear reduction in the proportion 
of infected mosquitoes with decreasing gametocyte density. Such a relation has 
been observed before 24,26 but could not be extended to submicroscopic densities 
until recently. An estimated 7.6% of mosquitoes became infected after feeding 
on a sample with a gametocyte concentration at the threshold of microscopical 
detection. Successful mosquito infection becomes unlikely below an estimated 
density of 250-300 gametocytes per mL.  
Under field conditions, submicroscopic gametocyte densities can also 
infect mosquitoes, although the association between gametocyte density and 
mosquito infection rates was less straightforward than in the laboratory 
experiments. A direct comparison between the experiments in the laboratory 
and the field can not be made for a number of reasons. There may be 
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differences in gametocyte fitness or maturity between cultured NF54 
gametocytes and natural infections as well as differences in compatibility of 
parasite isolates and vector species 27,28. Natural infections also regularly contain 
multiple parasite genotypes, opposed to a single infecting genotype in the in 
vitro culture. This could affect gametocyte development through in-host 
competition between parasite genotypes 29,30. Sexual stage-specific immune 
responses may also have influenced transmission efficiency in the field 
experiments (Chapter 12) 31.  
In the field experiments, we frequently observed mosquito infection at 
very low gametocyte densities. Successful mosquito infection by eight children 
with negative Pfs25 QT-NASBA results suggests that infection can even occur 
below the detection level of the Pfs25 QT-NASBA, which is 20-100 
gametocytes/mL. 17 Unlike for the laboratory experiments, we could not estimate 
a minimum gametocyte density for mosquito infection in the field. Gametocytes 
below levels of 100/mL may not be detected by Pfs25 QT-NASBA and this may 
explain transmission without detection of Pfs25 mRNA. Findings from laboratory 
and field experiments indicate that the threshold gametocyte density necessary 
to infect mosquitoes is below the theoretical threshold of 2 gametocytes per 
mosquito blood meal (2μL). Since the uptake of gametocytes by mosquitoes 
follows a Poisson or negative binomial distribution 32, some successful infections 
can occur when feeding on samples with lower gametocyte densities. Several 
biological mechanisms could facilitate successful mosquito infections at low 
gametocyte densities. Motility or aggregation of gametocytes may occur, 
favouring the encounter of males and females 32. This phenomenon could have 
influenced transmission efficiency in our experiments. Gametocytes may also 
preferentially accumulate in the subdermal capillaries 33,34. Although this could 
increase the transmission success of individuals with low peripheral gametocyte 
density under natural conditions, it will not have influenced our findings since we 
used the same venous blood samples for feeding experiments and gametocyte 
quantification. 
Both laboratory and field experiments clearly show the efficient 
transmission of low-density gametocytaemia, despite Anopheles immune 
responses that can substantially reduce transmission success 35. We observed a 
2-fold lower proportion of infected mosquitoes for children harbouring 
submicroscopic gametocyte densities (4.1%) compared to microscopic 
gametocyte densities (8.3%). This lower proportion of infected mosquitoes was 
counterbalanced by the higher prevalence of submicroscopic gametocytaemia in 
our population, resulting in a similar contribution to malaria transmission of 
carriers with microscopic and submicroscopic gametocytaemia at the time we 
conducted our experiments. The duration of gametocyte carriage is obviously a 
crucial factor to determine the overall contribution of submicroscopic 
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gametocytaemia to malaria transmission and this requires further research. 
Further studies should also determine the prevalence and infectiousness of 
submicroscopic gametocytaemia in other populations and the possible relations 
with seasonality and transmission intensity.  
Despite our selected population of children after antimalarial treatment, 
we feel that our findings are of public health importance. Interventions that aim 
to interrupt transmission will have to reduce gametocytaemia to densities well 
below the microscopic detection limit and should also target carriers with 
submicroscopic gametocytes. 
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Summary 
Recently developed molecular gametocyte detection techniques have shown that 
submicroscopic P. falciparum gametocytes are common in symptomatic patients 
and can infect mosquitoes. The relevance for the infectious reservoir of malaria 
in the general population remains unknown. In this study we investigated 
submicroscopic asexual parasitaemia and gametocytaemia in inhabitants of an 
area of hypo-endemic and seasonal malaria in Tanzania. 
Two cross sectional malariometric surveys were conducted in the dry and 
wet season of 2005 in villages in lower Moshi, Tanzania. Finger prick blood 
samples were taken to determine the prevalence of P. falciparum parasites by 
microscopy, rapid diagnostic test and real-time nucleic acid sequence-based 
amplification (QT-NASBA).  
In total, 2752 individuals participated in the surveys, of whom 1.9% 
(51/2721) had microscopically confirmed asexual parasites and 0.4% (10/2721) 
gametocytes. In contrast, QT-NASBA revealed that 32.5% (147/453) of the 
individuals harboured asexual parasites and 15.0% (68/453) gametocytes. No 
age dependency or seasonality was observed in submicroscopic parasite 
carriage.  
In conclusion, molecular detection techniques reveal that carriage of 
submicroscopic asexual parasite and gametocyte densities is relatively common 
in this low transmission area. Submicroscopic gametocytaemia is likely to be 
responsible for maintaining malaria transmission in the study area. 
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Introduction 
Gametocytes are the sexual stage malaria parasites responsible for transmission 
from man to mosquito. Successful mosquito infection requires the ingestion of 
mature gametocytes by mosquitoes taking a blood meal. The production of 
gametocytes is therefore essential for maintaining malaria transmission. This is 
particularly important in areas of low or seasonal malaria transmission where 
levels of man-vector contact are unpredictable and a consistent production of 
gametocytes appears necessary for parasite survival 1,2. 
Gametocyte carriage is most commonly assessed microscopically and is 
related to malaria transmission intensity. In high endemic areas most 
microscopic gametocyte carriers are children, while this negative age 
dependency disappears as transmission intensity decreases 3,4.  
Microscopically confirmed gametocyte carriage is generally uncommon in low 
transmission areas, especially in the dry season 1,5,6 although gametocyte 
carriers are vital in re-initiating malaria transmission in the subsequent 
transmission season. During the dry season, asexual parasite carriage can 
persist during below the microscopic threshold 7 and this may also be true for 
gametocyte carriage.  
Molecular gametocyte detection techniques have recently addressed 
submicroscopic Plasmodium falciparum gametocytaemia in microscopically 
confirmed asexual parasite carriers (Chapter 6, 7)1,2,8,9. Studies using either 
reverse transcriptase PCR (RT-PCR) or quantitative nucleic acid sequence-based 
amplification (QT-NASBA) have revealed that submicroscopic gametocytaemia is 
common in symptomatic parasite carriers and can persist for several months 
(Chapter 6, 7) 1,2,8,9. The prevalence and importance of submicroscopic 
gametocytaemia has however yet to be investigated in the general population. 
In this study we address this issue by determining the prevalence of 
(submicroscopic) asexual parasites and gametocytes in inhabitants of an area of 
low and seasonal malaria endemicity in Tanzania.  
 
Methods 
Study site 
This study was conducted in the villages Msitu wa Tembo and Magadini in Lower 
Moshi. The study area lies on the plains beneath Kilimanjaro in northern 
Tanzania (latitude 3° 33’ – 3° 44’ S; longitude 37°17’ – 37° 24’ E). Malaria 
transmission in the area is largely restricted to the long rainy season (May-July) 
and an unpredictable short rainy season (October-November). The remainder of 
the year is dry and hot and transmission is practically absent .The average 
annual rainfall is 615 mm (10 year average) and the entomologic inoculation 
rate was recently estimated at 2.3 infectious bites per person per year with 
Anopheles arabiensis as principle vector 10. Villagers predominantly belong to 
Chapter 8 
 104
Masai, Pare and Arusha tribes, and are mostly involved in self-subsistence 
farming and fishing. Two cross sectional surveys were conducted during the dry 
season (April) and wet season (August) in the year 2005, targeting a minimum 
of 1000 participants per survey. Families were selected using village censuses 
and computer randomised tables. A central point in each village was identified 
and villagers attended the survey on a first come first serve basis.  
 
Data collection 
Information on demographic, anthropometric and general health indicators were 
collected by means of a questionnaire. Each participant was examined by a 
qualified clinical attendant for signs of anaemia, fever and splenomegaly. A 
single blood sample was obtained by finger prick from each participant and used 
in the field for haemoglobin (Hb) measurement using a haemocue photometer 
(Angelholm, Sweden), detection of malaria parasites using a rapid diagnostic 
test (RDT) detecting P. falciparum specific histidine rich protein-2 (Paracheck®, 
Orchid Biomedical Systems, India; Eurocheck®, Euromedi Equip Limited, UK) 
and the preparation of microscopy and QT-NASBA samples. The RDT and Hb 
measurement were performed according to the manufacturer’s instructions and 
scored in the field. The comparability in sensitivity of the two rapid tests was 
confirmed in dilutions of cultured NF54 P. falciparum parasites 11 (Kappa-value: 
0.82, p=0.001). Those found to have malaria by RDT were given free treatment 
with sulphadoxine-pyrimethamine, according to the national guidelines. 
Individuals requiring further attention were treated accordingly or referred to the 
nearby hospital.  
Thin and thick blood smears were made and Giemsa stained in the field. 
Slides were subsequently double read in two different stations by experienced 
microscopists. Readings were compared for validation and slides giving 
discordant results were read by a third reader. The majority result was taken as 
final.  
Exactly 50μL of blood was collected in EDTA tubes for QT-NASBA. P. 
falciparum parasite detection by QT-NASBA was done as described elsewhere 
12,13. Nucleic acids were extracted from blood samples as described by Boom et 
al. 13. The first part of the RNA extraction was done in the field following the 
original Guanidinium isothiocyanate (GuSCN) RNA extraction method 14 until the 
nucleic acids were bound to silica dioxide particles. At this point, samples were 
stored at -20°C and transferred to the laboratory for completion of the extraction 
and QT-NASBA analysis. QT-NASBA was performed on a NucliSens EasyQ 
analyser (bioMérieux) for 18S rRNA and Pfs25 mRNA. The 18S QT-NASBA 
detects all circulating parasite stages; the Pfs25 QT-NASBA is gametocyte 
specific. Although the number of asexual parasites can not be directly 
determined by QT-NASBA, it can be estimated by subtracting the concentration 
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of gametocytes in the Pfs25 QT-NASBA from the total concentration of parasites 
in the 18S QT-NASBA. Nuclisens Basic kits were used for amplification according 
to the manufacturers manual. The number of gametocytes was calculated in 
relation to a standard gametocyte stage V dilution series 11, using the time point 
of amplification at which the fluorescence detecting target amplicons exceeded 
the mean fluorescence of three negative controls + 20 standard deviations. 
Parasite detection by QT-NASBA was done for a selection of 140-160 individuals 
from three age groups (< 5 years, ≥5 to 15 years and ≥ 15 years). Samples 
were randomly selected within age-strata using computer generated 
randomisation tables.  
 
Data analysis 
All data was double entered in a created computer access database and 
imported in SPSS 12.01 after validation. Age was categorized into < 5 years, ≥5 
to 15 years and > 15 years; haemoglobin status in severe (< 5g Hb/dl), 
moderate (< 8g/dl), and mild anaemia (<11g/dl). Proportions were compared 
between groups with the χ2-test or Fisher’s Exact test; means were compared 
with one-way ANOVA, student t-test or Wilcoxon Rank-sum test, where 
appropriate. The correlation between normally distributed continuous variables 
was quantified using the Pearson’s correlation coefficient, the relation between 
gametocyte prevalence and asexual parasite density by logistic regression 
models. Parasite density was analyzed on a log-scale and geometric mean 
densities per mL were calculated for parasite carriers with interquartile ranges 
(IQR). 
 
Ethical aspects 
All villagers who were invited for the survey were given detailed 
information about the study aim and procedures before they were asked to sign 
individual informed consent. Parents/guardians were asked to sign on behalf of 
children. The study protocol was approved by the ethical committees of both the 
Tanzanian National Institute of Medical Research (NIMR/HQ/Vol.IX/343) and the 
London School of Hygiene & Tropical Medicine.  
 
Results 
In total, 2752 individuals participated in the cross-sectional surveys, 1593 in the 
dry season and 1159 in the wet season (table 8.1). The prevalence of moderate 
or severe anemia (Hb<8g/dl) was 6.7% (185/2752) in the general population 
but was higher in children under five years of age, 15.6% (96/614) (χ2=97.73, 
p<0.001). Splenomegaly was uncommon with only 0.5% (15/2752) of the 
individuals having a Hackett’s score ≥2. 
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Table 8.1. Characteristics of the study population 
N 2752 
 Dry season, n 1593 
 Wet season, n 1159 
Age (Years), % (n)  
 < 5 22.3 (614) 
 5 – 15 27.3 (752) 
 >15 50.4 (1386) 
Sex, % male (n) 39.1 (1075) 
Tribe  
 Masai 25.9 (713) 
 Arusha 12.4 (340) 
 Pare 12.2 (336) 
 Others 49.5 (1362) 
Anaemia, % (n)  
 Normal 69.8 (1921) 
 Mild  23.0 (634) 
 Moderate  6.1 (168) 
 Severe 0.6 (17) 
Reported fever in  
previous two weeks, % (n) 
 
20.4 (562) 
Splenomegalia  
(Hackett’s score ≥2), % (n) 
 
0.54 (15) 
Anaemia haemoglobin was defined as nomal (≥11 g Hb/dl), mild (<11g/dl), moderate (<8 g/dl) 
and severe (<5 g/dl) anaemia. 
 
The rapid diagnostic test (RDT) detected parasites in 3.0% (48/1593) of the 
individuals in the dry season and 1.7% (20/1156) in the wet season (χ2=4.67, 
p=0.03). Asexual parasite prevalence as detected by microscopy was 1.9% 
(51/2721) and similar in the dry and wet season (table 8.2). The geometric 
mean asexual parasite density in parasite carriers was 2,225.6 (IQR 80.0-
29,396.8) *103 parasites/mL. Although there was a statistically significant 
positive association between the presence of parasites by RDT and microscopy 
(χ2=257.35, p<0.001), 72.1% (49/68) of the RDT positive samples were 
negative by microscopy and 62.7% (32/51) of the microscopy positive samples 
were negative by RDT. In contrast to the low prevalence of microscopically 
confirmed parasite carriers, the 18S QT-NASBA detected parasites in 32.5% 
(147/453) of the individuals. Parasite prevalence by 18S QT-NASBA was non-
significantly higher in the dry season (χ2=2.96, p=0.09, table 8.2). 
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Table 8.2. Parasite prevalence per season by different detection techniques 
 Parasite prevalence, % (95% CI) 
Season Rapid test* Microscopy Microscopy QT-NASBA QT-NASBA 
  Asexual  Gametocytes Asexual  Gametocytes 
Dry 3.0 (48/1593) 2.0 (32/1571)  0.4 (6/1571) 36.4 (78/214) 15.9 (34/214) 
Wet 1.7 (20/1156) 1.7 (19/1150) 0.3 (4/1150) 29.9 (69/239) 14.2 (34/239) 
Total 2.5 (68/2749) 1.9 (51/2721) 0.4 (10/2721)  32.5 (147/453) 15.0 (68/453) 
95% CI = 95% confidence interval; *Difference between dry and wet season: χ2 = 4.57, p = 0.03 
 
 
For those individuals who were 18S positive and Pfs25 QT-NASBA 
negative, 18S QT-NASBA parasite concentration was assumed to equal asexual 
parasite density. In those individuals who were both 18S and Pfs25 QT-NASBA 
positive, the total parasite concentration by 18S QT-NASBA was always higher 
than the gametocyte concentration by Pfs25 QT-NASBA, indicating that both 
asexual parasites and gametocytes were present. In these individuals asexual 
parasite density was estimated by subtracting the concentration in the Pfs25 QT-
NASBA from the total parasite concentration in the 18S QT-NASBA. In those 18S 
QT-NASBA positive, the estimated geometric mean density of asexual parasites 
was 491.9 parasites/ml (IQR 32.6 - 5607.9). A positive RDT was positively 
associated with 18S QT-NASBA parasite prevalence (χ2=15.46, p<0.001) 
although 1.6% (5/306) of the 18S QT-NASBA negatives were positive in the 
RDT. Gametocytes were detected by microscopy in 0.4% (10/2721) of the 
slides, the Pfs25 QT-NASBA detected gametocytes in 15.0% (68/453) of the 
individuals, independent of season (table 8.2). The geometric mean gametocyte 
density by Pfs25 QT-NASBA was 108.2 gametocytes/mL (IQR 20.0 – 1049.0). 
There was a strong correlation between the estimated density of asexual 
parasites by 18S QT-NASBA and Pfs25 QT-NASBA gametocyte prevalence 
(β=0.35, se 0.07, p<0.001) and density (r2 0.40, p=0.001).  
Parasite densities of those individuals whose samples were tested by QT-
NASBA and microscopy (n=453) are presented in figure 8.1. The vast majority 
of parasite carriers detected by 18S QT-NASBA harboured parasites at a low 
density and were not detected by microscopy (figure 8.1A). Only 7.5% (11/147) 
of 18S QT-NASBA positives were also detected by microscopy. One microscopic 
parasite carrier was negative in the 18S QT-NASBA. A similar observation was 
seen for gametocytes where 4.4% (3/68) Pfs25 QT-NASBA positives were 
confirmed by microscopy and all microscopic gametocyte carriers were positive 
in the Pfs25 QT-NASBA figure 8.1B). 
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Figure 8.1 Asexual parasite and gametocyte detection by microscopy and QT-NASBA. 
A. Open bars indicate the estimated asexual parasite density by QT-NASBA using the formula: 
total parasite density by 18S QT-NASBA – gametocyte density by Pfs25 QT-NASBA (n=147). For 
those samples that were positive by microscopy, microscopic asexual parasite densities are 
presented in solid bars (n=12). 
B. Open bars indicate gametocyte density determined by Pfs25 QT-NASBA (n=68). For those 
samples that were positive by microscopy, microscopic gametocyte densities are presented in solid 
bars (n=3).  
 
 
There was no statistically significant difference in QT-NASBA asexual parasite or 
gametocyte carriage in the different age groups, χ2=3.07, p=0.22 and χ2=1.11, 
p=0.57, respectively (figure 8.2). 
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Figure 8.2 The age-dependency of asexual parasite carriage and gametocyte carriage as 
determined by QT-NASBA. Shaded bars indicate parasite prevalence in the dry season, solid 
bars in the wet season. Error bars indicate the upper limit of the 95% confidence interval. Asexual 
parasite prevalence was detected by 18S QT-NASBA; gametocyte prevalence by Pfs25 QT-NASBA. 
 
 
Discussion 
In this study we investigated submicroscopic P. falciparum parasitaemia in a 
cross section of the general population of a low transmission area in Tanzania. 
While microscopically confirmed carriage of asexual parasites and gametocytes 
was very low, the QT-NASBA revealed that 32.5% of the individuals carried 
asexual parasites and 15% gametocytes.  
 
This high prevalence of submicroscopic parasitaemia was not related to 
age or season. The absence of a clear seasonal difference in parasite prevalence 
is most likely due to the limited rainfall in the year we conducted our study. The 
total rainfall in 2005 was only 34% of the 10-year average and was particularly 
poor in the months of April and May, usually the months of peak numbers of 
mosquitoes 10. The lack of age-dependency of parasite prevalence is in line with 
previous work in low transmission settings in our study area 15. Although 
asymptomatic parasite carriage is well known in areas with perennial 
transmission, it is remarkable in an area of low and seasonal malaria 
transmission. The prevalence of submicroscopic parasitaemia was previously 
determined in areas of low malaria transmission intensity although results are 
not directly comparable with ours because of differences in malaria transmission 
patterns 6 and the selection of individuals 16. Only 6-15% of individuals from an 
epidemic-prone area of low transmission in Kenya harboured parasites by PCR in 
the dry or wet season 6 and 40-50% of treated symptomatic patients retained 
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persisting parasitaemia by PCR during the dry season in an area of unstable 
malaria in Sudan 16.  
Our findings suggest that even in an area of very low transmission 
intensity, a substantial part of the population is capable of controlling infections 
in such a way that parasite densities remain extremely low. These asymptomatic 
parasite carriers can be expected to become gametocytaemic at some point 
during their infection if a regular number of asexual parasites is committed to 
the sexual pathway, as is suggested by mathematical models 17. Indeed, we 
observed that a relatively large proportion of parasite carriers harboured 
gametocytes at submicroscopic densities at the time of sampling. Our 
gametocyte prevalence of 15% measured by QT-NASBA compares with 12-52% 
in longitudinally followed individuals after antimalarial treatment in an area of 
unstable malaria in Sudan 1. Sequestration of gametocytes in sub dermal 
capillaries 18 suggests that some gametocyte carriers may have remained 
undetected by examining finger prick blood samples. The true proportion of 
gametocyte carriers in our population may therefore be even larger than 
detected by Pfs25 QT-NASBA. 
The relevance of these low-density gametocyte infections to the overall 
infectious reservoir of malaria needs some consideration. It is generally accepted 
that the presence of gametocytes does not always render the human host 
infectiousness to mosquitoes. Infectivity is influenced by several factors, 
including immune responses, gametocyte fitness and density (Chapter 12) 19-21. 
Thus, rather than gametocyte density per se, malaria transmission potential in 
mathematical models is often defined as the probability that a mosquito blood 
meal contains the threshold density of at least one gametocyte of each sex 20. 
This threshold is 1 gametocyte per μL assuming an average mosquito blood meal 
size of 2μL. In this study, only 30% of the gametocyte carriers harboured 
gametocytes at or above this theoretical threshold density. However, data are 
accumulating to suggest that this threshold density is too high; submicroscopic 
gametocyte densities are infectious to mosquitoes 22,23 and this has recently 
been shown using the Pfs25 QT-NASBA to detect gametocytes (Chapter 6) 8. 
Using this technique, mosquito infection can be successful at densities below 1 
gametocyte/μL, for both natural infections and cultured gametocytes (Chapter 7) 
24. Although the proportion of mosquitoes infected is lower for carriers with 
submicroscopic gametocytaemia 17 (Chapter 7) 24 they are present in substantial 
numbers and their contribution to malaria transmission can be considerable 
(Chapter 6, 7) 8,22,24. Population based infectiousness can be crudely based on 
the relative proportion of gametocyte carriers multiplied by their infectivity. 
When assuming a two-fold lower infectivity of submicroscopic gametocytaemia 
compared to microscopically detectable gametocyte densities, as was found in a 
study in western Kenya (Chapter 7) 24, the estimated transmission potential in 
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our population would be five-fold higher when based on the Pfs25 QT-NASBA 
compared to microscopy.  
The use of molecular techniques provides more precise measures of 
parasite prevalence. These measures suggest more asymptomatic infections and 
longer periods of carriage of asexual parasites, which will presumably affect the 
generation of effective immunity. The subsequent development of sexual stage 
parasites in these infections would mean that malaria transmission is maintained 
by a much larger number of low-density gametocyte carriers than previously 
thought.  
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Summary 
Transmission of Plasmodium falciparum malaria is initiated by sexual stages in 
the mosquito. Anti-Pfs48/45 and anti-Pfs230 sexual stage antibodies that are 
ingested together with parasites can reduce parasite development and 
subsequently malaria transmission.  
Acquisition of sexual stage immunity was studied in a cohort of 102 non-
immune Javanese individuals migrating to hyperendemic Papua Indonesia. 
Seroprevalence of antibodies against Pfs48/45, Pfs230 and functional 
transmission reducing activity (TRA) were measured upon arrival and at 6, 12 
and 24 months. Asexual parasitaemia and gametocytaemia were assessed 
fortnightly.  
TRA and seroreactivity increased with the number of P. falciparum 
infections. The longitudinally sustained association between TRA and antibodies 
against Pfs48/45 (OR 3.74, 95% CI 1.51-9.29) and Pfs230 (OR 3.72, 95% CI 
1.36-10.17) suggests that functional transmission reducing immunity is acquired 
following limited exposure to infection.  
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Introduction 
Successful transmission of Plasmodium falciparum parasites from humans to 
mosquitoes depends on the presence of infectious gametocytes in the 
circulation, which are derived from a small fraction of asexual parasites. After 
ingestion of the blood meal by mosquitoes, fertilization takes place in the 
midgut, which will ultimately result in the generation of infectious sporozoites in 
the salivary glands. Specific antibodies against sexual stages can interfere with 
fertilization and subsequent sporogonic development when co-ingested with the 
blood meal, as shown in natural and experimental infections 1-4. This 
transmission reducing activity (TRA) is associated with antibodies directed 
against the sexual stage specific antigens Pfs48/45 and Pfs230 5-8. The rate of 
development and persistence of TRA is largely unknown. While it was suggested 
to be low-grade and rapidly transient 9 persistent TRA has also been observed 10. 
Acquisition of immunity directed against asexual blood stage parasites has been 
intensively studied people migrating from a non-endemic to a malaria endemic 
area 11-15. In these transmigrants, clinical and parasitological immunity 
developed quickly after exposure 13 with inconsistent evidence for an 
independent role of age 11-16. 
The objective of this study is to examine the development of sexual stage 
specific immunity in a longitudinal cohort of Javanese children and adults from 
non-endemic Java, following migration to malaria endemic Papua. Antibody 
reactivity against sexual stage specific antigens Pfs230 and Pfs48/45 were 
determined and compared to antibodies against asexual stage antigen glutamate 
rich protein (GLURP) and whole parasite extracts. GLURP-specific antibodies 
have previously been associated with protection against high levels of 
parasitaemia 17 and clinical disease 18-20. The development of sexual stage 
specific immunity was evaluated by detecting circulating antibodies against 
Pfs230 and Pfs48/45 and by assessing functional TRA in the standard 
membrane-feeding assay.  
 
 
Methods 
Study population.  
The study site was a newly created transmigration village (designated SP2), 
located near the north-eastern coast of Papua, Indonesia. After informed 
consent, healthy volunteer adults between 20-40 years of age and children 
between 6-12 years of age were included in the study, which was approved by 
all convening scientific and ethical review boards under U.S. Department of 
Defence Protocol #30820. Subjects were excluded if admitting a history of 
residence in a malaria endemic area in the previous five years. Details on 
recruitment, follow-up and the epidemiology of malaria in this cohort have been 
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described elsewhere 16. Enrolment started in 1996 and follow-up ended in 1999. 
The subjects originated from Java and were enrolled in the study within 48 hrs 
of arrival in Papua, Indonesia. Malaria transmission in Java has been very low for 
many decades, typically around 0.01 malaria cases/1000 person-years after the 
exclusion of the few foci of hypo-endemic transmission 21. In contrast, malaria 
transmission in Papua is perennial and often hyper- to holo-endemic, with 
incidence rates from 500 to 5000 infections/1000 person-years22.  
 
Follow up.  
Malaria episodes were actively detected over a period of 24 months by periodic 
clinical assessments and blood smears. Blood smears were collected at two-week 
intervals or at any time a subject presented to the clinic with symptoms (chills, 
fever, etc.) suggesting malaria infection. Blood was microscopically examined for 
P. falciparum and P. vivax asexual parasites and gametocytes by Giemsa-stained 
blood films. Parasites were counted against the number of white blood cells. A 
slide was considered negative after examination of 200 microscopic fields, 
corresponding to 1600 to 2400 white blood cells and a estimated diagnostic 
threshold of 5 parasites per μl. Parasite densities were calculated using a normal 
density of 8000 white blood cells per μL blood. The first episode of symptomatic 
or asymptomatic P. falciparum malaria was recorded as first infection. Each 
subsequent P. falciparum parasitaemia was classified as a new infection if it 
occurred more than 28 days after directly observed chemotherapy of the 
previous infection. Sera were collected on the day of arrival and after 6, 12 and 
24 months at SP2 16. In order to study the acquisition of immunity in time, we 
selected samples from subjects for whom at least 3 samples were available. We 
selected 51 subjects aged 6-12 years and 51 subjects aged 20-40 years. The 
incidence of malaria infection in these individuals was not different from that of 
the general population. 
 
Enzyme Linked Immunosorbent Assays.  
Antigen preparation. Mature gametocytes of P. falciparum (NF54 strain) were 
produced in an automated static culture system as described by Ponnudurai et 
al.23, isolated 4 and stored at -700C until used. NF54 gametocytes were extracted 
in 25 mM Tris-HCl (pH 8.0) supplemented with 150 mM NaCl, 1.0% sodium 
desoxycholate (DOC) and 1 mM phenylmethylsulphonyl fluoride. Centrifugation 
pelleted insoluble debris (13,000g for 5 min at room temperature) and the 
supernatant provided antigen for ELISA’s (whole parasite, Pfs48/45 and Pfs230). 
Pfs230 and Pfs48/45 capture ELISA. Anti-Pfs230 IgG antibodies were 
assayed by coating 10μg/mL of anti-Pfs230 mouse mAb 63F6D7-F(ab)2 
fragments in phosphate buffered saline (PBS, pH 7.4) on Sterilin® ELISA plates 
(PS, ref 53011, International Medical Products B.V., Zutphen, the Netherlands). 
Acquisition of sexual stage immunity 
117 
For Pfs48/45, the plates were coated with anti-Pfs48/45 rat mAb 85RF45.3. 
Plates were blocked with 5% (wt/vol) low-fat dry milk (Marvel, Premier 
International Foods Ltd, Spalding, Lines, United Kingdom) in PBS. For Pfs230 or 
Pfs48/45 antigen capture, plates were incubated with gametocyte extract 
(250,000 parasite equivalents/well). Sera (1:100 dilution) were added to the 
wells and incubated for 2 hrs. Bound IgG antibodies were detected by horse-
radish-peroxidase (HRPO)-labeled goat anti-human IgG (Pierce 31412). Wells 
were washed three times with PBS and subsequently incubated with tetramethyl 
benzidine (TMB) substrate solution for 20 min. The colour reaction was stopped 
with 4N H2SO4, and optical density (OD) read at 450 nm (Anthos 2001 
microplate reader: Labtec BV). All incubations were carried out at room 
temperature. All serum samples were tested in duplicate with a concurrent 
positive control and a minimum of 4 negative (Dutch blood bank donor) controls 
per plate. Sera were considered positive if OD exceeded three standard 
deviations above the mean of negative controls.  
Whole parasite and GLURP ELISA. Antibodies against whole parasite extract 
and GLURP served as markers for general anti-parasite and specific asexual 
stage immunity, respectively. Sterilin® ELISA plates (PS, ref 53011, International 
Medical Products B.V., Zutphen, the Netherlands) were coated overnight with 
250,000 parasites per well by diluting a stock containing 30x106 parasites/mL in 
extraction buffer with PBS (as above). After blocking with 5% milk/PBS, sera 
were incubated 2 hr at room temperature (1/100 dilutions in 0.1% milk-TPBS). 
Anti-GLURP85-213 antibodies were measured in plasma samples by ELISA24. 
Microtiter plates (NUNC™ Maxisorp, Nalge Nunc International Corp, Life Techn, 
The Netherlands) were coated overnight at 4°C with 50 μL of 0.2µg GLURP85-213 
/mL final concentration in 0.05 M carbonate buffer pH 9.6. After washing, wells 
were incubated with 2.5 % (wt/vol) milk in PBS. Plasma samples were diluted in 
PBS/0.05% Tween 20/1.25% milk. For the detection of anti- GLURP85-213 IgG 
antibodies, rabbit anti-human IgG peroxidase (Dako, P-214) was used 1/10.000 
in PBS/0.05% Tween 20/1.25% milk. The remainders of both tests were carried 
out as for Pfs230 and Pfs48/45described above. 
 
Standard Membrane Feeding Assay (SMFA).  
Experimental infections of mosquitoes were carried out as previously described 
25,26. Three to five-day old, colony-reared Anopheles stephensi were allowed to 
membrane feed on freshly cultured mature NF-54 P. falciparum gametocytes in 
batches of 50 mosquitoes each in the presence of serum. A maximum of 17 
transmigrant serum samples were compared to three batches of a single (Dutch 
blood bank donor) control serum. Immediately after the feed, non-fed and 
partially fed mosquitoes were removed. Blood-fed mosquitoes were kept at 26°C 
and 80% humidity for seven days. Surviving mosquitoes (>90%) were dissected 
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and oocysts counted from extracted midguts. Twenty mosquitoes per batch were 
examined for oocysts. An SMFA experiment was considered valid when in all 
three control batches the percentage of infected mosquitoes was 90% or more. 
The observed transmission reducing activity (TRA) of serum was determined as 
the percentage reduction in oocyst numbers in test samples as compared to 
controls 27. Functional TRA was defined as a minimum of 50% reduction in 
oocysts numbers in the standard SMFA. Not all sera were analysed in the SMFA 
because of resource limitations. A random sample of individuals was therefore 
selected and all their available serum samples were tested in the same SMFA 
experiment. 
 
Statistical analyses.  
Analyses focused on the relation between the development of (functional) sexual 
stage specific immunity and cumulative exposure to P. falciparum, quantified as 
the cumulative number of infections with asexual stage P. falciparum parasites. 
Statistical analyses were carried out using SPSS for Windows, version 10 (SPSS 
Inc., Chicago, IL) and Stata 7.0 (Stata Corporation, 4905 Lakeway Drive, 
College Station, Texas 77845 USA). Prevalence of antibodies and functional TRA 
(dichotomous variables) as a function of exposure to asexual P. falciparum 
parasites was tested using multiple logistic regression models by Generalized 
Estimating Equations (GEE). Regression coefficients β were calculated with 95% 
confidence intervals (95% CI). Prevalence was logit-linked analyzed. The 
number of infections was included as a continuous variable and a random effect 
was included in the models to allow for correlations within individuals. Age group 
(20-40 years vs. 6-12 years) and number of P. vivax infections were included in 
the models as covariates. Interaction terms were added to the models to assess 
a possible modifying effect of age on the relation between exposure to infections 
and the development of immunity. 
 
 
Results 
The malariometric indices of the study population are presented in table 9.1. The 
vast majority of individuals experienced at least one episode of malaria, with a 
median number of 3 infections during the 24-month period of follow-up. While 
prevalence of infection was similar for adults and children, the latter were 
exposed to higher densities of asexual parasites (P = 0.02, table 9.1). 
Gametocytes were detected in 26% of the children and 29% of the adults with 
no statistically significant difference in gametocyte prevalence or density. 
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Table 9.1 Characteristics and Plasmodium falciparum malariometric indices of 102 study 
subjects from the SP2 cohort during 24 months of follow-up in Papua, Indonesia 
 
 Children Adults P-value 
N 51 51  
Age, median (IQR)  9 (8-11) 32 (28-37)  
Number (percentage) of individuals infected  49 (96.0%) 49 (96.0%) 1.0 
Number of infections per person, median (IQR) 3 (1-3) 3 (2-4) 0.53 
Asexual parasite density, GM (IQR) 2792  
(879-11,962) 
1697  
(520-5920) 
0.02 
Number (percentage) of individuals gametocytaemic  13 (25.5%) 15 (29.4%) 0.66 
Gametocyte density, GM (IQR) 112 (40-280) 176 (48-579) 0.21 
IQR = interquartile range; GM = geometric mean parasite density in parasites/μL for P. falciparum 
asexual parasite or gametocyte carriers only. 
 
The cumulative number of infections per 6 months is presented in figure 9.1. By 
six months, 20% of the 102 migrants had experienced two or more infections; 
by 24 months, this proportion had increased to 73%. The cumulative number of 
subjects in whom gametocytes were observed in peripheral blood films was 0, 2, 
8 and 18 for time points 0, 6, 12 and 24 months post migration, respectively. 
 
Figure 9.1. Cumulative prevalence of asexual stage infections in a cohort of 102 non-
immune migrants from Java to Papua, Indonesia experiencing one to over four 
Plasmodium falciparum infections during 2 years of follow-up in a malaria-endemic area.  
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Seroreactivity against whole P. falciparum extracts and asexual stage specific 
antigens increased with cumulative exposure (figure 9.2A). Antibody prevalence 
in the whole parasite ELISA rose to 98% after two infections and maintained 
high after further infections. The prevalences of antibodies against sexual stage 
specific antibodies Pfs48/45 and Pfs230 were also increased after two infections 
(figure 9.2B). The proportion of serum samples with TRA gradually rose from 
10% (3/29) prior to migration, increasing to 27% (3/11) after more than four 
infections. 
There was a clear association between the presence of gametocytes at the 
time of sampling and TRA (OR 5.22, 95% CI 1.87-14.56). Nevertheless, only 
31.3% (10/32) of sera with TRA were derived from individuals with patent 
gametocytaemia at the time (n=9) or prior to sampling (n=1). After adjustment 
for the number of infections, TRA was significantly associated with the 
prevalence of anti-Pfs48/45 antibodies (OR 3.74, 95% CI 1.51-9.29) and anti-
Pfs230 antibodies (OR 3.72, 95% CI 1.36-10.17). No statistically significant 
association existed between TRA and the prevalence of anti-whole parasite (OR 
4.21, 95% CI 0.53-33.18) or anti-GLURP (OR 1.90, 95% CI 0.83-4.34) 
antibodies. 
 
 
 
Figure 9.2. Proportion of serum samples with P. falciparum specific antibodies as a 
function of the number of prior P. falciparum infections.  
A. seroreactivity for whole parasite (open circles) and asexual-stage specific GLURP (closed 
squares)  
B. seroreactivity for sexual-stage specific Pfs230 (asterisks) and Pfs48/45 (open triangles), and 
functional TRA>50% (closed circles). For TRA, exactly 20 mosquitoes were dissected per serum 
sample included in the SMFA. The control samples resulted in a median number of 21 oocysts (IQR 
7-46) per mosquito. Error bars indicate the upper limit of the 95% confidence interval. 
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analyses of the data presented in figure 9.2 (table 9.2). There was a statistically 
significant increase in positive response after P. falciparum infections for all 
ELISA’s, which was strongest for the whole parasite assay. There also was a 
statistically significant positive association between the prevalence of TRA and 
the number of infections (table 9.2).  
 
Table 9.2 The regression coefficient of the number of prior Plasmodium falciparum 
infections as a predictor of seroreactivity or transmission reducing activity 
* Number of individuals (number of measurements); ¥regression coefficient β (95% confidence 
interval); †estimate adjusted for age group; ¶estimate adjusted for number of P. vivax infections 
 
 
Figure 9.3. The prevalence of Pfs230 seroreactivity as a function of the number of prior 
P. falciparum infections. The prevalence of Pfs230 antibodies is depicted for children (shaded 
bars) and adults (black bars). Error bars indicate the upper limit of the 95% confidence interval. 
The number of observations for children: 0 (n = 32); 1 (n = 41); 2 (n = 18); 3 (n = 20); 4 (n = 
5); >4 infections (n = 3). For adults: 0 (n = 42); 1 (n = 35); 2 (n = 28); 3 (n = 12); 4 (n = 7); 
>4 infections (n = 9). Logistic trend lines are added to the figures for children (dashed line) and 
adults (solid line). 
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GLURP 102 (296) 0.49 (0.21-0.77) †, ¶  0.001 
Pfs48/45  95 (268) 0.40 (0.24-0.57) <0.001 
Pfs230  89 (252) 0.46 (0.25-0.67) † <0.001 
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Seroprevalence of antibodies against Pfs230 (figure 9.3), whole parasite and 
GLURP were consistently higher in adults (data not shown). In adults, 23.8% 
(10/42) of individuals had anti-Pfs230 antibodies prior to exposure, compared to 
0% (0/32) in children. This higher seroprevalence for adults remained apparent 
throughout follow-up. While the intercept of the trend lines was higher in adults 
(P = 0.001), the slope of both lines was not different (P = 0.62), indicating a 
similar relation between number of infections and Pfs230 seroreactivity for 
adults and children. In the GEE models (table 9.2), the relation between number 
of infections and whole parasite, GLURP and Pfs230 seroreactivity was not 
different between children and adults. 
 
 
Discussion 
This study shows that sexual stage specific seroreactivity develops after a 
limited number of P. falciparum infections in a cohort of non-immune 
transmigrants. The prevalence of anti-Pfs48/45 and anti-Pfs230 antibodies and 
functional TRA increase with the number of infections experienced.  
 
Development of sexual stage specific immunity resembles that of immunity 
against asexual stages with similar patterns for acquisition of antibodies against 
GLURP, Pfs230 and Pfs48/45. We found that reactivity against all antigens 
develops quickly after exposure, with seroprevalence increasing with number of 
infections. In line with previous studies, immune response therefore seems to 
require recent but not necessarily long-term exposure 11-13. Sexual stage specific 
antibody responses seem to be part of the initial immune response, which 
corroborates previous studies in individuals after a primary infection with P. 
falciparum 28,29. The finding is nevertheless remarkable since exposure to sexual 
stage parasites is generally considered to be much lower than to asexual 
parasites. In this study, less than one third of the individuals presented with 
microscopically detectable gametocytes on any occasion during the two-year 
follow-up. This apparent low exposure may be due to the poor sensitivity of 
microscopy for detecting low-density gametocytaemia 30, which can contribute 
substantially to the total exposure to gametocytes 31. Sexual stage specific 
antibodies may be induced by these low density gametocytes or by gametocytes 
that are sequestered in capillary vessels 32. The combined possibilities may 
explain the frequently observed reactivity against sexual stage specific antigens 
in the absence of microscopically detectable gametocytes. In addition to these 
antibody responses, we also frequently observed functional TRA without 
concurrent or prior detection of gametocytes. Although we may have missed 
some gametocytaemic periods as a result of our fortnightly screening we 
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conclude that submicroscopic levels of gametocytaemia do play an important 
role in eliciting sexual stage specific immune responses.  
We found no evidence for age as key determinant for the development of 
immune responses in our population of 6-40 year old transmigrants. Although 
other studies reported an age-dependent acquisition of clinical and parasitic 
immunity 12,13, we do not find a similar effect for our selected markers of asexual 
and sexual stage specific immunity. The reactivity in ELISA’s was higher in 
adults but could reflect background reactivity due to the presence of cross-
reactive antibodies reacting with common epitopes 15. We did not detect a 
difference in the relation between exposure to infection and the acquisition of 
(sexual stage specific) immunity for different age groups. 
Our most important finding is the presence of functional TRA in a 
substantial proportion of the individuals increasing with exposure. This has not 
been shown before for P. falciparum, but is analogous to transmission blocking 
immunity in P. vivax, where TRA is more prevalent and efficient after repeated 
infections 33-35 . In this study, over one quarter of the individuals experiencing 
more than four P. falciparum infections showed TRA, i.e. >50% reduction in 
oocysts numbers. This pattern of increasing prevalence of TRA accompanies the 
occurrence of anti-Pfs230 and anti-Pfs48/45 antibodies, as previously shown 8,36-
39. The rapid development of TRA and associated antibodies is particularly 
promising, since Pfs230 and Pfs48/45 are considered as candidates for inclusion 
in future transmission-blocking vaccines 28. 
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Summary 
Immunity to the sexual stages of Plasmodium falciparum is induced during 
natural infections and can significantly reduce the transmission of parasites to 
mosquitoes (transmission reducing activity; TRA) but little is known about how 
these responses develop with increasing age/exposure to malaria. Routinely TRA 
is measured in the standard membrane feeding assay (SMFA).  
We collected sera from a total of 199 gametocyte carriers (median age 4 
years, quartiles 2 and 9 years) near Ifakara, Tanzania. 128 samples were tested 
in the SMFA and generated TRA data classified as a reduction of >50% and 
>90% of transmission. TRA of >50% was highest in young children (aged 1-2) 
with a significant decline with age (χ2 trend = 5.79, p=0.016). TRA was 
associated with prevalence of antibodies to both Pfs 230 and Pfs48/45 (OR 4.03, 
p=0.011 and OR 2.43 p=0.059 respectively). A TRA of >90% reduction in 
transmission was not age related but was associated with antibodies to Pfs48/45 
(OR 2.36, p=0.055).  
Our data confirm that antibodies are an important component of naturally 
induced TRA. However, whilst a similar but small proportion of individuals at all 
ages have TRA >90%, the gradual deterioration of TRA>50% with age suggests 
decreased antibody concentration or affinity. This may be due to decreased 
exposure to gametocytes probably as a result of increased asexual and/or 
gametocyte specific immunity.  
 
Sexual stage immunity and age 
129 
Introduction 
Immunity against the sexual stages of the Plasmodium falciparum parasite can 
develop after exposure to gametocytes 1. This immunity is primarily antibody 
mediated and affects transmission by preventing fertilisation 2,3. Sexual stage 
specific antigens that induce transmission-blocking immunity (TBI) can thus 
form potentially useful components of a malaria vaccine 2,4,5. However complete 
blockade of transmission is rare 6 and it is more appropriate to define this as 
transmission reducing activity (TRA) 7.  
It is well known that naturally occurring immunity to asexual stages of the 
malaria parasite develops with age and exposure 8,9 and that anti-parasite 
immunity follows the development of anti-disease immunity. By comparison 
relatively little is known about the development of immunity to the sexual stage 
of the malarial parasite, its age-dependency and the dynamics of the antibodies 
responsible for TRA. Studies have shown that antibody responses to the key pre-
fertilisation antigens are induced as part of the initial immune response during 
infection 1,5,6. However, whether maturation of these responses occurs with 
subsequent exposure is unclear 1. In the Gambia there was no correlation with 
age and prevalence and intensity of immune responses to native Pfs230 10 whilst 
in Papua New Guinea responses to Pfs48/45 and Pfs230 in competition ELISAs 
are suggestive of increase in prevalence and titre of antibodies with age 11. The 
importance of these antigens is emphasised by the correlation between 
antibodies induced against them and TRA (Pfs48/45 6,12-15 & Pfs230 4,12,16,17). 
Such a correlation has not been shown for the gametocyte protein Pfs16 though 
antibodies to Pfs16 are present in many individuals living in malaria endemic 
areas 18. 
TRA is typically assessed using the standard membrane feeding assay 
(SMFA) 19. Although the SMFA is labour intensive and therefore not ideally suited 
for testing large numbers of sera, it remains the gold standard and was used in 
this study on TRA in Tanzanian gametocyte carriers. In a previous study we 
examined the dynamics of gametocyte production in a population of 
symptomatic P. falciparum malaria patients from a hyperendemic area of 
Tanzania. Findings suggested age/exposure related immunity manifested as 
lower gametocyte prevalence with increasing age 20. The current study 
investigates the relationship between age and functional TRA of sera from the 
gametocyte carriers in this population, against cultured parasites of the NF54 
strain of P. falciparum. We also evaluate the correlation between TRA and 
several serological assays.  
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Methods 
Gametocyte carriers and control sera 
Field sera were obtained from gametocyte carriers recruited at a dispensary in 
Ifakara, Tanzania, as described elsewhere 20. Briefly, all individuals presenting at 
the dispensary with P. falciparum parasitaemia were asked to return for several 
follow-up visits. On each return visit a blood slide was taken and examined 
extensively for gametocytes. A slide was declared negative if no parasites were 
seen after examination of 100 fields. Gametocyte density was assessed by 
counting against 500 leucocytes, trophozoite density by counting against 200 
leucocytes. Gametocyte and trophozoite counts were converted to numbers of 
parasites per μL by assuming a standard leucocyte count of 8000/μL 21. Afebrile 
individuals found positive for gametocytes were asked to give a venous blood 
sample. After obtaining written informed consent, venous blood samples were 
collected and allowed to clot. Sera were then aliquoted and stored at -20°C. A 
brief questionnaire was completed for each volunteer after collection of blood, 
detailing history of symptoms, drug consumption and other demographic details. 
All individuals were assessed by trained clinical staff and treated in accordance 
with national guidelines. Ethical permission for the study was given by the 
Tanzanian National Institute for Medical Research and informed consent was 
obtained from all participants or their parents/guardians.  
Positive control sera were obtained from a Dutch expatriate who worked in 
an endemic malaria area in Tanzania for more than 30 years. 
Negative control sera were obtained from Dutch bloodbank donor volunteers, 
without any history of malaria, collected in the absence of a patent infection. 
 
Parasites 
Gametocytes of the NF54 strain of P. falciparum were cultivated using the 
‘shaker’ system 22. Mature gametocytes were isolated at 37˚C. To prevent 
activation parasite culture was diluted ten fold in M199, containing 0.1% glucose 
(M199-G). After centrifugation for 15 minutes at 2,000g the pelleted parasites 
were resuspended in M199-G, loaded on a cushion of 18% Nycodenz [Axis-
Shield PoC AS, Oslo, Norway] and centrifuged for 30 minutes at 5,000g as 
described by Vermeulen et al. 23.  
NF54 gametocytes were extracted in 25 mM Tris-HCl (pH 8.0) supplemented 
with 150 mM NaCl, 1.0% Sodium Desoxycholate (DOC), 1 mM phenyl-
methylsulphonyl fluoride. Insoluble debris was pelleted by centrifugation (13,-
000g, 5 min at room temperature) and the supernatant used as the antigen 
source in the different ELISAs (Pfs48/45 and Pfs230). 
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Standard membrane feeding assay (SMFA) 
Experimental infections of mosquitoes were carried out as previously described 
24,25. Three to five day old A. stephensi were allowed to feed on cultured P. 
falciparum gametocytes of NF54, in the presence of control or test serum. Test 
serum was diluted in non-immune control serum (0.75 v/v) and suspension 
dilution was 0.33 v/v. After feeding, blood-fed mosquitoes were kept at 26°C. 
Surviving mosquitoes were dissected seven days later, and oocysts counts were 
made. Midguts of 20 mosquitoes were examined for oocysts. The test was 
considered valid when all three batches fed on samples containing control sera 
showed at least 90% infection. The observed transmission reducing activity 
(TRA) of serum was determined as the percentage reduction in oocyst numbers 
in test samples as compared to paired controls 26. Functional transmission 
reducing activity was defined as a minimum of 50% reduction in oocysts 
numbers in the standard SMFA. Individuals with TRA>50% were considered 
transmission reducers and those with TRA>90% as transmission blockers.  
 
Enzyme Linked Immunosorbent Assays 
IgG1 antibodies against Pfs230. The presence of anti Pfs230 specific human 
antibodies of the IgG1 isotype was determined by coating 10μg/mL of anti-
Pfs230 mouse mAb 63F6D7-F(ab)2 fragment in phosphate buffered saline (PBS 
pH7.2) on ELISA-plates (Sanbio U-bottom, high binding). Free sites were 
blocked with 5% milk in phosphate buffered saline (PBS), and Pfs230 was 
captured from a gametocyte extract (200.000 parasite equivalents/well). Three-
fold serial dilution’s of the test sera (1:25, 1:100, 1:200) was added to the wells 
and incubated for 60 min. Bound IgG1 subclass antibodies were detected by 
HRPO-labelled goat anti-human IgG1[Pierce]. Wells were washed with PBS and 
subsequently incubated with tetramethyl benzidine (TMB) substrate solution for 
20 min. The colour reaction was stopped with 4N H2SO4, and the optical density 
was read in a Titertek Multiscan spectrophotometer at 450 nm. All serum 
samples were tested in duplicate. Negative and positive controls were included 
on each plate. Sera were considered positive if the optical density (OD) was 
greater than two standard deviations above the mean of the negative control 
sera.  
IgG1 antibodies against Pfs48/45. Anti-Pfs48/45 specific human antibodies 
were measured by coating 10μg/mL of anti-Pfs48/45 rat mAb 85RF45.2b in PBS 
on ELISA-plates (Sanbio U-bottom, high binding). The remainder of the test was 
carried out as described above. Each serum was tested individually with and 
without gametocyte extract. Sera were considered positive by the same criteria 
as for Pfs230 ELISA.  
Circumsporozoite antibodies (NANP5) ELISA. Samples were tested for the 
presence of circumsporozoite antibodies as a measure of exposure to infectious 
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mosquito bites using a one-stage ELISA 27. Briefly, one μg/mL (NANP5) 
conjugated to bovine serum albumin, [F Esposito, Università di Camerino, Italy] 
in PBS was coated on round-bottom PVC Microtitre ® plates [Dynex Technologies 
INC., USA] for 60 minutes. After washing and blocking open wells with 5% milk 
(marvel dried skim milk) in PBS (pH 7.2), 50 μL of a 1:100 serum dilution in PBS 
with 0,05% Tween and 0,2% milk (MTPBS) was added and incubated for 90 min. 
After washing, 50 μL of goat anti human immunoglobulin labelled with 
peroxidase (ImmunoPure, diluted 1:40 000 in MTPBS) was added for 60 min. 
The remainder of the procedure and the evaluation of sera were carried out as 
described above for IgG1 antibodies against Pfs230. All incubations were carried 
out at room temperature. 
 
Data Analysis 
Data were analysed using SPSS statistical software version 9.0 and STATA 
version 7.0. The presence of an age-dependent trend in parasitological 
characteristics was tested using linear regression. For this purpose gametocyte 
and trophozoite densities were log-transformed. Age dependency of TRA and 
reactivity in ELISA assays was initially tested using the χ2 test for trend. The 
association between seroreactivity in serological assays and reduction of 
transmission in the SMFA was tested in logistic regression and quantified using 
odds ratios. 
 
 
Results 
Sera were collected from a total of 199 gametocyte carriers (median age 4 
years, quartiles 2 and 9 years), 47% (94/199) of the subjects were male. The 
parasitological characteristics of the gametocyte carriers are summarised in 
Table 10.1. Trophozoite prevalence, trophozoite density and gametocyte density 
decreased with age. 
 
Standard membrane feeding assay (SMFA) 
Sera of 128 subjects were tested in the membrane feeding assay. A total of 
53.9% (69/128) of the sera showed ≥50% reduction in number of oocysts. 
Figure 10.1 shows the age dependent transmission-blocking activity as assessed 
in the SMFA. The proportion of sera resulting in ≥50% reduction was 64.6% 
(31/48) in 1-2 year old children and decreased with age (p=0.016). The 
proportion of sera able to reduce transmission by 90% or more remained 
consistent at all ages.  
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Table 10.1 Parasitological characteristics of study population: trophozoite prevalence 
and geometric means of the gametocyte density and trophozoite density. 
 
IQR = interquartile range; * Geometric mean gametocyte density; linear regression, age group: β 
= -0.18 (se=0.080); p = 0.029; ¥ Trophozoite prevalence, Chi-square test for trend: χ2= 2.43 
p=0.12; ¶ Geometric mean asexual parasite density; linear regression, age group: β = -0.42 
(se=0.18); p = 0.025 
Figure 10.1. Age dependence of transmission reducing activity in the standard 
membrane feeding assay. Solid line = transmission reduction (>50%), chi square test for trend 
χ2 = 5.79, p=0.016. Broken line = transmission reduction (>90%), chi square test for trend χ2 = 
0.13, p=0.71. Error bars indicate the upper limit of the 95% confidence interval. The number of 
individuals was 48, 37, 19 and 24 for age groups 1-2 years, 3-6 years, 7-15 years and >15 years 
respectively.  
 
Antibody responses and transmission reduction 
Serological reactivities as assessed by ELISA are summarised in Table 10.2. 
Testing for anti- circumsporozoite antibodies was performed to assess the 
exposure to infectious mosquito bites 28. Overall 59.2% (116/196) of the 
gametocyte carriers were positive for anti-NANP5 antibodies, indicating a high 
Age group 
 
Number Gametocyte density/μL 
(IQR) * 
Trophozoite 
prevalence % ¥ 
Trophozoite density/μl 
(IQR) ¶ 
1-2 years 76 81.2 (32 -200) 59.2 899.4 (118- 6420) 
3-6 years 60 98.2 (40 -253) 50.0 521.8 (95 - 1156) 
7-15 years 31 83.0 (32 -208) 48.4 674.8 (160 - 2340) 
≥ 16 years 32 41.4 (16 -105) 43.8 192.2 (34 - 966) 
Total 199 77.7 (32 -200) 52.3 599.4 (120 -1889) 
0
0,2
0,4
0,6
0,8
1-2 years 3-6 years 7-15 years >=16 years
pr
op
or
tio
n 
re
du
ce
rs
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exposure. The prevalence of anti-NANP5 antibodies increased with age, probably 
as a result of cumulative exposure to malaria infections. There was no age 
dependency observed for the presence of anti-Pfs48/45 antibodies, which was 
poorly recognised. Antibodies to Pfs 230 were weakly correlated with age 
(p=0.093). 
 
Table 10.2: Prevalence of serological reactivity to sporozoite (NANP5) and sexual stage 
antigens (Pfs230 and Pfs48/45) 
Age group  NANP5
* % (N) Pfs230¥ % (N) Pfs48/45 % (N) 
1-2 years 45.2 (73) 16.7 (72) 23.3 (73) 
3-6 years 60.0 (60) 13.8 (58) 13.3 (60) 
7-15 years 67.7 (31) 20.0 (30) 12.9 (31 ) 
≥ 16 years 81.3 (32) 31.3 (32) 28.1 (32) 
Total 59.2 (196) 18.8 (192) 19.4 (196) 
*NANP5 and age:χ2for trend 13.1 p=0.0003; ¥Pfs230 and age:χ2 for trend 2.8 p=0.093 
 
A TRA of 50% was negatively associated with age (OR=0.62; 95% CI 0.43-0.88) 
as is shown in table 10.3. Sera with detectable levels of antibodies to Pfs230 
and, to a lesser extent, Pfs48/45 were significantly associated with this level of 
TRA. A TRA of >90% was associated with antibodies to Pfs48/45 (table 10.3) at 
borderline level of significance. The prevalence of anti NANP5 antibodies was not 
associated with TRA at either level (data not shown). Neither asexual 
prevalence, density nor gametocyte density were significant predictors of TRA in 
the logistic regression models nor did they confound any of the associations 
described above.  
 
Table 10.3: Adjusted odds ratio (OR) of the probability of functional transmission 
reducing activity (TRA) in the SMFA. 
 TRA –50  TRA –90  
 OR (95% CI) P-value OR (95% CI) P-value 
Age group 0.62  
(0.43 – 0.88) 
0.017 0.90  
(0.58 – 1.37) 
0.63 
Pfs230 seroprevalence 4.03  
(1.37 – 11.86) 
0.033 2.46  
(0.83 – 7.31) 
0.105 
Pfs48/45 seroprevalence 2.43  
(0.97-6.12) 
0.068 2.62  
(0.98-7.00) 
0.055 
TRA-50 = transmission reducing activity with >50% reduction; TRA-90 = transmission reducing 
activity with >90% reduction. 
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Discussion 
In this study 54% of the sera from gametocyte carriers were capable of reducing 
transmission of gametocytes to mosquitoes in standard membrane feeding assay 
(SMFA) with cultured parasites. This prevalence is comparable with results from 
Cameroon 19,29. However the ability to reduce transmission of gametocytes to 
mosquitoes by more than 50% of controls was highest in the youngest age 
group and then decreased significantly with age. The most efficient level of TRA 
(a reduction in transmission of 90%) was stable at ~20% in all age groups. 
These data are intriguing and seem to contrast with immune responses to the 
asexual stages of P. falciparum where effective immunity matures with age.  
 
A recent study from Cameroon found no relation between age and TRA 7 
and an earlier study from the same area suggested a positive relation 29, 
contrary to our findings in Tanzania. However, both studies used the direct 
feeding assay (DMFA) to assess TRA which is often less sensitive due to its 
reliance on circulating gametocyte density in the infected individual. In this 
assay mosquitoes feed on peripheral blood washed and resuspended in either 
autologous or a control serum. Natural gametocyte densities and resultant 
oocyst loads are typically low making statistical assessment of TRA difficult. 
Moreover neither study included the youngest children where we observed the 
highest level of TRA>50%, this may have obscured the trend. In the most recent 
of these studies the proportion of individuals defined as transmission reducers 
dropped from 30% in the 5-10 year age group to 10.3% in the 11-20 year age 
group 7. 
It is interesting to postulate why, with increasing age and cumulative 
exposure to parasites, TRA seems to decrease rather than increase. Firstly, it 
may be a variety of mechanisms which reduce the numbers of sexual forms to a 
level which is insufficient for maintenance of effective TRA. This could be due to 
asexual stage immunity where numbers are controlled such that subsequent 
gametocyte densities are also reduced. Secondly, cross-stage immunity against 
PfEMP1 affecting both asexual and the earlier developmental sexual stages of 
the parasite which have similar sequestration profiles has also been described 30. 
A third possibility is a human immune response specifically directed against later 
stage sexual parasites which differ from asexual forms in their sequestration site 
and presumably use different ligands yet to be described 31. There is 
epidemiological support for this as an explanation 32 that could reduce 
gametocyte prevalence or longevity (Chapter 2) 33. Thus the higher gametocyte 
densities in children induce higher levels of transmission reducing activity. As 
age increases, gametocyte densities and the stimulus for TRA decrease. The 
dynamics of antibody development will also be affected by the frequency of 
infection. In Sri Lanka, an area of low transmission intensity, no correlations 
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were seen with the antibodies to Pfs230 and Pfs48/45 and the ability to block 
transmission, suggesting the rate of re-infection influences maturity of the 
immune response 34. 
The finding may also be a consequence of poor immunogenicity of the 
sexual stage antigens investigated 35. It has been hypothesised that the poor 
memory response generated by the antigens Pfs230 & Pfs48/45 is a result of a 
T-cell independent response 36 and/or clonal imprinting 37. The gradual decline of 
TRA>50 in these individuals may be due to changes in the antibody repertoire. 
Although TRA was correlated with antibodies against Pfs48/45 and Pfs230, none 
of those antibodies showed a similar age-dependent decrease in prevalence. Our 
analysis was restricted to antibodies of the subclass IgG1 it may be that isotype 
switching (noted with other malaria antigens notably MSP-1 –19 38) results in a 
less effective TRA. This may be particularly relevant for Pfs230 as complement 
mediated lysis of gametes has been correlated with antibodies to this antigen 17 
and murine monoclonal antibodies to Pfs230 which block transmission are all of 
complement fixing isotypes 39,40.  
Clear relationships between serology, TRA and age may have been 
obscured by the fact that gametocyte carriers were sampled at first presentation 
with gametocytes and the development of sexual stage immunity may take 
longer during the course of a natural infection. Data from Papua New Guinea 
documented a complicated profile of anti Pfs48/45 antibody kinetics (defined by 
competition ELISA) in children one month after a clinical attack 11. It may be 
that effective immunity is only apparent once gametocytes have disappeared 
from the peripheral blood having been cleared and presented to the immune 
system. This is an important area for future study and could provide important 
information on the influence of age related TRA on the infectious reservoir for 
malaria.  
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Summary 
Next to children, adults form a substantial part of the infectious reservoir that is 
responsible for the spread of malaria in human populations. The objective of this 
longitudinal study was to determine sexual stage immune responses to 
Plasmodium falciparum and the infectiousness to mosquitoes in adults from an 
area with intense malaria transmission.  
A cohort of 43 Tanzanian adults was followed for 18 months. Mosquitoes 
were collected fortnightly; parasitological data monthly and serum every 3 
months. Serological assays were performed for antibodies to sexual stage 
antigens Pfs230 and Pfs48/45 and circumsporozoite protein (NANP5)(n=199). 
Functional transmission reducing activity (TRA) was assessed by standard 
membrane feeding assay (n=85).  
The overall EIR was 165.5 infectious bites per person per year (95% CI 
117.2 – 227.2). Cumulative parasite prevalence was 67.4 % (29/43) for asexual 
stages and 34.9% (15/43) for gametocytes. Enrolment antibody prevalence was 
95.3% (41/43) for NANP5, 18.9% (7/37) for Pfs230 and 7% (3/43) for Pfs48/45 
epitope 3. TRA >50% reduction was seen in 48.2% (41/85) and TRA >90% 
reduction in 4.7% (4/85) of the samples.  
Thus, sexual stage immune responses were low, inconsistent over time 
and not related to age. Our findings suggest that the low level sexual stage and 
transmission blocking immunity is likely to be the result of an effective asexual 
stage immunity that limits gametocyte numbers and thereby the antigenic 
stimulus necessary to maintain effective sexual stage immunity. As a 
consequence, the relative infectivity of older individuals is less likely to be 
affected by sexual stage immunity. 
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Introduction 
Successful transmission of Plasmodium falciparum from man to mosquitoes 
depends not only on the presence of mature gametocytes in the peripheral 
bloodstream but also on human host immunity. Host immunity can affect 
transmission indirectly by attacking asexual stage parasites 1 and directly by 
cross-stage immunity affecting asexual and sexual stage parasites 2 or sexual 
stage specific immunity. The latter may reduce gametocyte prevalence 3 or 
longevity (Chapter 2) 4 but can also reduce the infectiousness of gametocytes by 
preventing fertilization or arresting the development of zygotes in the mosquito 
midgut 5-7. This phenomenon is called transmission reducing activity (TRA) and is 
observed in sera from individuals from malaria endemic countries 8,9. TRA has 
been correlated with the presence of antibodies against P. falciparum gamete 
surface antigens Pfs230 8,10,11 and Pfs48/45 8,12.  
Sexual stage specific immunity appears to develop rapidly after exposure 
(Chapter 9) 13,14, but may be short-lived 15 and is hypothesised to depend on 
recent rather than cumulative exposure (Chapter 12) 16. Exposure to 
gametocytes is lower in adults compared to children 17,18 and, as a consequence, 
sexual stage specific antibody responses would be expected to decrease rather 
than increase with age. The recently reported negative age dependency of TRA 
in gametocytaemic children (Chapter 10) 19 seems to support this hypothesis 
although data confirming this trend in adults is lacking. Information on sexual 
stage specific immunity in adults is relevant for future transmission reducing 
interventions since adults contribute considerably to the human infectious 
reservoir 17. 
Our objective was therefore to determine sexual stage immune responses 
to P. falciparum in a cohort of Tanzanian adults resident in an area of high but 
seasonally variable transmission intensity. We determine the prevalence of 
sexual stage antibodies and functional TRA in relation to age and compare two 
villages of different transmission intensity. 
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Methods 
Study site 
This study was conducted in Ichima and Miwangani, hamlets of the village of 
Idete 30 kilometres distance from Ifakara, south-eastern Tanzania. The 
transmission of P. falciparum is different for both villages although intense and 
perennial with Anopheles gambiae and A. funestus as the major vectors. P. 
falciparum is present in over 90% of malaria cases 20. Six households were 
selected from Ichima and from Miwangani. All occupants who were 16 years of 
age or older were asked to participate in the study. Only those subjects who 
voluntarily gave signed informed consent were enrolled. Scientific and ethical 
clearance for the project was obtained from the Tanzanian Commission for 
Science and Technology (COSTECH) and the Ifakara Health Research and 
Development Centre (IHRDC).  
 
Entomology 
CDC light traps were used as described previously 21 to catch mosquitoes 
fortnightly in each room that was occupied by study participants. The presence 
of sporozoites was determined by ELISA and entomologic inoculation rate (EIR) 
was calculated using a conversion factor (1.605), which takes into account the 
difference between light trap catches and human landing catches 22. EIR was 
expressed as number of infectious bites per person per year for both villages 
separately and the method described by Drakeley et al. was used for calculating 
confidence intervals 23. Season was defined as wet season (March - May); cool 
season (June – September) and hot season (October – February) based on 
meteorological data 23.  
 
Parasitology 
Screening for asexual parasites and gametocytes of P. falciparum took place 
monthly for a period of 16 months. Finger prick blood samples were collected 
and thick blood smears were dried, stained with 10% Giemsa and examined 
microscopically. A slide was considered negative if no asexual parasites were 
seen after examination of 100 fields. Gametocyte and trophozoite densities were 
assessed by counting against 500 and 200 leukocytes, respectively, and 
converted to parasites per μl by assuming a standard leukocyte count of 
8000/μL. Every three months a venous blood sample was taken, centrifuged and 
serum separated and frozen at -80° for laboratory analyses. 
 
Antigen preparation  
Mature gametocytes of P. falciparum (NF54 strain) were produced as described 
elsewhere 19 in an automated static culture system as described by Ponnudurai 
et al. 24 and stored at -700C until used. NF54 gametocytes were extracted in 25 
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mM Tris-HCl (pH 8.0) supplemented with 150 mM NaCl, 1.0% sodium 
desoxycholate (DOC) and 1 mM phenylmethylsulphonyl fluoride. Centrifugation 
pelleted insoluble debris (13,000g for 5 min at room temperature) and the 
supernatant provided antigen for ELISA’s. 
 
Standard Membrane Feeding Assay 
Experimental infections of mosquitoes were carried out as previously described 
25,26. Three to five day old Anopheles stephensi mosquitoes were allowed to feed 
on cultured NF54 P. falciparum gametocytes, in the presence of control or test 
serum. Heat-inactivated test serum was diluted in non-immune control serum 
that was not heat-inactivated (0.75 v/v). The suspension dilution was 0.33 v/v. 
After feeding, blood-fed mosquitoes were kept at 26°C. Surviving mosquitoes 
were dissected seven days later, and oocysts counts were made. Midguts of 20 
mosquitoes were examined for oocysts. The test was considered valid when all 
three batches fed on samples containing control sera showed at least 90% 
infection. The observed transmission reducing activity (TRA) of serum was 
determined as the percentage reduction in oocyst numbers in test samples as 
compared to paired controls 27. Not all sera were analysed in the standard 
membrane feeding assay (SMFA) because of resource limitations. We therefore 
selected four months to obtain information on TRA in the three different seasons 
as well as from the beginning and the end of the study-period. Thus, all available 
sera from September, December 1997 and March, December 1998 were 
assayed.  
 
Enzyme Linked Immunosorbent Assays (ELISA) 
ELISA assays for circumsporozoite protein (NANP5) and Pfs230 IgG1 were 
preformed as described elsewhere 19. Serum was diluted 1/100 for Pfs230 
antibody detection and the titer was determined for NANP5 antibodies, starting 
with a 1/100 serum dilution. 
The presence of anti-Pfs48/45 specific human antibodies was determined 
for different epitopes since there may be variation in their functionality 28. 
Antibodies were measured by coating 10μg/mL of anti-Pfs48/45 mouse mAb 
32F3 or 32F1 recognizing epitope 1 and 2b of Pfs48/45) in PBS for one hour on 
ELISA-plates (Sanbio U-bottom, high binding). Free sites were blocked with 5% 
milk in phosphate buffered saline (PBS) for 30 minutes, and gametocyte extract 
(200,000 parasite equivalents/well) was incubated for two hours. After three 
washes with PBS, wells were incubated with a mixture of 30 μl 1/20 diluted test 
serum and 30 μL HRPO-labeled anti-Pfs48/45 mAb for one hour (final dilution 
1/40). Different anti-Pfs48/45 mAb’s were used for epitope 1: 85RF45.1 
(0.1μg/mL); epitope 2b: 85RF45.2b (1μg/mL); epitope 3: 85RF45.3 (1μg/mL) 
and epitope 5: 85RF45.5 (1μg/mL). Wells were washed with PBS and 
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subsequently incubated with tetra methyl benzidine (TMB) substrate solution for 
20 min. The color reaction was stopped with 4N H2SO4, and the optical density 
was read in a Titertek Multiscan spectrophotometer at 450 nm. All serum 
samples were tested in duplicate. Negative and positive controls were included 
on each plate. In this competition ELISA, sera were considered positive when the 
optical density (OD) was equal or lower than the mean plus two standard 
deviations of the negative control blood bank sera. 
 
Data analyses 
Parasite densities were analyzed after natural log-transformation. Geometric 
mean parasite density with inter quartile range (IQR) was calculated for parasite 
carriers only. Functional transmission reducing activity was categorized as >50% 
reduction in the number of oocysts in the mosquito midgut (TRA >50%) or >90 
reduction (TRA >90%) (Chapter 9) 13,27. Nonparametric Wilcoxon Rank-sum 
tests were used to test differences between groups for statistical significance in 
case of continuous variables. Pearson correlation coefficients were calculated to 
assess the association between continuous variables. Multiple logistic regression 
models with Generalized Estimating Equations (GEE) were used to test the 
influence of age as continuous variable on dichotomous variables such as 
parasite prevalence and immune reactivity. A random effect was included in the 
models to allow for correlations within individuals. A similar procedure was 
carried out using GEE for continuous dependent variables. Statistical analyses 
were preformed using procedures available in SPSS 12.0 and STATA 8.0. 
 
 
Results 
Entomology  
The overall EIR was 165.5 ib/p/yr (95% CI 117.2 – 227.2). The EIR was 
consistently higher in Ichima (276.9 ib/p/yr, 95% CI 189.5 – 390.9) compared 
to Miwangani (61.9 ib/p/yr, 95% CI 22.7 – 134.7). In the cool season (June – 
September) the EIR was lowest with 227.5 infectious bites per person per year 
in Ichima and 0 in Miwangani. In the hot season (October – February) these 
values were 274.6 and 80.2, respectively, and in the wet season (March – May) 
376.7 and 83.7. The number of mosquitoes that was caught per month shows a 
similar picture, fluctuating over time but being consistently higher in Ichima 
(figure 11.1) 
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Figure 11.1. The average number of mosquitoes per trap per month in Ichima and 
Miwangani. Diamonds and dotted line = Ichima, triangles andsolid line = Miwangani. Data were 
missing for September 1998 because the roads were inaccessible due to heavy rains. 
 
Parasitology  
Forty-three adults with a median age of 28 years (IQR 21-50) were followed for 
16 months. Asexual parasite prevalence at inclusion was 14.0% (6/43) with a 
geometric mean parasite density of 228.3 parasites/μL (IQR 108.4 – 463.3). One 
individual had detectable gametocytes at enrolment. During the 16 month study, 
the cumulative asexual parasite prevalence was 67.4% (29/43); for 
gametocytes this was in 34.9% (15/43). The peak point prevalence was 33.3% 
(11/33) for asexuals and 9.1% (3/33) for gametocytes. Only 27.6% (8/29) of 
the asexual parasite carriers harboured asexual parasites on at least two 
consecutive visits. One person harboured gametocytes on more than one 
occasion. Gametocytaemia coincided with asexual parasitaemia in 25% (4/16) of 
the cases. The association between parasitaemia and immune responses with 
age is presented in table 11.1. While data are presented in age categories, 
statistical analyses were performed using age as a continuous variable. The 
adjusted estimates show a statistically significant negative relation between age 
and both asexual parasite prevalence (GEE: β = -0.052; se = 0.016; p = 0.001) 
and asexual parasite density (GEE: β = -0.024; se = 0.0084; p = 0.004). 
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Estimates were adjusted for potential confounding factors such as the village of 
residence and season and a random effect was added to allow for within 
individual correlations.  
There was no statistically significant relation between age and either gametocyte 
prevalence or gametocyte density (table 11.1).  
 
Serological reactivity 
Reactivity to circumsporozoite protein derived NANP5, was highly prevalent in 
this population where 95.3% (41/43) of the subjects had detectable antibodies 
at enrolment (range of titers 50 – 1600). Despite the study population consisting 
of adults only (range 16 – 63 years), there was an age dependent increase in 
anti-NANP5 antibody prevalence (table 11.1, GEE: β = 0.26; se = 0.10; p = 
0.001). Individuals who remained free of asexual parasites throughout the study 
(n = 14) had a median NANP5 titer at enrolment of 400 (IQR 200 – 800) 
compared to 200 (IQR 100 – 400) for those newly infected during follow-up (n = 
23) (Wilcoxon rank-sum test, p = 0.01), suggesting an association of 
circumsporozoite antibodies with responses that are protective against infection 
with P. falciparum.  
In contrast to antibodies to NANP5 , the prevalence of antibodies against 
sexual stage specific antigens was relatively low. Antibodies against Pfs48/45 at 
enrolment were detected in 2.3% (1/43) of the subjects for epitope 1, in 2.3% 
(1/43) for epitope 2b, in 7% (3/43) for epitope 3 and in none of the subjects for 
epitope 5. None of the individuals showing reactivity against Pfs48/45 epitope 1, 
2 or 5 had antibodies on more than one occasion. Eleven individuals showed 
reactivity against Pfs48/45 epitope 3 (table 11.2). Of those, 63.6 % (7/11) was 
seropositive only once. Two individuals were consistently seropositive and 
although these individuals harboured asexual parasites during the study period, 
gametocytes were not detected. Seroconversion from Pfs48/45 epitope 3 
positive to negative was observed in six individuals. Antibodies against Pfs230 
were detected in 18.9% (7/37) of the individuals at enrolment (table 11.2). 
Fifteen individuals showed Pfs230 antibodies at least once during the study 
period, and 46.7% (7/15) of those were seropositive on only one occasion. Two 
individuals were consistently positive in the Pfs230 ELISA, both had patent 
asexual parasitaemia and gametocytaemia during the study. The consistent 
Pfs230 responders were not the same individuals as those who consistently 
showed antibodies against Pfs48/45 epitope 3. Conversion from Pfs230 
seropositive to negative was observed in eleven individuals.  
On basis of their prevalence, only antibodies against sexual stage specific 
Pfs48/45 epitope 3 and Pfs230 were considered useful for more detailed 
analyses. The prevalence of these sexual stage specific antibodies fluctuated 
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throughout the study period without a statistically significant association with 
gametocyte prevalence, season (data not shown) or age (table 11.1). 
 
Table 11.1. The regression coefficient of age as a predictor of parasitaemia, 
seroreactivity or transmission reducing activity. 
 Age   GEE GEE 
 <20 years 20-30 years ≥30 years Age Age 
Individuals 7 17 19 β (se) p-value 
      
Parasitology      
Asexual parasite 
positive, % (n/N) 
42.4  
(36/85) 
15.1  
(28/186) 
10.9 
(24/220) 
-0.052 
(0.016) 
0.001 
Asexual parasite  
density GM (IQR)* 
341.3  
(160.0-659.1) 
213.3  
(120.0-406.3) 
180.1  
(80.0-320.0) 
-0.024 
(0.0084) 
0.004 
Gametocyte 
positive, % (n/N) 
5.9  
(5/85) 
2.6  
(5/186) 
2.3  
(5/220) 
-0.016 
(0.018) 
0.39 
Gametocyte density 
GM (IQR)* 
26.3  
(16.0-39.2) 
20.2  
(16.0-32.0) 
37.0  
(16.0-91.9) 
0.013 
(0.011) 
0.23 
      
Immune responses      
NANP5 prevalence 
(n/N) 
77.8  
(28/36) 
97.3  
(71/73) 
100  
(90/90) 
0.26 
(0.10) 
0.01 
Pfs48/45.3 
prevalence (n/N) 
19.4  
(7/36) 
5.5  
(4/73) 
12.2 (11/90) 0.0067 
(0.025) 
0.79 
Pfs230 prevalence 
 (n/N) 
30.0  
(9/30) 
11.4  
(8/70) 
21.1 (16/76) 0.028 
(0.024) 
0.24 
TRA >50%  
prevalence (n/N) 
45.5  
(5/11) 
55.6  
(20/36) 
42.1 (16/38) -0.022 
(0.014) 
0.13 
n = number of observations with a positive result; N = total number of observations. GM = 
geometric mean; IQR = interquartile range; TRA >50% = transmission reducing activity with 
>50% reduction; β = coefficient for age in years using a GEE model adjusting for village and 
season and allowing for within individual correlations; se = standard error. *Geometric mean 
density for parasite carriers only. Individuals contribute to one age category but multiple 
observations per individual are included. 
 
There was also no statistically significant relation between seroreactivity 
against Pfs48/45 epitope 3 and Pfs230 (OR = 1.66, 95% CI 0.49-5,57). Antibody 
responses were not related to concurrent presence of asexual parasites or 
gametocytes. However, antibodies against Pfs48/45 epitope 3 appeared more 
common in individuals who had patent asexual parasitaemia on the previous 
visit (OR = 2.27, 95% CI 0.82 – 6.30), although not statistically significant. 
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Table 11.2. Longitudinal survey of antibody responses to NANP5, Pfs48/45 epitope 3 and 
Pfs230 antigens in Tanzanian adults.  
 
Donor Age Village NANP5 Pfs48/4. 3 Pfs230 SMFA 
1 56 Ichima + . . + . . – . .+ . . – . . . . . 0 . . . . . 
2 28 Ichima + + + . + + – – – . – – – – – . . + 0 0 1 . . 0 
3 58 Ichima + + + + + . – – – – – . + – – . . . 0 0 1 . . . 
4 35 Ichima + + + + + + – – – + – – + – – . – – 1 0 2 . . 1 
5 25 Ichima + + + . + + – – – . – – . – – . – – . 0 1 . . 0  
22 36 Ichima + + + . + . – – – . – . – – – . – . . 1 2 . . . 
23 21 Ichima + + + . . . – – – . . . – – – . . . . 1 1 . . . 
24 30 Ichima + + . + + + – – . – – + – – . – – .  . 0 . . . 0  
25 54 Ichima + + + + + +  – – – – – –  . – – – – –  . 0 0 . . 1 
26 22 Ichima + + . + + . – – . – – . – – . – – . . 1 . . . . 
27 63 Ichima + + . + + + – – . – – – – – . + + + . 1 . . . 0 
28 23 Ichima + + + + + + – – – – – – – – – – – –  . 1 1 . . . 
29 28 Ichima + + . + + + – – . – + – – – . – – – . 0 . . . 0  
30 56 Ichima + . . . + + – . . . – – – . . . – – . . . . . . 
31 26 Ichima + + + + . + – – – + . – – – – – . – . 0 1 . . . 
32 23 Ichima + + + . . .  – – – . . . – – – . . .  . 1 1 . . . 
33 20 Ichima + + . . . . – – . . . . – – . . . .  . 1 . . . . 
34 24 Ichima + + . + + + – – . – – – – + . – + + . 1 . . . . 
35 17 Ichima + + + . + + – + – . – – – – – . – – . 0 1 . . . 
36 58 Ichima + . + + + + – . – – – – – . – – – – . . 0 . . . 
37 62 Ichima + + + + + + – – – – – + – – + – – – . 0 1 . . 0 
38 45 Ichima + + + + + . – – – – – . – – . . . . . 0 0 . . . 
39 38 Ichima + + . . . . – – . . . . – – . . . . . 0 . . . . 
40 20 Ichima + + + . . . – – – . . . – – – . . . . 1 0 . . . 
6 55 Miwangani + + . + + + – – . – – – – – . – – – 0 0 . . . . 
8 28 Miwangani + + . + . . – – . – . . – – . – . . 1 0 . . . . 
9 50 Miwangani + + + + + + – – – – – – . + + – – + . 0 . . . . 
11 16 Miwangani + + + + + +  + + + + + + . – + – – – . 0 . . . 0 
12 44 Miwangani + + + + + + – – – – – – – – – – – . 0 0 0 . . . 
13 28 Miwangani + + + + . + – – – – . – – – – – . – 1 0 1 . . 0 
14 24 Miwangani + + + + + + – – – – – – – – + + – – 1 0 0 . . . 
18 18 Miwangani + . . . . . – . . . . . – . . . . . 1 . . . . . 
19 19 Miwangani + + . + + + + + . + + + + – . . . . 2 1 . . . . 
20 27 Miwangani + + + + + + – – – – – – . – – – – – . 0 . . . . 
21 23 Miwangani + . . . . . – . . . . . – . . . . . 1 . . . . . 
41 39 Miwangani + + + + + + – – – – – – – – + – – – . 1 . . . . 
42 21 Miwangani – + + + + – + + – – – – + – – – + – . 1 1 . . 0 
43 18 Miwangani – – – – – – – – – – – – – – – – – – 1 0 1 . . . 
44 16 Miwangani + – + + + – – – – – – – + + + + + + . 1 . . . . 
45 58 Miwangani + + + + + + – + + – – – + – + + + + 1 0 2 . . . 
46 16 Miwangani + + + + + + – – – – – – . – . . . .  . . . . . . 
47 18 Miwangani + + + + + + – – – – – – + – – + – – 0 0 . . . . 
48 54 Miwangani + . + . . . – . – . . . – . – . . . 1 . 1 . . . 
Each symbol represents a separate serum sample. Samples were collected at three-month 
intervals, giving a maximum of six observations per individual. + = antibody positive; – = 
antibody negative; . = missing. Missing values are either missing samples (all assays) or a high 
background reactivity (Pfs230). For the SMFA, available samples from September 1997, December 
1997, March 1998 and December 1998 were analysed, giving a maximum of four observations per 
individual. 0 = <50%TRA (no reduction), 1 = >50%TRA; 2 = >90% TRA. 
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Transmission reducing activity 
A total of 85 experiments were considered valid in the standard membrane 
feeding assay. Only 4.7% (4/85) of the sera was capable of blocking 
transmission (TRA >90%) while TRA >50% was observed for 48.2% (41/85) of 
the sera. There was no statistically significant relation between TRA and age 
(figure 11.2, table 11.1). There was also no statistically significant relation 
between TRA and the presence of gametocytes either at the time of sampling or 
at the previous time-point. There was no consistency in TRA in sera from the 
same individuals measured at different time-points (table 11.2). In line with 
previous findings, TRA was related to antibodies against sexual stage antigens. 
There was a positive relation between TRA >90% and reactivity to Pfs230 (OR = 
6.2; 95% CI 0.79 – 48.5) and Pfs48/45 epitope 3 (OR = 9.13; 95% CI 1.13 – 
73.9). We observed no statistically significant association between TRA >50% 
and reactivity to either Pfs230 (OR = 1.2; 95% CI 0.38 – 4.05) or Pfs48/45 
epitope 3 (OR = 0.69; 95% CI 0.18 – 2.63). 
 
 
 
Figure 11.2: Transmission reducing activity against age. The dotted line represents ≥90% 
reduction, solid line ≥50% reduction in the SMFA. Error bars indicate the upper limit of the 95% 
confidence interval. Note that more than one observation per individual is included.  
 
Differences between villages 
Despite the differences in EIR between villages, asexual parasite prevalence and 
density did not differ significantly (table 11.3). Gametocyte prevalence and 
density were non-significantly elevated in Miwangani compared to Ichima (GEE: 
β = 0.84; se = 0.48; p = 0.08 and GEE: β = 0.65; se = 0.38; p = 0.12, 
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respectively). Antibodies against circumsporozoite protein NANP5 were common 
in both villages. The prevalence of anti-Pfs230 antibodies to the sexual stage 
antigens was significantly higher in Miwangani than in Ichima (GEE: Pfs230 β = 
1.31; se = 0.62, p = 0.04). A similar trend was seen for Pfs48/45 epitope 3, 
albeit not statistically significant (GEE: β = 0.85; se = 0.69, p = 0.22). Although 
the analyses allowed for clustering of observations from the same individual, it is 
possible that the difference between Miwangani and Ichima is a consequence of 
the consistent responders to Pfs230 (n = 2) and Pfs48/45 epitope 3 (n = 2), 
who all lived in Miwangani (table 11.2). We chose to include these individuals in 
the analyses because exclusion may dilute the true effect of transmission 
intensity on sexual stage immune responses. There was no statistically 
significant difference in the prevalence of TRA between the villages (table 11.3). 
 
Table 11.3. The regression coefficient of village as a predictor of parasitaemia, 
seroreactivity or transmission reducing activity.  
 Village  GEE  
 Ichima Miwangani Village  Village 
Individuals 24 19 β (se) p-value 
     
Parasitology     
Asexual parasite prevalence (n/N) 18.4 (51/226) 17.3 (37/177) -0.32 (0.36) 0.37 
Asexual parasite density, GM (IQR) 212.9 (120.0-440.0) 302.6 (138.6-558.6) 0.060 (0.19) 0.76 
Gametocyte prevalence (n/N) 2.2 (6/277) 4.7 (10/214) 0.84 (0.48) 0.08 
Gametocyte density, GM (IQR) 21.6 (16.0-35.4) 29.9 (16.0-35.4) 0.65 (0.38) 0.12 
     
Immune responses     
Circumsporozoite protein (NANP5), 
prevalence (n/N) 
100.0 (105/105) 89.4 (84/94) -  
Pfs48/45.3 prevalence (n/N) 6.7 (7/105) 16.0 (15/94) 0.85 (0.69) 0.22 
Pfs230 prevalence (n/N) 10.6 (10/94) 28.0 (23/59) 1.31 (0.62) 0.04 
TRA >50% prevalence (n/N) 47.9 (23/48) 48.6 (18/37) 0.029 (0.44) 0.94 
n = number of observations with a positive result; N = total number of observations. GM = 
geometric mean; IQR = interquartile range; TRA >50% = transmission reducing activity with 
>50% reduction; β = coefficient for village using a GEE model adjusting for age and season and 
allowing for within individual correlations; se = standard error. Note that there are multiple 
observations per individual. 
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Discussion 
In this study we assessed functional transmission reducing activity and related 
factors longitudinally in a cohort of Tanzanian adults. While individuals were 
exposed to intense malaria transmission, gametocytaemia was uncommon. The 
prevalence of sexual stage specific immune responses and functional 
transmission blocking immunity was similarly low. It is likely that these two 
observations are directly linked. Together they further support the hypothesis 
that, unlike asexual stage immunity, efficient sexual stage immunity decreases 
with age (Chapter 12) 16. 
 
Unlike the carriage of NANP5 antibodies (Chapter 10) 19, sexual stage 
antibody responses did not become more common with age and were detected 
in only a minority of our adult population. Immune responses to Pfs48/45 
epitope 1, 2b, and 5 were very low in the study group. Antibodies against 
Pfs48/45 epitope 3 were present in 7% of the individuals at enrolment and the 
combined seroprevalence of all four epitopes of Pfs48/45 was threefold lower 
than total Pfs48/45 IgG1 antibodies detected in gametocyte carriers of a similar 
age group (Chapter 10) 19. This could either be due to the difference in 
approach, testing per epitope being less sensitive, or by a lower prevalence of 
antibodies in the absence of concurrent gametocytaemia. Antibodies against 
Pfs230, that is considered to be more immunogenic 29,30, were similar in this 
study and in gametocyte carriers from a nearby area (Chapter 10) 19.  
 
In this study we observed that sexual stage immune responses were short 
lived and that there was little consistency in immune response over time. The 
short lived nature of sexual stage immune responses has been documented 
previously for P. vivax which requires frequent boosting 31,32. The apparent lack 
of immunologic memory is possibly explained by a T-cell independent generation 
of transmission blocking antibodies or antibodies directed against non-protein 
targets 15,33. Thus, although some individuals were consistent responders to 
Pfs230 or Pfs48/45 epitope 3, the majority of responders converted from 
seropostive to seronegative within the study period. Previous reports from Papua 
New Guinea, Indonesia (Chapter 10) 13,30,34 showed that sexual stage specific 
immunity increased with age and cumulative exposure. However, these studies 
were in individuals residing in an area of low malaria transmission intensity or in 
migrants. Differing levels of asexual immunity between these groups and our 
study cohort may explain the differences in the sexual stage immunity.  
4.7% of the sera from the current study showed TRA >90% and TRA 
>50% was observed in 48% of the sera. None of the individuals from our cohort 
of whom multiple samples were tested showed consistent TRA on each time-
point. TRA >90% was significantly lower in this cohort than in a cross sectional 
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group of gametocyte carriers recruited at a nearby clinic (Chapter 10) 19. The 
lack of consistency of sexual stage immune responses that we observe contrasts 
with findings from The Gambia where antibody levels against Pfs230 were stable 
in adults 29. This difference may be the result of a lower or irregular exposure to 
sexual stage parasites in our population that was exposed to intense perennial 
malaria transmission compared to seasonal transmission in The Gambia 29. 
Recognition of sexual stage antigens does not appear to be genetically 
determined 29 and the absence of sexual stage antibodies in a large proportion of 
the population may therefore be the result of a low recent exposure to sexual 
stage antigens.  
Gametocyte carriage is well known to decrease with age (Chapter 12) 16-
18,35 and during our 18-month study period, gametocytes were detected in only 
one-third of the individuals. Although we will have missed some episodes of 
gametocyte carriage due to monthly sampling and microscopy is a relatively 
insensitive tool to detect gametocytes 35, exposure to gametocytes was clearly 
low in our population . Our observation on the kinetics of sexual stage immunity 
are probably the result of acquired immunity to asexual stages (Chapter 12) 16 in 
this adult population who were exposed to intense malaria transmission. The 
comparison of the two villages further supports a negative association between 
transmission intensity and the exposure to gametocytes and sexual stage 
immunity. We observed a lower exposure to gametocytes in the village exposed 
to higher transmission intensity, as was previously described 36. In addition, we 
find lower sexual stage antibody prevalences at higher transmission intensity. It 
is logical to assume that these lower antibody responses are a direct result of 
the lower exposure to sexual stage antigens. 
 
In summary, our findings suggest that sexual stage specific immunity and the 
resulting TRA depend on recent exposure to gametocytes, which is low in our 
cohort. Although we observe no age-dependency, functional TRA and sexual 
stage immune responses were low in our adult population. Together with the 
recently reported negative age-dependency of TRA in younger gametocyte 
carriers (Chapter 10) 19, our findings fit in well with the hypothesis that sexual 
stage immunity may be uncommon in older individuals living at high levels of 
transmission intensity (Chapter 12) 16. Functional transmission blocking 
immunity may be restricted to those most exposed to gametocytes (Chapter 12) 
16 and the relative infectivity of older individuals, who have acquired immunity to 
asexual stage parasites, is less likely to be affected by sexual stage immunity. 
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Summary 
Gametocytes and sporogonic stages are responsible for the spread of malaia 
disease and drug resistance in the population. Sexual stage immunity affects the 
infectiousness of gametocytes to mosquitoes and specific antibodies including 
anti-Pfs48/45 and anti-Pfs230 antibodies are found in individuals with limited 
prior exposure to malaria. These sexual stage antibodies are rapidly acquired 
after infection and are relatively prevalent in gametocytaemic individuals. 
Functional transmission reducing activity (TRA) is found after primary infections 
and in young children and appears to depend on recent rather than cumulative 
exposure to gametocytes. Exposure to gametocytes decreases with age most 
likely as a consequence of the acquisition of asexual-stage immunity that 
controls asexual parasite density and consequently gametocytaemia. This results 
in a lower exposure to the antigenic load of gametocytes in semi-immune 
individuals. Since sexual stage immunity is probably short-lived in the absence 
of gametocytes, we hypothesize that sexual stage immunity will wane, resulting 
in low antibody and TRA prevalences in clinically semi-immune carriers. 
  
Sexual stage antibodies in endemic populations 
161 
Introduction  
A small proportion of a-sexual parasites differentiates into gametocytes, which 
represent the sexual forms of the parasite. Gametocytogenesis starts inside the 
red blood cell when a committed merozoite, develops into a male (micro-) or 
female (macro-) gametocyte. The events that trigger sexual development are 
poorly understood 1. Various stimuli have been implicated such as anaemia, 
specific antibodies and drugs 2-6. However, mathematical models 7 and recent 
work in human experimental infections 8 show that parasites are committed to 
sexual stages immediately after hepatic schizogony.  
The parasites develop through five distinct morphological gametocyte 
stages (I-V) in 1-2 weeks. Stage I to IV gametocytes sequester from the 
peripheral blood during maturation 9,10. Patterns may be distinct from asexual 
stages and sequestration in organs such as the spleen or immunologically 
privileged sites like the bone marrow may reduce the risk of immunological 
clearance 10. Stage V gametocytes circulate in the bloodstream and become 
infectious to mosquitoes after 2-3 days of maturation. When mature 
gametocytes are ingested by a mosquito, transformation of the gametocytes into 
gametes is initiated and fertilization of female by male gametes takes place in 
the lumen of the mosquito midgut. Within 24 hours after fertilization, non-motile 
zygotes transform into motile ookinetes. Ookinetes have to traverse two 
barriers: the peritropic matrix/membrane and the midgut epithelium. After 
ookinetes reach the extracellular space, they transform into oocysts between the 
midgut epithelium and the overlaying basal lamina. Thousands of sporozoites are 
formed which will migrate to the salivary glands, ready for new human infection. 
The period in the mosquito midgut is a vulnerable moment in the parasite life 
cycle. Unprotected by the red blood cell, parasites are exposed for several hours 
to blood products that have been co-ingested with the blood meal 11. Specific 
antibodies, complement and granulocytes have been shown to decrease or 
abrogate the sporogonic development 12-16.  
In this paper, we discuss naturally acquired sexual-stage immune 
responses to P falciparum and their effects on transmission from men to 
mosquito.  
 
The development of sexual-stage specific immunity 
Sexual-stage specific immunity is acquired after exposure to gametocyte 
antigens. The development of an immune response to gametocytes is 
unsurprising given that the vast majority of gametocytes are not taken up by 
mosquitoes but are cleared by the host immune system. Although it has been 
reported that innate and cellular immune mechanisms may be involved in sexual 
stage immunity, it is generally well accepted that antibodies are the primary 
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mediators, either alone or together with complement or white blood cells 
12,13,17,18.  
Antibody responses against pre-erythrocytic and blood stage specific 
antigens increase with cumulative exposure. The prevalence of these antibodies 
is low in children and much higher or almost universal in adults in endemic 
areas, the rate of acquisition depending on transmission intensity 19,20. The 
presence of asexual stage antibodies associates with control of parasite growth, 
reduces parasitaemia and consequently clinical disease.  
The prevalence of gametocytes gradually decreases with age following a 
similar pattern as asexual parasitaemia, from which they are derived (figure 
12.1) 21-25. Cumulative exposure to malaria, rather than age, is responsible for 
this decrease in gametocyte prevalence, as was shown by a study comparing 
endemic population and newly arrived migrants from non-endemic areas 26. 
Similar to asexual immunity, one may assume that sexual stage antibodies and 
functional immunity will increase with age at a rate that depends on 
transmission intensity. Sexual-stage immunity can be effective against 
gametocytes inside the human host or against gametocyte-derived target 
antigens expressed and accessible to antibodies inside the mosquito midgut. The 
effect of antibodies on infectiousness of gametocytes can be assessed by 
sporogonic development in mosquitoes after an infectious blood meal. 
Figure 12.1 The exposure to gametocytes in different age groups. 
Gametocyte prevalence per age group in the general population in studies conducted in Kenya 21, 
Tanzania 22, The Gambia 22, Mali 23, Burkina Faso 24 and Papua New Guinea 25. 
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Antigens on the membrane of gametocyte-infected  
erythrocyte  
Data are limited on the immune responses directed to gametocytes while inside 
the human host. It is clear that disruption at any stage during the long 
gametocyte maturation period could have profound effects on parasite 
transmission and this area is ripe for investigation. There is some evidence for 
cross-reactive asexual and sexual-stage immunity 27-29 and specific anti-
gametocyte immune mechanisms 26,30 that may clear gametocytes at some 
stage during their development. Immune responses against gametocytes can be 
directed against common parasite antigens, which are expressed on the surface 
of gametocyte infected erythrocytes and include extensive multigene families, 
var, rif, stevor and more recently surfin’s 31. The var genes are involved in the 
expression of PfEMP-1 molecules 32 that are expressed on erythrocytes infected 
with both trophozoites and early gametocyte stages (I,IIa) 28,33. PfEMP-1 is the 
primary mechanism for cytoadherence and sequestration of asexual parasites 34 
and PfEMP-1 antibodies may reduce gametocytaemia indirectly by controlling 
asexual parasitaemia or directly by affecting gametocyte maturation 28,29. Closely 
linked to var genes is the repetitive interspersed family (rif) 35, which is 
associated with rapid parasite clearance 36. There is no evidence that rifin’s are 
expressed in sexual-stage parasites 37. Stevor (subtelomeric variable open 
reading frame) gene transcripts 38 are transiently present early in the 
development of gametocytes and may play a role in gametocyte sequestration 
and adhesion 37 although their role in reducing gametocytaemia has not been 
elucidated. Gametocyte prevalence can be influenced by immune responses 
against asexual parasites 30 and possibly by immune responses directed against 
gametocytes 26-28,30. Flow cytometric analysis of early stage gametocytes may 
provide clues as to which antigens are recognized and whether this recognition 
correlates with transmission from man to mosquito.39 
Independent of the rate of gametocyte development or clearance, immune 
responses may also affect the infectiousness of gametocytes. This type of 
immunity depends on a different set of antigens.  
 
Gametocyte and gamete antigens 
Most serological field data concern antigens that are expressed in gametocytes 
and gametes in de mosquito midgut shortly after ingestion of the blood meal 
(Table 12.1). These antigens include Pfs48/45 and Pfs230, which are involved in 
fertilization and therefore a prime target for transmission blocking antibodies 
and vaccine development 11.  
Pfs48/45 : Pfs48/45 is expressed in gametocytes and on the gamete 
membrane and essential for fertilization in male gametocytes. The biological 
function of Pfs48/45 in female gametocyte remains obscure 40-42. Five distinct B-
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cell epitopes have been defined by a panel of anti Pfs48/45 monoclonal 
antibodies (Mabs) with epitope I and V as best targets for transmission-blocking 
Mabs 43-47. 
Pfs230: Pfs230 expression is similar to that of Pfs48/45, starting from 
stage II gametocytes onwards. Although expressed on the gamete membrane, 
Pfs230 does not contain a GPI anchor but associates after proteolytic cleavage 
with Pfs48/45 48. Pfs230 has five distinct epitopes 49, Several studies show that 
transmission blocking by anti-Pfs230 mAbs is fully dependent on a complement-
fixing isotype and the presence of active complement. There is a perfect 
association between the capacity to block transmission and complement-
mediated lysis of P. falciparum macrogametes in vitro 50,51. 
Pfs16: Expression of Pfs16 is the earliest sexual-stage specific antigen in 
gametocyte development that occurs in committed ring stages.52. Expression 
continues from stage I gametocytes throughout maturation in male and female 
gametocytes, although at a lower level in stage V gametocytes 53. Pfs16 is an 
integral membrane protein present on the parasitophorous vacuole membrane 54 
and is not essential but contributes to the generation of gametocytes 55. The 
prevalence of antibodies to recombinant Pfs16 or Pfs16 peptides is high in 
endemic sera (Chapter 10) 56,57; however, the correlation of these responses 
with antibodies to natural antigens is poor (Roeffen, unpublished data).  
Pfg27 is expressed throughout the cytoplasm of sexually committed 
parasites but not on the surface membrane 53,58. Disruption of the Pfg27 gene 
results in a loss of sexual phenotype 59. 27kD immune responses were detected 
by immunoprecipitation in a small set of sera from Papua New Guinea60.  
Pfs25 and Pfs28 are well-known transmission-blocking vaccine candidates, 
but these antigens are only expressed during late sporogony and consequently 
naturally acquired antibodies have not been found in endemic sera 23,60  
 
Table 12.1. The expression of a selection of P. falciparum antigens in sexual and 
sporogonic stages 
 Human Mosquito 
 Gametocyte Gamete / Zygote 
 Internal RBC Membrane Membrane 
PfEMP-1  X  
Pfs48/45 X  X 
Pfs230 X  X 
Pfs16 X   
Pfg27 X   
Pfs25/Pfs28   X 
RBC = red blood cell 
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Infection from man to mosquito  
The infectiousness of gametocytes and the effect of serum factors on the 
infection from men to mosquito can be measured in bio assays where 
gametocytes are fed to Anopheles mosquitoes. There is a good correlation 
between infectiousness in these membrane feeding assays and feeding of 
mosquitoes directly on the skin 61 in microscopically confirmed gametocyte 
carriers. 
Two types of membrane feeding assays are commonly used: i) In the 
standard membrane feeding assay, cultured gametocytes are fed to mosquitoes 
in the presence of an (endemic) test sample or non-malaria control serum 62,63. 
This assay can detect transmission reducing factors in test samples. ii) In the 
direct membrane feeding assay, which can be conducted in the field, blood 
samples from naturally infected gametocyte carriers are fed to mosquitoes in the 
presence of autologous serum or control serum after a washing step 25,64,65. This 
assay can measure the infectiousness of the gametocyte carrier and the 
presence of plasma factors that may influence the rate of mosquito infection. 
Transmission reduction in both membrane feeding assays is determined by 
comparing the number of developed oocysts in mosquitoes fed with test versus 
control serum.  
On average, maximally 40-75% of naturally infected gametocyte carriers 
is infectious to mosquitoes 21,64-67. The proportion of infectious gametocyte 
carriers may decrease with age 22,23,65 but this is closely related to gametocyte 
density. An effect of age on infectiousness that is independent of gametocyte 
density, was found in some 21,23 but not all studies 22,25,65.  
The possible age dependency and the poor correlation between 
transmission success and gametocyte density 65,68 suggest that additional factors 
including immune responses may contribute to the reduced gametocyte 
infectiousness. A role for the host’s immune response was first detected in 
studies in animal models where immunization with parasite mixtures and purified 
gametes induced the production of stage specific antibodies capable of blocking 
the sexual and sporogonic development in the mosquito 69-73. In addition, several 
studies have demonstrated the ability of immune human serum to reduce the 
infectivity of gametocytes to mosquitoes 47,64,74-78.  
The degree of transmission reducing activity varies in different studies; 
more than 50% reduction of oocyst numbers is found with 25-55% of the 
endemic sera (Chapter 10) 56,64,74,75,78. Antibodies against Pfs48/45 and Pfs230 
have been associated with transmission reducing activity and their 
seroprevalence has been studied in endemic populations.  
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Antibodies to Pfs48/45 and Pfs230 and transmission 
reducing activity  
Serology 
A variety of techniques and antigen sources have been used in sero-
epidemiological studies in different endemicities and age groups. Pfs230 
antibody prevalence as detected by IgG1 and competition ELISA is 25-60% and 
more prevalent than anti-Pfs48/45 antibodies (10-40%) in endemic sera 
14,64,77,79. Seroreactivity against both antigens is higher when measured by 
immunoprecipitation 49,74,78,80. Almost all these results are obtained with sera 
from gametocyte carriers. The few studies that compared infected and 
uninfected individuals show that the seroprevalence in the uninfected population 
is much lower for both Pfs48/45 and Pfs230 (Chapter 9) 81-83. This suggests that 
the half life of these antibodies is relatively short in the absence of circulating 
gametocytes. 
Antibodies against Pfs48/45 and Pfs230 are acquired after one or few 
infections (Chapter 9) 81,83,84. Despite the rapid induction of these sexual stage 
specific responses, prevalences of anti-Pfs48/45 and anti-Pfs230 antibodies are 
generally low in semi-immune populations when compared to antibodies to 
asexual stage antigens. Although an effect of cumulative malaria exposure on 
sexual stage immunity was observed in Papua New Guinea 83, other studies 
contradict an important influence of cumulative exposure. If cumulative 
exposure determines seroreactivity, one would expect an increase in 
seroprevalence with age, as is typically seen for asexual-stage specific 
antibodies 19,20,85,86. Although a cross-sectional study from Papua New Guinea 
indicated that Pfs48/45 seroreactivity may be highest in adults 87, no relation 
with age has been found in several other studies (Chapter 10,11)(vdKolk, 
unpublished; Ouedraogo, unpublished) 56,77. Similarly, there is no convincing 
evidence for an age-dependency of anti-Pfs230 antibodies (Chapter 10, 
11)(vdKolk, unpublished; Ouedraogo, unpublished) 56,77.  
Two studies directly determined the influence of transmission intensity on 
the prevalence of Pfs48/45 and Pfs230 antibodies. In one study in high endemic 
areas in Cameroon, a five-fold difference in transmission intensity did not result 
in a marked difference in antibody prevalence (vdKolk, unpublished). A study in 
lower and highly seasonal transmission areas in Burkina Faso found a 
significantly lower prevalence of sexual stage specific antibodies in the higher 
transmission area (Ouedraogo, unpublished).  
 
Functional assay 
Membrane feeding assays can be used to assess transmission reducing activity 
(TRA) in field sera. The relationship between TRA and sexual stage specific 
antibodies in these sera has been investigated in several studies. A good 
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correlation was observed between anti-Pfs230 antibodies in Gambian 77,80 and 
Papua New Guinean sera (Chapter 9) 74,81, but no correlation was found in 
Cameroonian 47,64 or Sri Lankan 78 sera. The same is true for anti-Pfs48/45 
antibodies where a positive relation was found with TRA in some studies 
(Chapters 9, 10, 11) 47,56,64,77,81,82 but not in other studies 74,78,80. Naturally 
acquired TRA is found in individuals with recent and/or limited prior exposure to 
malaria as was shown in young children and transmigrants from a malaria non-
endemic to an endemic area (Chapter 9) 77-79,81. In certain epidemiological 
settings TRA may be negatively related to age (Chapter 10) 56 although the data 
are limited and further work is needed 75,77,88.  
In summary, sexual stage antibodies are rapidly acquired after infection 
and relatively prevalent in gametocytaemic individuals, suggesting the need for 
the continued presence of antigen. TRA is found after primary infections and in 
young children and may depend on recent rather than cumulative exposure to 
gametocytes. The prevalence of sexual stage antibodies seems to be negatively 
associated with transmission intensity and lacks a convincing association with 
age. TRA is associated with antibodies against Pfs48/45 and Pfs230 although the 
strength of the associations differs between populations. 
 
A model for the epidemiology of sexual stage immunity  
Although not consistent with all studies, an attempt has been made to 
incorporate most of the presented data into an epidemiological model of sexual 
stage immunity (figure 12.2). Our hypothesis is that sexual stage specific 
immunity is rapidly acquired but, in contrast to asexual immunity, declines with 
increasing exposure to infection, i.e. in older age groups. 
The high prevalence of gametocytes in little exposed individuals induces  
functional antibodies and, if titers are sufficiently high, transmission reducing 
activity. The acquisition of asexual-stage immunity controls asexual parasite 
density and consequently gametocytaemia, resulting in lower exposure to the 
antigenic load of gametocytes. Sexual-stage specific immunity is considered to 
be short-lived in the absence of gametocytes and therefore related to recent, 
rather than cumulative exposure. As a result, sexual stage immunity is highest 
in young children, where exposure to gametocytes is highest. Exposure to 
gametocytes will decrease with increasing age and developing asexual stage 
immunity.  
Consequently, sexual stage immunity will wane, resulting in low antibody 
and TRA prevalences in semi-immune (non-gametocyte) carriers. This profile is 
likely to be dependent on transmission intensity with a shift to the left in high 
endemic areas and to the right in low endemic areas.  
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Figure 12.2 Model of sero-epidemiology in relation to exposure 
Relative level of immunity against sexual, asexual and sporozoite stages in the population as a 
function of malaria exposure. The dashed area represents functional transmission reducing 
activity. 
 
 
Conclusion 
The epidemiology of sexual stage specific immune responses has been relatively 
little studied compared to pre-erythrocytic and a-sexual stage immunity. The 
obvious reason is that no direct relationship of this type of immunity can be 
expected with clinical protection. However, there is a relationship between the 
presentation of clinical disease and the pattern of transmission, which is 
determined by the human and mosquito reservoir and which shows an enormous 
geographical variation. Reduction of malaria transmission can significantly 
contribute to malaria control 89.  
Gametocytes and sporogonic stages are responsible for the spread of disease 
and drug resistance in the population. Further understanding of the 
epidemiology of gametocytaemia and related sexual stage immunity can 
significantly contribute to the implementation and success of interventions and 
control. This includes all interventions since gametocytes emerge from the 
asexual parasite pool and a reduction in potential gametocyte carriage would 
have wide reaching benefits.  
It is clear that further studies are needed to test the presented model and 
to further unravel the complex relationship between transmission and 
transmission reducing immunity. Among such questions are the functional role in 
endemic sera of sexual stage antibodies, notably anti-Pfs48/45 and anti-Pfs230, 
their longevity and their relationship with transmission intensity. 
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The work described in this thesis deals with the prevalence of (low density) 
gametocytes and their infectiousness to mosquitoes, possible ways to reduce 
gametocytaemia by antimalarial drugs and human immune responses reducing 
the infectiousness of gametocytes to mosquitoes.  
 
The prevalence of (submicroscopic) gametocytaemia in 
different populations 
Studies on gametocyte development in naturally infected individuals commonly 
rely on microscopical examination of patients treated with antimalarial drugs 1-10, 
leaving many question unanswered on the occurrence of gametocytes in the 
general population. In Chapter 2 of this thesis, we determined gametocyte 
dynamics by microscopy in asymptomatic individuals in the absence of treatment 
11. One in five parasitaemic individuals developed gametocytaemia in the month 
they were followed, often at densities of 16-32 gametocytes/μL (1-2 
gametocytes observed while screening 100 microscopic fields). Once detected, 
gametocytaemia frequently dropped below the microscopic detection limit at the 
following visit to appear again later. This commonly observed phenomenon of 
gametocytes circulating at densities close to the microscopic threshold 12-16 
illustrates the insensitivity of microscopy for detecting gametocytes. The more 
sensitive quantitative nuclear acid sequence-based amplification (QT-NASBA) 
technique was used in this thesis to explore the prevalence and potential 
importance of low-density gametocytaemia. Pfs25 QT-NASBA detects a 3-5 
times higher proportion of gametocytaemic individuals (Chapter 5, 6) 17-19. One 
could argue that any molecular gametocyte detection technique will increase the 
proportion of gametocytaemic individuals and that this increase is neither 
unexpected nor automatically relevant. The prevalence of submicroscopic 
gametocytaemia in different populations and its contribution to the human 
infectious reservoir are key issues in judging the importance of our findings.  
We determined submicroscopic gametocytaemia in areas of very different 
malaria endemicity. In symptomatic children from a high endemic area in 
western Kenya 80-90% harboured gametocytes at enrolment (Chapters 5, 6) 
17,18. The proportion of gametocyte densities that is below the microscopic 
threshold is illustrated in figure 13.1 that presents their Pfs25 QT-NASBA 
gametocyte densities. Lines indicate the threshold density for detection by 
microscopy or quantitative buffycoat (QBC). Approximately 75% of the 
gametocyte carriers detected by Pfs25 QT-NASBA are below the threshold of 
microscopic examination of 100 fields (i.e. 5 gametocytes/μL).  
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Figure 13.1 Gametocyte detection by different detection techniques. Bars indicate 
gametocyte densities by Pfs25 QT-NASBA in symptomatic malaria infections in a high endemic 
area in western Kenya 17, 18. Lines indicate the threshold density for detection by quantitative 
buffycoat (QBC) and microscopic examination of 100 fields, 500 or 200 white blood cells. 
 
It is important to acknowledge that these results are derived from a highly 
selected population that is characterised by several known risk factors for 
gametocytaemia such as young age 20-24, a relatively high density asexual 
parasitaemia (Chapter 2) 3,5,11, and possibly a longer duration of infection 1,2,6 
with multiple parasite clones 25. Although these factors may certainly have 
contributed, studies conducted in very different settings confirm the abundance 
of submicroscopic gametocytaemia. In an area of very low transmission intensity 
in Tanzania where less than 1% of the general asymptomatic population 
harboured microscopically detectable gametocytes, Pfs25 QT-NASBA detected 
gametocytes in 15% of the individuals (Chapter 8) 26. In addition, cross-
sectional surveys in area of seasonal malaria in Burkina Faso indicate that a 
staggering 70% of the general population harbours gametocytes by Pfs25 QT-
NASBA in the peak transmission season compared to 21% by microscopy 
(Ouédraogo, unpublished observations).  
In summary, our findings from three areas of different transmission 
intensity indicate that 70-93% of all gametocyte carriers harbour gametocytes at 
densities below the microscopic detection threshold. Unlike previously assumed, 
gametocyte carriage does not occur in a minority of asexual parasite carriers but 
appears to accompany asexual parasites in 50-89% of the individuals. Future 
work should determine the exact relation between transmission intensity, 
seasonality and submicroscopic gametocytaemia. We nevertheless consider it 
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likely that in all transmission settings a considerable proportion of gametocyte 
carriage, probably the majority, occurs below the microscopic detection limit.  
 
The relevance of submicroscopic gametocytaemia for malaria 
transmission 
Importantly, gametocyte carriage does not equal infectiousness to mosquitoes. 
This depends on gametocyte fitness and density 8,20,27-30. The latter will of course 
be of particular importance in determining the relevance of submicroscopic 
gametocytaemia. Assessing the infectiousness of individuals to mosquitoes is a 
laborious task. This may be a reason why experiments are often restricted to 
microscopically confirmed gametocyte carriers despite evidence for the 
infectiousness of individuals who were gametocyte free according to microscopy 
20,27,31-35. Studies directly relating gametocyte densities with the infectiousness to 
mosquitoes typically found weak positive associations 24,27,28,30,32,34-39. In the 
previous section we concluded that submicroscopic gametocytaemia may be 
common in all transmission settings. In Chapter 7 of this thesis, we have shown 
that there is a positive association between gametocyte density and mosquito 
infection rates but that mosquito infection is common at submicroscopic 
gametocyte densities 19. The infectivity of low concentrations of NF54 
gametocytes was assessed under laboratory conditions and mosquito infection 
became unlikely below a density of 250-300 gametocytes/mL. In contrast, we 
did not observe a minimum gametocyte density for natural infections and 
mosquito infection was even observed at densities below 100 gametocytes/mL. 
We expected to find a minimum gametocyte density for successful 
mosquito that would be in agreement with the theoretical minimum density of 
one male and one female gametocyte per mosquito blood meal of 2μL. The 
typically female biased gender ratio of gametocytes 40-43 ordinarily resulting in 
one male gametocyte per 3-4 female gametocytes 44, would give a minimum 
density in the order of 2-5 gametocytes per mosquito blood meal. Since the 
uptake of gametocytes by mosquitoes involves a chance element, some 
successful infections can occur when feeding on samples with lower gametocyte 
densities. However, when assuming a Poisson distribution with a mean of 0.3 
gametocytes/μL, the lowest NF54 gametocyte density at which mosquito 
infection was observed, suggest that only 0.1% of randomly drawn 2μL samples 
will contain two or more gametocytes. This contrasts with our finding of 2-5% 
infected mosquitoes at this density and suggests that a different distribution 
should be assumed 45. Biological mechanisms have been suggested that can 
increase the transmission success at low densities and thereby explain the 
apparent heterogeneity in gametocyte uptake by mosquitoes. Gametocytes may 
aggregate to favour the encounter of male and female gametocytes 45,46. In 
double gametocyte infections, male and and female gametocytes may even 
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appear within a single erythrocyte 47. Low densities of sexual stage antibodies 
may also enhance the efficiency of gametocytes in infecting mosquitoes 48 and 
gametocytes may sequester in the small capillaries to maximise the chance of 
uptake by a feeding mosquito 44,46,49. These phenomena could play an important 
role in natural malaria transmission and gametocyte aggregation or double 
gametocyte infections may also have influenced our results. Nevertheless, they 
may not adequately explain our findings in the field where mosquito infection 
was observed at very low densities and where technical explanations should 
therefore be considered. This is also indicated by QT-NASBA gametocyte 
densities below 20 gametocytes/mL (Chapter 7, 8), which is below one 
gametocyte per 50μL blood sample.  
Parasite nucleic acids were obtained and stored under field conditions. 
Although a complete loss of RNA or a failure to extract nucleic acids was 
excluded by the detection of parasitic 18S rRNA in all infectious samples, some 
degradation may have occurred. If Pfs25 mRNA was lost, this would have 
decreased the measured gametocyte density by Pfs25 QT-NASBA. To prevent 
similar uncertainties in future studies, a spiking control of exogenous RNA should 
be added to samples prior to processing. Variation in the Pfs25 QT-NASBA assay 
itself could also play a role. Since gametocyte quantification in the Pfs25 QT-
NASBA depends on Pfs25 RNA expression in field isolates relative to that in 
cultured gametocytes, any difference in expression between NF54 and field 
strains would bias results. If Pfs25 RNA expression is lower in gametocytes from 
the field, quantification of field samples will underestimate gametocyte densities. 
Both RNA degradation and a lower Pfs25 RNA expression could explain the 
efficient mosquito infection at low measured gametocyte densities. Before this 
issue is clarified, Pfs25 QT-NASBA gametocyte densities of individual samples 
should be considered with some caution.  
Despite these possible limitations, it is evident that the infectiousness of 
submicroscopic gametocyte densities is not a biological rarity but in fact a very 
common observation (Chapter 7) 19. Submicroscopic gametocytaemia can be 
crucial in determining the transmission potential of a given population. Although 
the proportion of infected mosquitoes is lower when feeding on carriers with 
submicroscopic compared to microscopic gametocyte densities, this can be 
counterbalanced by the much higher prevalence of submicroscopic 
gametocytaemia in the population. In symptomatic children in western Kenya, 
submicroscopic gametocytaemia appeared equally important for post-treatment 
malaria transmission compared to microscopic gametocytaemia (Chapter 7) 19. 
Based on the efficiency of mosquito infection at low gametocyte densities, we 
also hypothesize that carriers harbouring submicroscopic gametocytaemia are 
responsible for maintaining malaria transmission in an area in northern Tanzania 
of very low transmission intensity (Chapter 8) 26. 
Chapter 13 
 180
The possibility to reduce malaria transmission by 
antimalarial drugs 
Prompt antimalarial drug treatment is an important tool, not only for reducing 
the burden of disease but also for reducing malaria transmission. While 
successful clearance of asexual parasites by antimalarial drug treatment will 
interrupt gametocyte development, the short-term effect of antimalarials on 
gametocytaemia is not straightforward. In this thesis, we found an initial 
increase in gametocyte carriage following treatment (Chapter 2) 11, as is 
commonly found for chloroquine (CQ) and sulphadoxine-pyrimethamine (SP) 1-
3,8,50-53. Our longitudinal study directly comparing gametocyte development in 
the presence and absence of antimalarial treatment suggests that this initial rise 
in gametocytaemia is a direct result of SP treatment. Treatment outcome can 
further influence post-treatment gametocytaemia. Evidence is accumulating that 
treatment failure results in an increased gametocyte production. This was 
previously shown for treatment with chloroquine (CQ) 1,2,5,10,50 and is now also 
becoming evident for sulphadoxine-pyrimethamine (SP) 2,9,54 (Chapter 2, 3) 11,55. 
We observed a higher risk of gametocyte carriage and a higher density of 
gametocytaemia in individuals experiencing clinical treatment failure (Chapter 2, 
3) 11,55. This may simply be the result of unsuccessful clearance of asexual 
parasites, allowing a continuous production of gametocytes. However, the timing 
of the peak gametocytaemia suggests that alternative mechanisms also play a 
role.  
The higher prevalence and density of gametocytes on day 7 after 
unsuccessful treatment is commonly seen 1,3,8,50,51 but this peak comes too early 
to be the result of newly produced gametocytes from parasites persisting after 
treatment. The simple reason is that gametocyte development requires 8-12 
days 12,40. It therefore seems plausible that the peak gametocytaemia is stress-
induced 40 and is at least partly the result of the efflux of sequestered 
gametocytes that were present before treatment but whose release was 
triggered by treatment 8. Some of these gametocytes may be immature 8,56. 
Timing becomes even more intriguing when we realise that the higher 
gametocytaemia in resistant infections not only occurs too early to allow normal 
development but an increased gametocyte prevalence of resistant infections may 
even be apparent before treatment is initiated (Chapter 4) 2,57-60. The most likely 
explanation is that the higher pre-treatment gametocyte prevalence reflects 
events that took place prior to enrolment. Unsuccessful treatment of a malaria 
episode would allow for both gametocyte development and the selection of 
resistant parasite strains.  
Alternatively, resistant parasite strains could have a higher gametocyte 
production as a result of some intrinsic characteristic of resistant parasites. 
Although this was not observed in in vitro models 53 and is strictly hypothetical, 
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it seems to be supported by our work in Ghana where we determined 
gametocytaemia as a function of parasite genotype. We observed a higher 
gametocyte prevalence in parasites carrying mutations related to SP treatment 
failure 61, both after and before treatment (Chapter 4)57. These findings were not 
explained by the previous use of SP that was determined in the blood of patients 
at enrolment. Of course, there is always a possibility that mutant parasite strains 
with gametocytes persist for a longer period than the 3-4 weeks that 
pyrimethamine is demonstrable in blood (T. Eggelte, personal communication). 
However, SP was not used as firstline treatment when the study was conducted 
and SP use was very rare in our study population 62. One could therefore 
speculate about possibilities that mutant parasites produce more gametocytes 
compared to wildtype parasites, even in the absence of drug pressure. Mutations 
in the dhfr gene are unlikely to be directly related to gametocyte production but 
may infer a certain cost for parasites in the absence of drug pressure 63,64 that 
may translate in a lower growth rate per parasite lifecycle 65. Therefore, it could 
take longer to cross the threshold parasite density before fever occurs 66 in 
resistant infections. As a consequence, resistant infections may remain 
untreated for a longer period of time, allowing for gametocyte development 67. A 
longer duration of resistant infections before clinic attendance could also play a 
role in the observation that infections with mutant parasites more often present 
as severe malaria anaemia 68.  
While there is no direct evidence for a higher intrinsic gametocyte 
production of resistant parasites, a higher infectiousness of resistant parasites to 
mosquitoes has been observed previously 1,51,69. A higher gametocyte production 
and transmission potential of mutant parasite strains would be particularly 
worrying since it would facilitate the spread of drug resistance. 
 
Artemisinin-based combination therapy 
An important tool against the spread of drug resistant parasites is the 
employment of alternative antimalarial drugs that combine a high therapeutic 
efficacy with a beneficial effect on gametocytes, such as artemisinin-based 
combination therapy (ACT) 4,8,70-73. In our study area in western Kenya where SP 
mono-therapy fails in ~50% of the infections (Chapter 2, 3, 6) 11,17,55, addition of 
three doses of artesunate (AS) to SP or treatment with Artemether-Lumefantrine 
(AL) greatly increased therapeutic efficacy (Chapter 6) 17. The impact of ACT on 
post-treatment gametocytaemia was highly dependent on the method of 
gametocyte detection. Microscopy showed a dramatic reduction in circulating 
gametocytes after ACT (SP+AS or AL) 4,8,70-73 while this reduction was gradual 
and more modest when Pfs25 QT-NASBA was used (Chapter 5, 6) 17,18. ACT acts 
against the early stages of gametocytes 8,51,69 and Pfs25 QT-NASBA 
gametocytaemia after ACT may simply reflect the carriage of unaffected mature 
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gametocytes. Many children harboured gametocytes by Pfs25 QT-NASBA for 
several weeks after treatment and the duration of gametocyte carriage appeared 
longer than the 7-10 days that was estimated by microscopy (Chapter 2) 11. The 
duration of gametocyte carriage needs to be re-assessed in longitudinal studies 
with a long follow-up period and molecular detection methods for both asexual 
parasites and gametocytes. 
Importantly, the effect of ACT on low-density gametocytaemia was 
insufficient to prevent malaria transmission or substantially reduce the 
proportion of infectious individuals on day 14 after treatment (Chapter 6) 17. It is 
difficult to extrapolate this important finding to the potential impact of wide-
scale employment of ACT on malaria transmission in the general population. 
First of all, many individuals in malaria endemic areas will carry infections 
asymptomatically, be infectious to mosquitoes but will not receive ACT. 
Secondly, the influence of ACT on the duration of infectiousness is unknown 
since post-treatment malaria transmission is often measured on only one time-
point 8,51,70. Although the influence of ACT on malaria transmission shortly after 
treatment may be modest, its impact on the duration of gametocyte carriage 
appears substantial. We observed consistently lower gametocyte prevalences by 
Pfs25 QT-NASBA after ACT (Chapter 5, 6) 17,18. Gametocytes that were detected 
after ACT were also circulating at lower densities than those after treatment with 
SP or SP + amodiaquine. This translates in a lower proportion of infected 
mosquitoes after ACT treatment (Chapter 6, 7) 17,19 that is probably more 
marked when the entire post-treatment period is considered. Importantly, the 
higher treatment efficacy in itself will reduce the proportion of individuals 
harbouring persisting infections and will therefore have a beneficial effect on 
gametocyte carriage and malaria transmission.  
Although there is some first evidence of a reduced susceptibility of some 
parasite strains for artemisinin 74 and of ACT selecting for mutant re-infecting 
parasite strains 75, the potency and short half-life of artemisinin 72,76-78 and the 
evidence that ACT reduces the spread of mutant parasite strains 69,79 indicate 
that it is the best available tool to counteract drug-resistance. When is comes to 
reducing overall malaria transmission, ACT alone may not be sufficient. A 
reduction in malaria incidence following the employment of ACT79 is likely to be 
restricted to areas of low transmission intensity where the majority of infections 
are symptomatic and where ACT coverage is excellent. Any attempt to reduce 
malaria transmission by mass drug administration with ACT 80,81 needs to take 
the high prevalence and long duration of post-treatment submicroscopic 
gametocytaemia into account when considering the coverage and timing of 
interventions. 
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Human immune responses reducing malaria transmission 
Similar to treatment outcome that depends not only on characteristics of 
parasites and drugs but also on immunity 82,83, malaria transmission is also 
influenced by human immune responses that can reduce or block successful 
parasite development in the mosquito. Although it has been long acknowledged 
that sexual stage specific immune responses may differ from asexual stage 
immunity in acquisition and persistence 48,84, there have been few attempts to 
determine its rate of development or dynamics. Sexual stage antigens appear 
poorly immunogenic 48,85 but the literature is inconsistent about the relation 
between (repeated) exposure and sexual stage immunity 48,86 87,88 and its 
longevity 48,86,87,89 or age relatedness 48,88. Little is known about the acquisition of 
sexual stage specific antibody responses and functional transmission reducing 
activity (TRA) following natural exposure to asexual parasites or gametocytes. In 
microscopically confirmed gametocyte carriers, we observed a negative age-
dependency of TRA (Chapter 10) 90. This observation did not coincide with a 
reduced prevalence or density of sexual stage antibodies against Pfs230 or 
Pfs48/45 and could not be explained by differences in gametocyte density at the 
time blood samples were taken. Nevertheless, it seems to be confirmed by a 
higher infectiousness of older individuals in Kenya (Chapter 7) 19 and Burkina 
Faso (Ouédraogo, unpublished observations). The most likely explanation for a 
lower prevalence of TRA in older individuals is a lower recent exposure to 
gametocytes. Microscopic gametocyte prevalence decreases with age (Chapter 
2) 11,20-24 and a lower recent exposure to sexual stage antigens may hinder the 
maintenance of effective sexual stage immune responses 91. The study design, 
however, made it impossible to directly test the validity of this concept. As is 
commonly done 88,89,92,93, samples were taken from patent gametocyte carriers 
on one time-point without information on the duration of gametocyte carriage or 
the previous exposure to malaria infections. The duration and density of 
gametocyte carriage may influence sexual stage specific immune responses, 
making it difficult to correlate a single estimate of gametocyte density with 
concurrent levels of sexual stage specific antibodies. Longitudinal studies are 
clearly needed to fully understand the rate at which sexual stage immunity is 
acquired. 
In this thesis we describe two longitudinal studies in very different 
populations. In naïve individuals from Java who were observed for two years 
following their migration to a hyperendemic area, a rapid acquisition of sexual 
stage immunity was observed that was independent of age (Chapter 9) 94. 
Although serological responses were measured only twice per year, a positive 
relation between the number of experienced infections and sexual stage specific 
immune responses was apparent. Not only did the prevalence of anti-Pfs230 and 
anti-Pfs48/45 antibodies increase, functional TRA was also acquired following 
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malaria exposure. A single infection appeared sufficient to elicit TRA in one-third 
of the individuals. This proportion increased with cumulative exposure 87, 
although this may be a sign of the repeated exposure in a short time-period, as 
was observed for P. vivax 91, rather than a long-lasting immune memory. A lack 
of immune memory was suggested by our second longitudinal study in adults 
living in a high endemic area in Tanzania (Chapter 11). Despite intense exposure 
to malaria infections and a high prevalence of anti-sporozoite antibodies, sexual 
stage immune responses were only present in a minority of the individuals. 
There appeared to be little consistency in immune responses with many adults 
converting from seropositive to seronegative within the 18-month study period. 
Although a substantial proportion of the sera was capable of reducing 
transmission in the SMFA, complete blockade of transmission was observed in 
only ~5% of the sera (Chapter 11) compared to ~20% in patent gametocyte 
carriers (Chapter 10) 90. This lower prevalence of functional transmission 
blocking immunity could be the result of a low exposure to microscopically 
confirmed gametocytes in adults living in a high endemic area. Gametocyte 
exposure is inversely related to transmission intensity 7,95, which was also 
observed in our Tanzanian adults where those exposed to fewer infectious bites 
more frequently harboured gametocytes and also showed a higher prevalence of 
sexual stage specific antibodies (Chapter 11).  
A hypothetical model for the acquisition of sexual stage specific immunity 
is proposed in Chapter 12 96 where we conclude that sexual stage specific 
immunity is rapidly acquired but depends on recent exposure to gametocytes. 
This exposure to gametocytes decreases with the acquisition of asexual-stage 
immunity that controls asexual parasite density and consequently 
gametocytaemia. Contrary to asexual-stage immunity, sexual stage immunity 
may therefore be most common in younger age groups or in areas of low 
transmission intensity. The model in Chapter 12 is consistent with most of the 
available literature but relies on microscopy for estimating the antigenic 
exposure, i.e. gametocyte carriage. Based on our findings with Pfs25 QT-NASBA, 
we know this may not be accurate and it is tempting to speculate about a 
possible role of submicroscopic gametocytaemia in the development or 
persistence of sexual stage specific immunity. If we assume that most asexual 
parasite carriers harbour accompanying low levels of gametocytes (Chapter 
5,6,8) 17,18,26, any malaria infection could theoretically initiate or boost sexual 
stage immunity. Interestingly, very few individuals from our cohort of Javanese 
transmigrants were exposed to microscopically detectable levels of 
gametocytaemia on Irian Jaya although half of them experienced three or more 
clinical episodes of P. falciparum malaria (Chapter 9)94. We observed a distinct 
positive association between the number of infections experienced and sexual 
stage specific immune responses. In line with this, Graves et al. found no 
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difference between the asexual parasite and gametocyte carriers in sexual stage 
specific immunity although there was a clear difference with those who were 
malaria negative 87. In addition, sexual stage immune responses were detected 
in primary infections in travellers in the absence of patent gametocytaemia 97, a 
finding that could be explained by our observation that low densities of parasites 
committed to sexual development can be detected within weeks after primary 
infection 98. If a large proportion of the asexual parasite infections is 
accompanied by submicroscopic gametocytaemia, all these observations suggest 
that exposure to submicroscopic gametocyte densities can elicit sexual stage 
immune responses. Clearly, data are too scarce to draw any conclusions and the 
accumulated evidence that gametocytes are poorly immunogenic 48,85 and sexual 
stage specific immune responses are relatively uncommon in endemic 
populations (Chapter 12) 96 argue against an important role of submicroscopic 
gametocytaemia in maintaining sexual stage immunity. Our findings 
nevertheless suggest that submicroscopic gametocytaemia may play a role in 
eliciting sexual stage specific immune responses and further studies should 
define its relative importance for the acquisition and boosting of sexual stage 
immunity.  
Even if submicroscopic gametocyte densities would turn out to be too low 
to be immunogenic, our knowledge of the prevalence and infectiousness of 
submicroscopic gametocytaemia does underline the importance of sexual stage 
specific immunity and transmission blocking vaccines. One important value of 
transmission blocking vaccines is to protect other vaccines by preventing the 
spread of resistant parasite strains. Any pre-erythrocytic or blood-stage vaccine 
with less than 100% efficiency in preventing blood stage infection would benefit 
enormously from the prevention of the transmission of escaping parasites 99. 
With our current knowledge of the omnipresence of low density gametocytaemia 
and its efficiency in driving malaria transmission, transmission blocking vaccines 
appear an essential component to ensure the long term efficiency of any multi-
stage malaria vaccine.  
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Summary 
Plasmodium falciparum is responsible for the majority of malaria attributed 
morbidity and mortality. Humans are infected with this malaria species through 
the bite of an infected mosquito. The transmission cycle is completed when a 
mosquito is in turn infected after feeding on an infectious individual. 
Malaria parasites can appear as asexual and sexual forms (gametocytes) 
in the human peripheral blood. While asexual parasites are responsible for 
clinical disease, gametocytes do not cause clinical symptoms but ensure the 
transmission of malaria from man to mosquito. For successful malaria 
transmission, gametocytes need to be ingested by Anopheles mosquitoes that 
are taking a blood meal on a human host. Gametocytes develop in the mosquito 
and ultimately render the mosquito infectious to human beings.  
Although gametocytes are essential for the spread of malaria, they are 
only observed in a small proportion of Plasmodium falciparum infections. This 
seems to contrast with the highly efficient transmission of malaria that is 
observed in many endemic areas. One of the important conclusions of this thesis 
is that this apparent paradox may simply be the result of the limited sensitivity 
of commonly used tools to detect gametocytes in the human blood. Mosquitoes 
appear more successful in finding gametocytes than the human eye.  
 
In this thesis, we show that gametocytes occur in a large proportion of 
children who are infected with malaria parasites but do not suffer from clinical 
disease. Gametocytes are most common in the younger age groups, who also 
seem to harbour gametocytes for a longer period of time (Chapter 2). Shortly 
after treatment with the commonly used antimalarial drug Fansidar®, 
gametocyte carriage seems to be increased (Chapter 2). The magnitude of this 
increase is related to treatment outcome. Children suffering treatment failure 
are more likely to carry gametocytes than those whose asexual parasites are 
cleared by Fansidar® (Chapter 2, 3). This is a worrying finding that suggests that 
the spread of resistant parasites may be enhanced. In Chapter 4 we provide 
further evidence for this hypothesis. In a completely different setting we studied 
genetic markers for resistance to Fansidar®. Children who were infected with 
resistant parasites were more likely to carry gametocytes than those who were 
carrying susceptible parasites (Chapter 4).  
 
In several studies in this thesis, we used a novel technique for detecting 
gametocytes. This quantitative molecular technique (QT-NASBA) is based on the 
detection of genetic material (RNA) of mature gametocytes and is up to 1000 
times more sensitive than routine microscopy. Using the QT-NASBA, we found 
that gametocytes are far more prevalent than suggested by microscopy. While 
microscopy detects gametocytes in roughly 20% of the children with 
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uncomplicated malaria, the QT-NASBA detects gametocytes in 80-90% of the 
same individuals (Chapter 5, 6). Although these gametocytes circulate at very 
low densities, these are sufficient to infect mosquitoes (Chapter 6, 7). The 
proportion of infected mosquitoes decreases with decreasing gametocyte density 
but mosquito infection is surprisingly efficient at low densities (Chapter 7). The 
relatively lower infectiousness of low density gametocytes is counterbalanced by 
their commonness. Low density gametocyte carriage is very common in 
symptomatic patients (Chapter 5, 6) and in the general population (Chapter 8) 
and appears to be responsible for maintaining malaria transmission in certain 
areas (Chapter 8).  
Even in the light of this effective malaria transmission, there are tools 
available to reduce malaria transmission. Antimalarial drugs can reduce the 
occurrence or persistence of gametocytes. Combination therapy with artemisinin 
(ACT) appears to be the most efficient treatment to effectively cure infected 
individuals and to reduce their gametocyte carriage (Chapter 6). However, the 
impact of ACT on malaria transmission may be more modest than expected 
when based on microscopy. After ACT many individuals harbour persisting low 
density gametocytes (Chapter 5, 6) and, as a result, remain infectious to 
mosquitoes (Chapter 6). 
In addition to antimalarial drugs, immune responses can also influence 
malaria transmission. When gametocytes die in the human body, an immune 
response can be elicited. The resulting human antibodies can be ingested by a 
mosquito together with the gametocytes when it is taking a blood meal. These 
co-ingested antibodies can interfere with further parasite development. This type 
of immunity is called sexual stage immunity and can result in functional 
transmission reducing activity, a reduction in the infectiousness of gametocytes. 
This sexual stage immunity is acquired rapidly after several malaria infections 
(Chapter 9) but appears to be short-lived (Chapter 10, 11). As a result, sexual 
stage immunity may require a constant exposure to gametocytes (Chapter 12). 
Since gametocytes are most common in young children (Chapter 2) and their 
prevalence decreases in higher age groups, sexual stage immunity may also 
wane with age (Chapter 10-12).  
 
The findings in this thesis on the abundance of low density 
gametocytaemia and their role in malaria transmission underline the importance 
of transmission reducing interventions for malaria control. A transmission-
blocking vaccine could be of great value for this purpose. By reducing the 
efficiency of malaria transmission, a transmission blocking vaccine may also play 
an important role in preventing the spread of resistant parasite strains.  
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Samenvatting 
De meest gevaarlijke vorm van malaria wordt veroorzaakt door de parasiet 
Plasmodium falciparum. De mens wordt met deze parasiet besmet door de beet 
van een geïnfecteerde mug. De transmissiecyclus is rond wanneer een mug op 
haar beurt geïnfecteerd wordt door een infectieus mens. 
In het menselijk bloed kan men zowel aseksuele en seksuele stadia van 
de malaria parasieten aantreffen. Aseksuele parasieten zijn verantwoordelijk 
voor de met malaria geassocieerde ziekte en de door haar veroorzaakte sterfte. 
Seksueel stadium parasieten (gametocyten) veroorzaken daarentegen geen 
klinische symptomen maar zorgen voor de overdracht van malaria van de mens 
naar de mug. Transmissie van malaria transmissie vindt alleen plaats als 
volwassen gametocyten opgezogen worden door een Anopheles mug die een 
‘bloedmaal’ neemt bij een mens. De gametocyten ontwikkelen zich vervolgens in 
de mug totdat deze in staat is nieuwe mensen te infecteren.  
Hoewel gametocyten in deze zin essentieel zijn voor de verspreiding van 
malaria, worden ze slechts aangetroffen bij een klein deel van de mensen die 
geïnfecteerd zijn met Plasmodium falciparum. Dit lijkt haaks te staan op de 
efficiënte transmissie van malaria in veel gebieden in Afrika. Een van de 
belangrijke conclusies van dit proefschrift is dat deze schijnbare paradox 
eenvoudigweg het gevolg lijkt te zijn van onze beperkte middelen om de 
aanwezigheid van gametocyten in het menselijk bloed aan te tonen. Muggen 
blijken veel beter in staat gametocyten op te pikken dan het menselijk oog. 
 
In dit proefschrift tonen we aan dat gametocyten veel voorkomen bij 
kinderen die weliswaar geïnfecteerd zijn met malaria maar die hier geen 
symptomen van ondervinden (Hoofdstuk 2). Gametocyten komen het meest 
voor bij jonge kinderen, die ze ook langer bij zich lijken te dragen dan oudere 
kinderen (Hoofdstuk 2). Na behandeling met het veelgebruikte antimalaria 
middel Fansidar® lijkt het aantal gametocyt-dragers in eerste instantie toe te 
nemen. De omvang van deze toename is afhankelijk van de uitkomst van de 
behandeling. Kinderen bij wie de behandeling zonder succes is, hebben een 
aanzienlijk grotere kans gametocyten te ontwikkelen dan kinderen bij wie 
Fansidar® succesvol alle aseksuele parasieten heeft gedood (Hoofdstuk 2, 3). Dit 
is een verontrustende bevinding die suggereert dat kinderen na onsuccesvolle 
behandeling meer muggen kunnen besmetten en dat parasietenstammen die 
resistent zijn voor het gebruikte medicijn zich sneller kunnen verspreiden in de 
populatie. In hoofdstuk 4 leveren we aanvullend bewijs voor deze hypothese. In 
een volledig andere omgeving onderzochten we mutaties in het genetisch 
materiaal van parasieten die verantwoordelijk zijn voor Fansidar® resistentie. 
Kinderen die geïnfecteerd waren met Fansidar resistente stammen hadden een 
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grotere kans op gametocyt-dragerschap dan kinderen die besmet waren met 
Fansidar gevoelige stammen.  
 
Bij een aantal studies in dit proefschrift is gebruik gemaakt van een recent 
ontwikkelde techniek om gametocyten te detecteren. Deze kwantitatieve 
moleculaire techniek (QT-NASBA) is gebaseerd op het aantonen van genetisch 
materiaal (RNA) van volwassen gametocyten en is tot 1000 maal gevoeliger dan 
het routinematig gebruik van de microscoop. Door gebruik te maken van de QT-
NASBA vonden we dat gametocyten veel meer voorkomen dan gesuggereerd 
wordt door microscopie. Terwijl microscopie bij slechts ~20% van de kinderen 
met symptomatische malaria gametocyten aantoont, vindt de QT-NASBA 
gametocyten bij 80-90% van dezelfde kinderen (Hoofdstuk 5, 6). In veel van de 
gevallen zijn de gametocyten in lage, submicroscopische, concentraties 
aanwezig. Toch blijken deze concentraties voldoende om muggen te infecteren 
(Hoofdstuk 6, 7). Het percentage geïnfecteerde muggen daalt weliswaar met een 
dalende concentratie van gametocyten maar zelfs bij submicroscopische 
concentraties blijkt de transmissie van malaria verassend efficiënt (Hoofdstuk 7). 
Hun verhoudingsgewijs lagere infectiviteit wordt bovendien ruimschoots 
gecompenseerd door het frequente voorkomen van submicroscopisch 
gametocyt-dragerschap in symptomatische patiënten (Hoofdstuk 5, 6) en de 
algemene bevolking (Hoofdstuk 8). Personen met submicroscopische gametocyt-
concentraties lijken zelfs verantwoordelijk te zijn voor het in stand houden van 
malaria transmissie in bepaalde gebieden (Hoofdstuk 8).  
 
Zelfs in het licht van deze efficiënte transmissie van malaria zijn er 
manieren om de transmissie te reduceren. Zo kunnen antimalaria middelen het 
ontstaan of voortduren van het dragerschap van gametocyten verminderen. 
Combinatietherapie met artemisine (ACT) lijkt de meest efficiënte aanpak om 
patiënten met succes te bevrijden van de ziekmakende aseksuele parasieten en 
tegelijk het aantal gametocyten te reduceren (Hoofdstuk 6). Helaas lijkt het 
effect van ACT op de transmissie van malaria bescheidener dan voorheen werd 
aangenomen. Zelfs na behandeling met ACT houden veel personen gedurende 
lange tijd lage concentraties gametocyten. (Hoofdstuk 5,6). Als gevolg hiervan 
blijkt een groot deel van de patiënten na behandeling in staat muggen te 
besmetten (Hoofdstuk 6). 
Naast antimalaria medicatie kan ook het menselijke immuunsysteem de 
transmissie van malaria beïnvloeden. Hoewel gametocyten in rode bloedcellen 
zitten en grotendeels ontoegankelijk zijn voor het menselijk immuunsysteem, 
kunnen er wel antistoffen gemaakt worden tegen afbraakproducten van 
gametocyten die in het menselijk lichaam sterven. Deze antistoffen kunnen 
samen met gametocyten opgenomen worden door een mug die een ‘bloedmaal’ 
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neemt. In de maag van de muggen kunnen de antistoffen vervolgens de 
ontwikkeling van de parasiet remmen. Dit type immuniteit wordt ‘seksueel 
stadium immuniteit’ genoemd en kan resulteren in functionele transmissie 
reducerende activiteit, een verminderde infectiviteit van gametocyten. Seksueel 
stadium immuniteit ontstaat in een vroeg stadium na blootstelling aan malaria 
(Hoofdstuk 9) maar lijkt kortdurend te zijn (Hoofdstuk 10,11). Als gevolg 
hiervan heeft seksueel stadium immuniteit wellicht een constante blootstelling 
aan gametocyten nodig om effectief te zijn (Hoofdstuk 12). Aangezien 
gametocyten het meest voorkomen bij kinderen (Hoofdstuk 2) en het 
percentage gametocyt-dragers afneemt met het vorderen van de leeftijd, zou 
seksueel stadium immuniteit ook wel eens af kunnen nemen bij het ouder 
worden (Hoofdstuk 10-12).  
 
De in dit proefschrift verkregen kennis over de overvloed aan submicroscopische 
gametocyten en hun rol in malaria transmissie onderstrepen het belang van 
transmissie-reducerence interventies voor het bestrijden van malaria. Een 
transmissie blokkerend vaccin zou hierbij van groot belang kunnen zijn. Door de 
efficiëntie van malaria transmissie te verminderen zou een dergelijk vaccin ook 
een belangrijke rol kunnen spelen bij het voorkómen van de verspreiding van 
resistente parasieten. 
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